#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Abnormal degree centrality in chronic users of codeine-containing cough syrups: A resting-state functional magnetic resonance imaging study
#Text=Codeine-containing cough syrups (CCS) have become one of the most popular drugs of abuse in young population worldwide.
1-1	0-8	Abnormal	_	
1-2	9-15	degree	_	
1-3	16-26	centrality	_	
1-4	27-29	in	_	
1-5	30-37	chronic	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-6	38-43	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-7	44-46	of	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-8	47-65	codeine-containing	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-9	66-71	cough	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-10	72-78	syrups	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-11	78-79	:	_	
1-12	80-81	A	_	
1-13	82-95	resting-state	_	
1-14	96-106	functional	_	
1-15	107-115	magnetic	_	
1-16	116-125	resonance	_	
1-17	126-133	imaging	_	
1-18	134-139	study	_	
1-19	140-158	Codeine-containing	_	
1-20	159-164	cough	_	
1-21	165-171	syrups	_	
1-22	172-173	(	_	
1-23	173-176	CCS	_	
1-24	176-177	)	_	
1-25	178-182	have	_	
1-26	183-189	become	_	
1-27	190-193	one	_	
1-28	194-196	of	_	
1-29	197-200	the	_	
1-30	201-205	most	_	
1-31	206-213	popular	_	
1-32	214-219	drugs	_	
1-33	220-222	of	_	
1-34	223-228	abuse	_	
1-35	229-231	in	_	
1-36	232-237	young	_	
1-37	238-248	population	_	
1-38	249-258	worldwide	_	
1-39	258-259	.	_	

#Text=However, the neurobiological mechanisms underlying CCS-dependence are yet ill-defined.
2-1	260-267	However	_	
2-2	267-268	,	_	
2-3	269-272	the	_	
2-4	273-288	neurobiological	_	
2-5	289-299	mechanisms	_	
2-6	300-310	underlying	_	
2-7	311-325	CCS-dependence	_	
2-8	326-329	are	_	
2-9	330-333	yet	_	
2-10	334-345	ill-defined	_	
2-11	345-346	.	_	

#Text=Therefore, understanding the brain abnormalities in chronic users of CCS is crucial for developing effective interventions.
3-1	347-356	Therefore	_	
3-2	356-357	,	_	
3-3	358-371	understanding	_	
3-4	372-375	the	_	
3-5	376-381	brain	_	
3-6	382-395	abnormalities	_	
3-7	396-398	in	_	
3-8	399-406	chronic	_	
3-9	407-412	users	_	
3-10	413-415	of	_	
3-11	416-419	CCS	_	
3-12	420-422	is	_	
3-13	423-430	crucial	_	
3-14	431-434	for	_	
3-15	435-445	developing	_	
3-16	446-455	effective	_	
3-17	456-469	interventions	_	
3-18	469-470	.	_	

#Text=The present study depicted the intrinsic dysconnectivity pattern of whole-brain functional networks at the voxel level in chronic users of CCS.
4-1	471-474	The	_	
4-2	475-482	present	_	
4-3	483-488	study	_	
4-4	489-497	depicted	_	
4-5	498-501	the	_	
4-6	502-511	intrinsic	_	
4-7	512-527	dysconnectivity	_	
4-8	528-535	pattern	_	
4-9	536-538	of	_	
4-10	539-550	whole-brain	_	
4-11	551-561	functional	_	
4-12	562-570	networks	_	
4-13	571-573	at	_	
4-14	574-577	the	_	
4-15	578-583	voxel	_	
4-16	584-589	level	_	
4-17	590-592	in	_	
4-18	593-600	chronic	_	
4-19	601-606	users	_	
4-20	607-609	of	_	
4-21	610-613	CCS	_	
4-22	613-614	.	_	

#Text=In addition, the degree centrality (DC) changes were correlated to the Barratt Impulsiveness Scale (BIS-11) total score, dose, duration of CCS use, and the age at first use of cough syrups.
5-1	615-617	In	_	
5-2	618-626	addition	_	
5-3	626-627	,	_	
5-4	628-631	the	_	
5-5	632-638	degree	_	
5-6	639-649	centrality	_	
5-7	650-651	(	_	
5-8	651-653	DC	_	
5-9	653-654	)	_	
5-10	655-662	changes	_	
5-11	663-667	were	_	
5-12	668-678	correlated	_	
5-13	679-681	to	_	
5-14	682-685	the	_	
5-15	686-693	Barratt	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[2]	
5-16	694-707	Impulsiveness	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[2]	
5-17	708-713	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[2]	
5-18	714-715	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[2]	
5-19	715-718	BIS	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[2]	
5-20	718-719	-	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[2]	
5-21	719-721	11	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[2]	
5-22	721-722	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[2]	
5-23	723-728	total	_	
5-24	729-734	score	_	
5-25	734-735	,	_	
5-26	736-740	dose	_	
5-27	740-741	,	_	
5-28	742-750	duration	_	
5-29	751-753	of	_	
5-30	754-757	CCS	_	
5-31	758-761	use	_	
5-32	761-762	,	_	
5-33	763-766	and	_	
5-34	767-770	the	_	
5-35	771-774	age	_	
5-36	775-777	at	_	
5-37	778-783	first	_	
5-38	784-787	use	_	
5-39	788-790	of	_	
5-40	791-796	cough	_	
5-41	797-803	syrups	_	
5-42	803-804	.	_	

#Text=The current study included 38 chronic CCS users and 34 matched control subjects.
6-1	805-808	The	_	
6-2	809-816	current	_	
6-3	817-822	study	_	
6-4	823-831	included	_	
6-5	832-834	38	_	
6-6	835-842	chronic	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[3]	
6-7	843-846	CCS	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[3]	
6-8	847-852	users	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[3]	
6-9	853-856	and	_	
6-10	857-859	34	_	
6-11	860-867	matched	_	
6-12	868-875	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
6-13	876-884	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[4]	
6-14	884-885	.	_	

#Text=All patients were evaluated using the BIS-11.
7-1	886-889	All	_	
7-2	890-898	patients	_	
7-3	899-903	were	_	
7-4	904-913	evaluated	_	
7-5	914-919	using	_	
7-6	920-923	the	_	
7-7	924-927	BIS	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[5]	
7-8	927-928	-	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[5]	
7-9	928-930	11	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[5]	
7-10	930-931	.	_	

#Text=Next, resting-state functional magnetic resonance imaging (rs-fMRI) datasets were acquired from these CCS users and controls.
8-1	932-936	Next	_	
8-2	936-937	,	_	
8-3	938-951	resting-state	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
8-4	952-962	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
8-5	963-971	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
8-6	972-981	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
8-7	982-989	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
8-8	990-991	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
8-9	991-998	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
8-10	998-999	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[6]	
8-11	1000-1008	datasets	_	
8-12	1009-1013	were	_	
8-13	1014-1022	acquired	_	
8-14	1023-1027	from	_	
8-15	1028-1033	these	_	
8-16	1034-1037	CCS	_	
8-17	1038-1043	users	_	
8-18	1044-1047	and	_	
8-19	1048-1056	controls	_	
8-20	1056-1057	.	_	

#Text=Whole-brain connectivity was analyzed using a graph theory approach: degree centrality (DC).
9-1	1058-1069	Whole-brain	_	
9-2	1070-1082	connectivity	_	
9-3	1083-1086	was	_	
9-4	1087-1095	analyzed	_	
9-5	1096-1101	using	_	
9-6	1102-1103	a	_	
9-7	1104-1109	graph	_	
9-8	1110-1116	theory	_	
9-9	1117-1125	approach	_	
9-10	1125-1126	:	_	
9-11	1127-1133	degree	_	
9-12	1134-1144	centrality	_	
9-13	1145-1146	(	_	
9-14	1146-1148	DC	_	
9-15	1148-1149	)	_	
9-16	1149-1150	.	_	

#Text=CCS-dependent individuals exhibited low DC values in the left inferior parietal lobule and the left middle temporal gyrus, while high DC values were noted in the right pallidum and the right hippocampus (P < 0.01, AlphaSim corrected).
10-1	1151-1164	CCS-dependent	_	
10-2	1165-1176	individuals	_	
10-3	1177-1186	exhibited	_	
10-4	1187-1190	low	_	
10-5	1191-1193	DC	_	
10-6	1194-1200	values	_	
10-7	1201-1203	in	_	
10-8	1204-1207	the	_	
10-9	1208-1212	left	_	
10-10	1213-1221	inferior	_	
10-11	1222-1230	parietal	_	
10-12	1231-1237	lobule	_	
10-13	1238-1241	and	_	
10-14	1242-1245	the	_	
10-15	1246-1250	left	_	
10-16	1251-1257	middle	_	
10-17	1258-1266	temporal	_	
10-18	1267-1272	gyrus	_	
10-19	1272-1273	,	_	
10-20	1274-1279	while	_	
10-21	1280-1284	high	_	
10-22	1285-1287	DC	_	
10-23	1288-1294	values	_	
10-24	1295-1299	were	_	
10-25	1300-1305	noted	_	
10-26	1306-1308	in	_	
10-27	1309-1312	the	_	
10-28	1313-1318	right	_	
10-29	1319-1327	pallidum	_	
10-30	1328-1331	and	_	
10-31	1332-1335	the	_	
10-32	1336-1341	right	_	
10-33	1342-1353	hippocampus	_	
10-34	1354-1355	(	_	
10-35	1355-1356	P	_	
10-36	1356-1357	 	_	
10-37	1357-1358	<	_	
10-38	1358-1359	 	_	
10-39	1359-1363	0.01	_	
10-40	1363-1364	,	_	
10-41	1365-1373	AlphaSim	_	
10-42	1374-1383	corrected	_	
10-43	1383-1384	)	_	
10-44	1384-1385	.	_	

#Text=Also, significant correlations were established between average DC value in the left inferior parietal lobule and attentional impulsivity scores and the age at first CCS use.
11-1	1386-1390	Also	_	
11-2	1390-1391	,	_	
11-3	1392-1403	significant	_	
11-4	1404-1416	correlations	_	
11-5	1417-1421	were	_	
11-6	1422-1433	established	_	
11-7	1434-1441	between	_	
11-8	1442-1449	average	_	
11-9	1450-1452	DC	_	
11-10	1453-1458	value	_	
11-11	1459-1461	in	_	
11-12	1462-1465	the	_	
11-13	1466-1470	left	_	
11-14	1471-1479	inferior	_	
11-15	1480-1488	parietal	_	
11-16	1489-1495	lobule	_	
11-17	1496-1499	and	_	
11-18	1500-1511	attentional	_	
11-19	1512-1523	impulsivity	_	
11-20	1524-1530	scores	_	
11-21	1531-1534	and	_	
11-22	1535-1538	the	_	
11-23	1539-1542	age	_	
11-24	1543-1545	at	_	
11-25	1546-1551	first	_	
11-26	1552-1555	CCS	_	
11-27	1556-1559	use	_	
11-28	1559-1560	.	_	

#Text=The rs-fMRI study suggested that the abnormal intrinsic dysconnectivity pattern of whole-brain functional networks may provide an insight into the neural substrates of abnormalities in the cognitive control circuit, the reward circuit, and the learning and memory circuit in CCS-dependent individuals.
12-1	1561-1564	The	_	
12-2	1565-1572	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
12-3	1573-1578	study	_	
12-4	1579-1588	suggested	_	
12-5	1589-1593	that	_	
12-6	1594-1597	the	_	
12-7	1598-1606	abnormal	_	
12-8	1607-1616	intrinsic	_	
12-9	1617-1632	dysconnectivity	_	
12-10	1633-1640	pattern	_	
12-11	1641-1643	of	_	
12-12	1644-1655	whole-brain	_	
12-13	1656-1666	functional	_	
12-14	1667-1675	networks	_	
12-15	1676-1679	may	_	
12-16	1680-1687	provide	_	
12-17	1688-1690	an	_	
12-18	1691-1698	insight	_	
12-19	1699-1703	into	_	
12-20	1704-1707	the	_	
12-21	1708-1714	neural	_	
12-22	1715-1725	substrates	_	
12-23	1726-1728	of	_	
12-24	1729-1742	abnormalities	_	
12-25	1743-1745	in	_	
12-26	1746-1749	the	_	
12-27	1750-1759	cognitive	_	
12-28	1760-1767	control	_	
12-29	1768-1775	circuit	_	
12-30	1775-1776	,	_	
12-31	1777-1780	the	_	
12-32	1781-1787	reward	_	
12-33	1788-1795	circuit	_	
12-34	1795-1796	,	_	
12-35	1797-1800	and	_	
12-36	1801-1804	the	_	
12-37	1805-1813	learning	_	
12-38	1814-1817	and	_	
12-39	1818-1824	memory	_	
12-40	1825-1832	circuit	_	
12-41	1833-1835	in	_	
12-42	1836-1849	CCS-dependent	_	
12-43	1850-1861	individuals	_	
12-44	1861-1862	.	_	

#Text=Highlights
#Text=The abuse of CCS has gained a severe foothold among young individuals worldwide.
13-1	1863-1873	Highlights	_	
13-2	1874-1877	The	_	
13-3	1878-1883	abuse	_	
13-4	1884-1886	of	_	
13-5	1887-1890	CCS	_	
13-6	1891-1894	has	_	
13-7	1895-1901	gained	_	
13-8	1902-1903	a	_	
13-9	1904-1910	severe	_	
13-10	1911-1919	foothold	_	
13-11	1920-1925	among	_	
13-12	1926-1931	young	_	
13-13	1932-1943	individuals	_	
13-14	1944-1953	worldwide	_	
13-15	1953-1954	.	_	

#Text=DC is one of the more reliable and compelling measures among several nodal network metrics.
14-1	1955-1957	DC	_	
14-2	1958-1960	is	_	
14-3	1961-1964	one	_	
14-4	1965-1967	of	_	
14-5	1968-1971	the	_	
14-6	1972-1976	more	_	
14-7	1977-1985	reliable	_	
14-8	1986-1989	and	_	
14-9	1990-2000	compelling	_	
14-10	2001-2009	measures	_	
14-11	2010-2015	among	_	
14-12	2016-2023	several	_	
14-13	2024-2029	nodal	_	
14-14	2030-2037	network	_	
14-15	2038-2045	metrics	_	
14-16	2045-2046	.	_	

#Text=The present study depicted intrinsic dysconnectivity pattern of whole-brain functional networks in CCS-dependent individuals.
15-1	2047-2050	The	_	
15-2	2051-2058	present	_	
15-3	2059-2064	study	_	
15-4	2065-2073	depicted	_	
15-5	2074-2083	intrinsic	_	
15-6	2084-2099	dysconnectivity	_	
15-7	2100-2107	pattern	_	
15-8	2108-2110	of	_	
15-9	2111-2122	whole-brain	_	
15-10	2123-2133	functional	_	
15-11	2134-2142	networks	_	
15-12	2143-2145	in	_	
15-13	2146-2159	CCS-dependent	_	
15-14	2160-2171	individuals	_	
15-15	2171-2172	.	_	

#Text=CCS-dependent individuals showed altered DC in the right pallidum, right hippocampus, left IPL and left middle temporal gyrus.
16-1	2173-2186	CCS-dependent	_	
16-2	2187-2198	individuals	_	
16-3	2199-2205	showed	_	
16-4	2206-2213	altered	_	
16-5	2214-2216	DC	_	
16-6	2217-2219	in	_	
16-7	2220-2223	the	_	
16-8	2224-2229	right	_	
16-9	2230-2238	pallidum	_	
16-10	2238-2239	,	_	
16-11	2240-2245	right	_	
16-12	2246-2257	hippocampus	_	
16-13	2257-2258	,	_	
16-14	2259-2263	left	_	
16-15	2264-2267	IPL	_	
16-16	2268-2271	and	_	
16-17	2272-2276	left	_	
16-18	2277-2283	middle	_	
16-19	2284-2292	temporal	_	
16-20	2293-2298	gyrus	_	
16-21	2298-2299	.	_	

#Text=Significant correlations were established between average DC value in the left IPL and attentional impulsivity scores and the age at first CCS use.
17-1	2300-2311	Significant	_	
17-2	2312-2324	correlations	_	
17-3	2325-2329	were	_	
17-4	2330-2341	established	_	
17-5	2342-2349	between	_	
17-6	2350-2357	average	_	
17-7	2358-2360	DC	_	
17-8	2361-2366	value	_	
17-9	2367-2369	in	_	
17-10	2370-2373	the	_	
17-11	2374-2378	left	_	
17-12	2379-2382	IPL	_	
17-13	2383-2386	and	_	
17-14	2387-2398	attentional	_	
17-15	2399-2410	impulsivity	_	
17-16	2411-2417	scores	_	
17-17	2418-2421	and	_	
17-18	2422-2425	the	_	
17-19	2426-2429	age	_	
17-20	2430-2432	at	_	
17-21	2433-2438	first	_	
17-22	2439-2442	CCS	_	
17-23	2443-2446	use	_	
17-24	2446-2447	.	_	

#Text=Introduction
#Text=Codeine-containing cough syrup (CCS)-dependent individuals refer to long-term and sustained administration of CCS (in which, codeine and ephedrine are intended for cough and analgesic function, respectively) for pleasure and hallucination.
18-1	2448-2460	Introduction	_	
18-2	2461-2479	Codeine-containing	_	
18-3	2480-2485	cough	_	
18-4	2486-2491	syrup	_	
18-5	2492-2493	(	_	
18-6	2493-2496	CCS	_	
18-7	2496-2497	)	_	
18-8	2497-2498	-	_	
18-9	2498-2507	dependent	_	
18-10	2508-2519	individuals	_	
18-11	2520-2525	refer	_	
18-12	2526-2528	to	_	
18-13	2529-2538	long-term	_	
18-14	2539-2542	and	_	
18-15	2543-2552	sustained	_	
18-16	2553-2567	administration	_	
18-17	2568-2570	of	_	
18-18	2571-2574	CCS	_	
18-19	2575-2576	(	_	
18-20	2576-2578	in	_	
18-21	2579-2584	which	_	
18-22	2584-2585	,	_	
18-23	2586-2593	codeine	_	
18-24	2594-2597	and	_	
18-25	2598-2607	ephedrine	_	
18-26	2608-2611	are	_	
18-27	2612-2620	intended	_	
18-28	2621-2624	for	_	
18-29	2625-2630	cough	_	
18-30	2631-2634	and	_	
18-31	2635-2644	analgesic	_	
18-32	2645-2653	function	_	
18-33	2653-2654	,	_	
18-34	2655-2667	respectively	_	
18-35	2667-2668	)	_	
18-36	2669-2672	for	_	
18-37	2673-2681	pleasure	_	
18-38	2682-2685	and	_	
18-39	2686-2699	hallucination	_	
18-40	2699-2700	.	_	

#Text=As CCS is cheap, convenient, and legal to purchase, the abuse of the drug has gained a severe foothold among young individuals worldwide and is considered as an increasing concern in modern society.
19-1	2701-2703	As	_	
19-2	2704-2707	CCS	_	
19-3	2708-2710	is	_	
19-4	2711-2716	cheap	_	
19-5	2716-2717	,	_	
19-6	2718-2728	convenient	_	
19-7	2728-2729	,	_	
19-8	2730-2733	and	_	
19-9	2734-2739	legal	_	
19-10	2740-2742	to	_	
19-11	2743-2751	purchase	_	
19-12	2751-2752	,	_	
19-13	2753-2756	the	_	
19-14	2757-2762	abuse	_	
19-15	2763-2765	of	_	
19-16	2766-2769	the	_	
19-17	2770-2774	drug	_	
19-18	2775-2778	has	_	
19-19	2779-2785	gained	_	
19-20	2786-2787	a	_	
19-21	2788-2794	severe	_	
19-22	2795-2803	foothold	_	
19-23	2804-2809	among	_	
19-24	2810-2815	young	_	
19-25	2816-2827	individuals	_	
19-26	2828-2837	worldwide	_	
19-27	2838-2841	and	_	
19-28	2842-2844	is	_	
19-29	2845-2855	considered	_	
19-30	2856-2858	as	_	
19-31	2859-2861	an	_	
19-32	2862-2872	increasing	_	
19-33	2873-2880	concern	_	
19-34	2881-2883	in	_	
19-35	2884-2890	modern	_	
19-36	2891-2898	society	_	
19-37	2898-2899	.	_	

#Text=According to a Report of the International Narcotics Control Board for 2012, the abuse of prescription and over-the-counter (OTC) drugs has continued to spread worldwide since 2009, which poses severe health and social challenges in several countries.
20-1	2900-2909	According	_	
20-2	2910-2912	to	_	
20-3	2913-2914	a	_	
20-4	2915-2921	Report	_	
20-5	2922-2924	of	_	
20-6	2925-2928	the	_	
20-7	2929-2942	International	_	
20-8	2943-2952	Narcotics	_	
20-9	2953-2960	Control	_	
20-10	2961-2966	Board	_	
20-11	2967-2970	for	_	
20-12	2971-2975	2012	_	
20-13	2975-2976	,	_	
20-14	2977-2980	the	_	
20-15	2981-2986	abuse	_	
20-16	2987-2989	of	_	
20-17	2990-3002	prescription	_	
20-18	3003-3006	and	_	
20-19	3007-3023	over-the-counter	_	
20-20	3024-3025	(	_	
20-21	3025-3028	OTC	_	
20-22	3028-3029	)	_	
20-23	3030-3035	drugs	_	
20-24	3036-3039	has	_	
20-25	3040-3049	continued	_	
20-26	3050-3052	to	_	
20-27	3053-3059	spread	_	
20-28	3060-3069	worldwide	_	
20-29	3070-3075	since	_	
20-30	3076-3080	2009	_	
20-31	3080-3081	,	_	
20-32	3082-3087	which	_	
20-33	3088-3093	poses	_	
20-34	3094-3100	severe	_	
20-35	3101-3107	health	_	
20-36	3108-3111	and	_	
20-37	3112-3118	social	_	
20-38	3119-3129	challenges	_	
20-39	3130-3132	in	_	
20-40	3133-3140	several	_	
20-41	3141-3150	countries	_	
20-42	3150-3151	.	_	

#Text=In the USA, prescription drug abuse is more prevalent than any other internationally controlled substance except for cannabis.
21-1	3152-3154	In	_	
21-2	3155-3158	the	_	
21-3	3159-3162	USA	_	
21-4	3162-3163	,	_	
21-5	3164-3176	prescription	_	
21-6	3177-3181	drug	_	
21-7	3182-3187	abuse	_	
21-8	3188-3190	is	_	
21-9	3191-3195	more	_	
21-10	3196-3205	prevalent	_	
21-11	3206-3210	than	_	
21-12	3211-3214	any	_	
21-13	3215-3220	other	_	
21-14	3221-3236	internationally	_	
21-15	3237-3247	controlled	_	
21-16	3248-3257	substance	_	
21-17	3258-3264	except	_	
21-18	3265-3268	for	_	
21-19	3269-3277	cannabis	_	
21-20	3277-3278	.	_	

#Text=In China, demonstrated that CCS is the maximally abused drug (50% of all documented abused substances) in adolescents.
22-1	3279-3281	In	_	
22-2	3282-3287	China	_	
22-3	3287-3288	,	_	
22-4	3289-3301	demonstrated	_	
22-5	3302-3306	that	_	
22-6	3307-3310	CCS	_	
22-7	3311-3313	is	_	
22-8	3314-3317	the	_	
22-9	3318-3327	maximally	_	
22-10	3328-3334	abused	_	
22-11	3335-3339	drug	_	
22-12	3340-3341	(	_	
22-13	3341-3344	50%	_	
22-14	3345-3347	of	_	
22-15	3348-3351	all	_	
22-16	3352-3362	documented	_	
22-17	3363-3369	abused	_	
22-18	3370-3380	substances	_	
22-19	3380-3381	)	_	
22-20	3382-3384	in	_	
22-21	3385-3396	adolescents	_	
22-22	3396-3397	.	_	

#Text=Previous studies have confirmed that mental functioning, behavior, and personality were abnormal in CCS-dependent individuals; these characteristics were similar to those expressed by heroin- and other illicit substances-dependent individuals.
23-1	3398-3406	Previous	_	
23-2	3407-3414	studies	_	
23-3	3415-3419	have	_	
23-4	3420-3429	confirmed	_	
23-5	3430-3434	that	_	
23-6	3435-3441	mental	_	
23-7	3442-3453	functioning	_	
23-8	3453-3454	,	_	
23-9	3455-3463	behavior	_	
23-10	3463-3464	,	_	
23-11	3465-3468	and	_	
23-12	3469-3480	personality	_	
23-13	3481-3485	were	_	
23-14	3486-3494	abnormal	_	
23-15	3495-3497	in	_	
23-16	3498-3511	CCS-dependent	_	
23-17	3512-3523	individuals	_	
23-18	3523-3524	;	_	
23-19	3525-3530	these	_	
23-20	3531-3546	characteristics	_	
23-21	3547-3551	were	_	
23-22	3552-3559	similar	_	
23-23	3560-3562	to	_	
23-24	3563-3568	those	_	
23-25	3569-3578	expressed	_	
23-26	3579-3581	by	_	
23-27	3582-3588	heroin	_	
23-28	3588-3589	-	_	
23-29	3590-3593	and	_	
23-30	3594-3599	other	_	
23-31	3600-3607	illicit	_	
23-32	3608-3628	substances-dependent	_	
23-33	3629-3640	individuals	_	
23-34	3640-3641	.	_	

#Text=However, accumulated evidence has demonstrated that illicit drugs, including heroin, have an effect on brain functional changes as measured by functional magnetic resonance imaging (fMRI) Furthermore, the abnormality of impulsive decision making in illicit drug-dependent individuals may be related to the deficient function of the orbitofrontal cortex and the right inferior parietal lobe.
24-1	3642-3649	However	_	
24-2	3649-3650	,	_	
24-3	3651-3662	accumulated	_	
24-4	3663-3671	evidence	_	
24-5	3672-3675	has	_	
24-6	3676-3688	demonstrated	_	
24-7	3689-3693	that	_	
24-8	3694-3701	illicit	_	
24-9	3702-3707	drugs	_	
24-10	3707-3708	,	_	
24-11	3709-3718	including	_	
24-12	3719-3725	heroin	_	
24-13	3725-3726	,	_	
24-14	3727-3731	have	_	
24-15	3732-3734	an	_	
24-16	3735-3741	effect	_	
24-17	3742-3744	on	_	
24-18	3745-3750	brain	_	
24-19	3751-3761	functional	_	
24-20	3762-3769	changes	_	
24-21	3770-3772	as	_	
24-22	3773-3781	measured	_	
24-23	3782-3784	by	_	
24-24	3785-3795	functional	_	
24-25	3796-3804	magnetic	_	
24-26	3805-3814	resonance	_	
24-27	3815-3822	imaging	_	
24-28	3823-3824	(	_	
24-29	3824-3828	fMRI	_	
24-30	3828-3829	)	_	
24-31	3830-3841	Furthermore	_	
24-32	3841-3842	,	_	
24-33	3843-3846	the	_	
24-34	3847-3858	abnormality	_	
24-35	3859-3861	of	_	
24-36	3862-3871	impulsive	_	
24-37	3872-3880	decision	_	
24-38	3881-3887	making	_	
24-39	3888-3890	in	_	
24-40	3891-3898	illicit	_	
24-41	3899-3913	drug-dependent	_	
24-42	3914-3925	individuals	_	
24-43	3926-3929	may	_	
24-44	3930-3932	be	_	
24-45	3933-3940	related	_	
24-46	3941-3943	to	_	
24-47	3944-3947	the	_	
24-48	3948-3957	deficient	_	
24-49	3958-3966	function	_	
24-50	3967-3969	of	_	
24-51	3970-3973	the	_	
24-52	3974-3987	orbitofrontal	_	
24-53	3988-3994	cortex	_	
24-54	3995-3998	and	_	
24-55	3999-4002	the	_	
24-56	4003-4008	right	_	
24-57	4009-4017	inferior	_	
24-58	4018-4026	parietal	_	
24-59	4027-4031	lobe	_	
24-60	4031-4032	.	_	

#Text=Compared to the illicit drug addiction of the so-called “street drugs,” less attention has been directed to the illicit use of drugs such as CCS.
25-1	4033-4041	Compared	_	
25-2	4042-4044	to	_	
25-3	4045-4048	the	_	
25-4	4049-4056	illicit	_	
25-5	4057-4061	drug	_	
25-6	4062-4071	addiction	_	
25-7	4072-4074	of	_	
25-8	4075-4078	the	_	
25-9	4079-4088	so-called	_	
25-10	4089-4090	“	_	
25-11	4090-4096	street	_	
25-12	4097-4102	drugs	_	
25-13	4102-4103	,	_	
25-14	4103-4104	”	_	
25-15	4105-4109	less	_	
25-16	4110-4119	attention	_	
25-17	4120-4123	has	_	
25-18	4124-4128	been	_	
25-19	4129-4137	directed	_	
25-20	4138-4140	to	_	
25-21	4141-4144	the	_	
25-22	4145-4152	illicit	_	
25-23	4153-4156	use	_	
25-24	4157-4159	of	_	
25-25	4160-4165	drugs	_	
25-26	4166-4170	such	_	
25-27	4171-4173	as	_	
25-28	4174-4177	CCS	_	
25-29	4177-4178	.	_	

#Text=The rapid development of neuroimaging techniques has provided many new methods for the detection of early changes in the brain in several neuropsychological diseases.
26-1	4179-4182	The	_	
26-2	4183-4188	rapid	_	
26-3	4189-4200	development	_	
26-4	4201-4203	of	_	
26-5	4204-4216	neuroimaging	_	
26-6	4217-4227	techniques	_	
26-7	4228-4231	has	_	
26-8	4232-4240	provided	_	
26-9	4241-4245	many	_	
26-10	4246-4249	new	_	
26-11	4250-4257	methods	_	
26-12	4258-4261	for	_	
26-13	4262-4265	the	_	
26-14	4266-4275	detection	_	
26-15	4276-4278	of	_	
26-16	4279-4284	early	_	
26-17	4285-4292	changes	_	
26-18	4293-4295	in	_	
26-19	4296-4299	the	_	
26-20	4300-4305	brain	_	
26-21	4306-4308	in	_	
26-22	4309-4316	several	_	
26-23	4317-4335	neuropsychological	_	
26-24	4336-4344	diseases	_	
26-25	4344-4345	.	_	

#Text=Diffusion-tensor imaging (DTI), a non-invasive tool for probing the microanatomical organization of human brain white matter (WM) in vivo, has been used to investigate the properties of WM in CCS-dependent individuals.
27-1	4346-4362	Diffusion-tensor	_	
27-2	4363-4370	imaging	_	
27-3	4371-4372	(	_	
27-4	4372-4375	DTI	_	
27-5	4375-4376	)	_	
27-6	4376-4377	,	_	
27-7	4378-4379	a	_	
27-8	4380-4392	non-invasive	_	
27-9	4393-4397	tool	_	
27-10	4398-4401	for	_	
27-11	4402-4409	probing	_	
27-12	4410-4413	the	_	
27-13	4414-4429	microanatomical	_	
27-14	4430-4442	organization	_	
27-15	4443-4445	of	_	
27-16	4446-4451	human	_	
27-17	4452-4457	brain	_	
27-18	4458-4463	white	_	
27-19	4464-4470	matter	_	
27-20	4471-4472	(	_	
27-21	4472-4474	WM	_	
27-22	4474-4475	)	_	
27-23	4476-4478	in	_	
27-24	4479-4483	vivo	_	
27-25	4483-4484	,	_	
27-26	4485-4488	has	_	
27-27	4489-4493	been	_	
27-28	4494-4498	used	_	
27-29	4499-4501	to	_	
27-30	4502-4513	investigate	_	
27-31	4514-4517	the	_	
27-32	4518-4528	properties	_	
27-33	4529-4531	of	_	
27-34	4532-4534	WM	_	
27-35	4535-4537	in	_	
27-36	4538-4551	CCS-dependent	_	
27-37	4552-4563	individuals	_	
27-38	4563-4564	.	_	

#Text=Positron-emission tomography (PET) has also been employed for examining the drug-addicted individuals. found that the perfusion of the orbitofrontal region, the occipital, and the temporal lobes was decreased in heroin addicts; these regions were responsible for the control of attention, motor speed, memory, and visual-spatial processing. demonstrated that the metabolic responses of the right medial orbital prefrontal cortex significantly increased in cocaine-addicted subjects. used the regional homogeneity (ReHo) analysis method and found that ReHo was diminished in the bilateral medial orbitofrontal cortex (mOFC) and the left dorsal striatum in CCS-dependent individuals.
28-1	4565-4582	Positron-emission	_	
28-2	4583-4593	tomography	_	
28-3	4594-4595	(	_	
28-4	4595-4598	PET	_	
28-5	4598-4599	)	_	
28-6	4600-4603	has	_	
28-7	4604-4608	also	_	
28-8	4609-4613	been	_	
28-9	4614-4622	employed	_	
28-10	4623-4626	for	_	
28-11	4627-4636	examining	_	
28-12	4637-4640	the	_	
28-13	4641-4654	drug-addicted	_	
28-14	4655-4666	individuals	_	
28-15	4666-4667	.	_	
28-16	4668-4673	found	_	
28-17	4674-4678	that	_	
28-18	4679-4682	the	_	
28-19	4683-4692	perfusion	_	
28-20	4693-4695	of	_	
28-21	4696-4699	the	_	
28-22	4700-4713	orbitofrontal	_	
28-23	4714-4720	region	_	
28-24	4720-4721	,	_	
28-25	4722-4725	the	_	
28-26	4726-4735	occipital	_	
28-27	4735-4736	,	_	
28-28	4737-4740	and	_	
28-29	4741-4744	the	_	
28-30	4745-4753	temporal	_	
28-31	4754-4759	lobes	_	
28-32	4760-4763	was	_	
28-33	4764-4773	decreased	_	
28-34	4774-4776	in	_	
28-35	4777-4783	heroin	_	
28-36	4784-4791	addicts	_	
28-37	4791-4792	;	_	
28-38	4793-4798	these	_	
28-39	4799-4806	regions	_	
28-40	4807-4811	were	_	
28-41	4812-4823	responsible	_	
28-42	4824-4827	for	_	
28-43	4828-4831	the	_	
28-44	4832-4839	control	_	
28-45	4840-4842	of	_	
28-46	4843-4852	attention	_	
28-47	4852-4853	,	_	
28-48	4854-4859	motor	_	
28-49	4860-4865	speed	_	
28-50	4865-4866	,	_	
28-51	4867-4873	memory	_	
28-52	4873-4874	,	_	
28-53	4875-4878	and	_	
28-54	4879-4893	visual-spatial	_	
28-55	4894-4904	processing	_	
28-56	4904-4905	.	_	
28-57	4906-4918	demonstrated	_	
28-58	4919-4923	that	_	
28-59	4924-4927	the	_	
28-60	4928-4937	metabolic	_	
28-61	4938-4947	responses	_	
28-62	4948-4950	of	_	
28-63	4951-4954	the	_	
28-64	4955-4960	right	_	
28-65	4961-4967	medial	_	
28-66	4968-4975	orbital	_	
28-67	4976-4986	prefrontal	_	
28-68	4987-4993	cortex	_	
28-69	4994-5007	significantly	_	
28-70	5008-5017	increased	_	
28-71	5018-5020	in	_	
28-72	5021-5037	cocaine-addicted	_	
28-73	5038-5046	subjects	_	
28-74	5046-5047	.	_	
28-75	5048-5052	used	_	
28-76	5053-5056	the	_	
28-77	5057-5065	regional	_	
28-78	5066-5077	homogeneity	_	
28-79	5078-5079	(	_	
28-80	5079-5083	ReHo	_	
28-81	5083-5084	)	_	
28-82	5085-5093	analysis	_	
28-83	5094-5100	method	_	
28-84	5101-5104	and	_	
28-85	5105-5110	found	_	
28-86	5111-5115	that	_	
28-87	5116-5120	ReHo	_	
28-88	5121-5124	was	_	
28-89	5125-5135	diminished	_	
28-90	5136-5138	in	_	
28-91	5139-5142	the	_	
28-92	5143-5152	bilateral	_	
28-93	5153-5159	medial	_	
28-94	5160-5173	orbitofrontal	_	
28-95	5174-5180	cortex	_	
28-96	5181-5182	(	_	
28-97	5182-5186	mOFC	_	
28-98	5186-5187	)	_	
28-99	5188-5191	and	_	
28-100	5192-5195	the	_	
28-101	5196-5200	left	_	
28-102	5201-5207	dorsal	_	
28-103	5208-5216	striatum	_	
28-104	5217-5219	in	_	
28-105	5220-5233	CCS-dependent	_	
28-106	5234-5245	individuals	_	
28-107	5245-5246	.	_	

#Text=These abnormalities were speculated to be related to the dysfunction of learning and memory in CCS-dependent individuals.
29-1	5247-5252	These	_	
29-2	5253-5266	abnormalities	_	
29-3	5267-5271	were	_	
29-4	5272-5282	speculated	_	
29-5	5283-5285	to	_	
29-6	5286-5288	be	_	
29-7	5289-5296	related	_	
29-8	5297-5299	to	_	
29-9	5300-5303	the	_	
29-10	5304-5315	dysfunction	_	
29-11	5316-5318	of	_	
29-12	5319-5327	learning	_	
29-13	5328-5331	and	_	
29-14	5332-5338	memory	_	
29-15	5339-5341	in	_	
29-16	5342-5355	CCS-dependent	_	
29-17	5356-5367	individuals	_	
29-18	5367-5368	.	_	

#Text=Using the voxel-based morphometry (VBM) analysis method, also found significantly decreased grey matter (GM) volume in CCS users in the bilateral ventral medial prefrontal cortex (vmPFC).
30-1	5369-5374	Using	_	
30-2	5375-5378	the	_	
30-3	5379-5390	voxel-based	_	
30-4	5391-5402	morphometry	_	
30-5	5403-5404	(	_	
30-6	5404-5407	VBM	_	
30-7	5407-5408	)	_	
30-8	5409-5417	analysis	_	
30-9	5418-5424	method	_	
30-10	5424-5425	,	_	
30-11	5426-5430	also	_	
30-12	5431-5436	found	_	
30-13	5437-5450	significantly	_	
30-14	5451-5460	decreased	_	
30-15	5461-5465	grey	_	
30-16	5466-5472	matter	_	
30-17	5473-5474	(	_	
30-18	5474-5476	GM	_	
30-19	5476-5477	)	_	
30-20	5478-5484	volume	_	
30-21	5485-5487	in	_	
30-22	5488-5491	CCS	_	
30-23	5492-5497	users	_	
30-24	5498-5500	in	_	
30-25	5501-5504	the	_	
30-26	5505-5514	bilateral	_	
30-27	5515-5522	ventral	_	
30-28	5523-5529	medial	_	
30-29	5530-5540	prefrontal	_	
30-30	5541-5547	cortex	_	
30-31	5548-5549	(	_	
30-32	5549-5554	vmPFC	_	
30-33	5554-5555	)	_	
30-34	5555-5556	.	_	

#Text=The study further explored the changes in spontaneous functional connectivity of the vmPFC-related circuitry and observed reduced integration in CCS users between the bilateral vmPFC and the bilateral hippocampal complex and between the bilateral vmPFC and the bilateral inferior parietal lobule (IPL).
31-1	5557-5560	The	_	
31-2	5561-5566	study	_	
31-3	5567-5574	further	_	
31-4	5575-5583	explored	_	
31-5	5584-5587	the	_	
31-6	5588-5595	changes	_	
31-7	5596-5598	in	_	
31-8	5599-5610	spontaneous	_	
31-9	5611-5621	functional	_	
31-10	5622-5634	connectivity	_	
31-11	5635-5637	of	_	
31-12	5638-5641	the	_	
31-13	5642-5655	vmPFC-related	_	
31-14	5656-5665	circuitry	_	
31-15	5666-5669	and	_	
31-16	5670-5678	observed	_	
31-17	5679-5686	reduced	_	
31-18	5687-5698	integration	_	
31-19	5699-5701	in	_	
31-20	5702-5705	CCS	_	
31-21	5706-5711	users	_	
31-22	5712-5719	between	_	
31-23	5720-5723	the	_	
31-24	5724-5733	bilateral	_	
31-25	5734-5739	vmPFC	_	
31-26	5740-5743	and	_	
31-27	5744-5747	the	_	
31-28	5748-5757	bilateral	_	
31-29	5758-5769	hippocampal	_	
31-30	5770-5777	complex	_	
31-31	5778-5781	and	_	
31-32	5782-5789	between	_	
31-33	5790-5793	the	_	
31-34	5794-5803	bilateral	_	
31-35	5804-5809	vmPFC	_	
31-36	5810-5813	and	_	
31-37	5814-5817	the	_	
31-38	5818-5827	bilateral	_	
31-39	5828-5836	inferior	_	
31-40	5837-5845	parietal	_	
31-41	5846-5852	lobule	_	
31-42	5853-5854	(	_	
31-43	5854-5857	IPL	_	
31-44	5857-5858	)	_	
31-45	5858-5859	.	_	

#Text=Enhanced functional connectivity was observed in CCS users between the bilateral vmPFC and the right insula (extending to the right dorsal striatum) and between the bilateral vmPFC and the right dorsolateral prefrontal cortex (dlPFC).
32-1	5860-5868	Enhanced	_	
32-2	5869-5879	functional	_	
32-3	5880-5892	connectivity	_	
32-4	5893-5896	was	_	
32-5	5897-5905	observed	_	
32-6	5906-5908	in	_	
32-7	5909-5912	CCS	_	
32-8	5913-5918	users	_	
32-9	5919-5926	between	_	
32-10	5927-5930	the	_	
32-11	5931-5940	bilateral	_	
32-12	5941-5946	vmPFC	_	
32-13	5947-5950	and	_	
32-14	5951-5954	the	_	
32-15	5955-5960	right	_	
32-16	5961-5967	insula	_	
32-17	5968-5969	(	_	
32-18	5969-5978	extending	_	
32-19	5979-5981	to	_	
32-20	5982-5985	the	_	
32-21	5986-5991	right	_	
32-22	5992-5998	dorsal	_	
32-23	5999-6007	striatum	_	
32-24	6007-6008	)	_	
32-25	6009-6012	and	_	
32-26	6013-6020	between	_	
32-27	6021-6024	the	_	
32-28	6025-6034	bilateral	_	
32-29	6035-6040	vmPFC	_	
32-30	6041-6044	and	_	
32-31	6045-6048	the	_	
32-32	6049-6054	right	_	
32-33	6055-6067	dorsolateral	_	
32-34	6068-6078	prefrontal	_	
32-35	6079-6085	cortex	_	
32-36	6086-6087	(	_	
32-37	6087-6092	dlPFC	_	
32-38	6092-6093	)	_	
32-39	6093-6094	.	_	

#Text=These results implied that the vmPFC plays a major role in chronic CCS abuse that might lead to disordered impulsive control.
33-1	6095-6100	These	_	
33-2	6101-6108	results	_	
33-3	6109-6116	implied	_	
33-4	6117-6121	that	_	
33-5	6122-6125	the	_	
33-6	6126-6131	vmPFC	_	
33-7	6132-6137	plays	_	
33-8	6138-6139	a	_	
33-9	6140-6145	major	_	
33-10	6146-6150	role	_	
33-11	6151-6153	in	_	
33-12	6154-6161	chronic	_	
33-13	6162-6165	CCS	_	
33-14	6166-6171	abuse	_	
33-15	6172-6176	that	_	
33-16	6177-6182	might	_	
33-17	6183-6187	lead	_	
33-18	6188-6190	to	_	
33-19	6191-6201	disordered	_	
33-20	6202-6211	impulsive	_	
33-21	6212-6219	control	_	
33-22	6219-6220	.	_	

#Text=Using independent component analysis (ICA), investigated the intrinsic brain network abnormalities in CCS-dependent males via resting-state fMRI (rs-fMRI).
34-1	6221-6226	Using	_	
34-2	6227-6238	independent	_	
34-3	6239-6248	component	_	
34-4	6249-6257	analysis	_	
34-5	6258-6259	(	_	
34-6	6259-6262	ICA	_	
34-7	6262-6263	)	_	
34-8	6263-6264	,	_	
34-9	6265-6277	investigated	_	
34-10	6278-6281	the	_	
34-11	6282-6291	intrinsic	_	
34-12	6292-6297	brain	_	
34-13	6298-6305	network	_	
34-14	6306-6319	abnormalities	_	
34-15	6320-6322	in	_	
34-16	6323-6336	CCS-dependent	_	
34-17	6337-6342	males	_	
34-18	6343-6346	via	_	
34-19	6347-6360	resting-state	_	
34-20	6361-6365	fMRI	_	
34-21	6366-6367	(	_	
34-22	6367-6374	rs-fMRI	_	
34-23	6374-6375	)	_	
34-24	6375-6376	.	_	

#Text=Compared to the healthy control group, the CCS-dependent individuals presented aberrant intrinsic connectivity within the default mode network (DMN), executive control network (ECN), and salience network (SN) (P < 0.05, AlphaSim corrected).
35-1	6377-6385	Compared	_	
35-2	6386-6388	to	_	
35-3	6389-6392	the	_	
35-4	6393-6400	healthy	_	
35-5	6401-6408	control	_	
35-6	6409-6414	group	_	
35-7	6414-6415	,	_	
35-8	6416-6419	the	_	
35-9	6420-6433	CCS-dependent	_	
35-10	6434-6445	individuals	_	
35-11	6446-6455	presented	_	
35-12	6456-6464	aberrant	_	
35-13	6465-6474	intrinsic	_	
35-14	6475-6487	connectivity	_	
35-15	6488-6494	within	_	
35-16	6495-6498	the	_	
35-17	6499-6506	default	_	
35-18	6507-6511	mode	_	
35-19	6512-6519	network	_	
35-20	6520-6521	(	_	
35-21	6521-6524	DMN	_	
35-22	6524-6525	)	_	
35-23	6525-6526	,	_	
35-24	6527-6536	executive	_	
35-25	6537-6544	control	_	
35-26	6545-6552	network	_	
35-27	6553-6554	(	_	
35-28	6554-6557	ECN	_	
35-29	6557-6558	)	_	
35-30	6558-6559	,	_	
35-31	6560-6563	and	_	
35-32	6564-6572	salience	_	
35-33	6573-6580	network	_	
35-34	6581-6582	(	_	
35-35	6582-6584	SN	_	
35-36	6584-6585	)	_	
35-37	6586-6587	(	_	
35-38	6587-6588	P	_	
35-39	6588-6589	 	_	
35-40	6589-6590	<	_	
35-41	6590-6591	 	_	
35-42	6591-6595	0.05	_	
35-43	6595-6596	,	_	
35-44	6597-6605	AlphaSim	_	
35-45	6606-6615	corrected	_	
35-46	6615-6616	)	_	
35-47	6616-6617	.	_	

#Text=However, the limitations of the study included the spontaneous functional connectivity of abnormal brain regions in a subnet of individuals.
36-1	6618-6625	However	_	
36-2	6625-6626	,	_	
36-3	6627-6630	the	_	
36-4	6631-6642	limitations	_	
36-5	6643-6645	of	_	
36-6	6646-6649	the	_	
36-7	6650-6655	study	_	
36-8	6656-6664	included	_	
36-9	6665-6668	the	_	
36-10	6669-6680	spontaneous	_	
36-11	6681-6691	functional	_	
36-12	6692-6704	connectivity	_	
36-13	6705-6707	of	_	
36-14	6708-6716	abnormal	_	
36-15	6717-6722	brain	_	
36-16	6723-6730	regions	_	
36-17	6731-6733	in	_	
36-18	6734-6735	a	_	
36-19	6736-6742	subnet	_	
36-20	6743-6745	of	_	
36-21	6746-6757	individuals	_	
36-22	6757-6758	.	_	

#Text=In addition, the spontaneous functional connectivity of abnormal brain regions in the whole-brain network is unknown.
37-1	6759-6761	In	_	
37-2	6762-6770	addition	_	
37-3	6770-6771	,	_	
37-4	6772-6775	the	_	
37-5	6776-6787	spontaneous	_	
37-6	6788-6798	functional	_	
37-7	6799-6811	connectivity	_	
37-8	6812-6814	of	_	
37-9	6815-6823	abnormal	_	
37-10	6824-6829	brain	_	
37-11	6830-6837	regions	_	
37-12	6838-6840	in	_	
37-13	6841-6844	the	_	
37-14	6845-6856	whole-brain	_	
37-15	6857-6864	network	_	
37-16	6865-6867	is	_	
37-17	6868-6875	unknown	_	
37-18	6875-6876	.	_	

#Text=Among the graph-based methods, DC is recently gaining attention.
38-1	6877-6882	Among	_	
38-2	6883-6886	the	_	
38-3	6887-6898	graph-based	_	
38-4	6899-6906	methods	_	
38-5	6906-6907	,	_	
38-6	6908-6910	DC	_	
38-7	6911-6913	is	_	
38-8	6914-6922	recently	_	
38-9	6923-6930	gaining	_	
38-10	6931-6940	attention	_	
38-11	6940-6941	.	_	

#Text=It counts the number of direct connections for a given voxel in a network and reflects the functional connectivity within the brain network.
39-1	6942-6944	It	_	
39-2	6945-6951	counts	_	
39-3	6952-6955	the	_	
39-4	6956-6962	number	_	
39-5	6963-6965	of	_	
39-6	6966-6972	direct	_	
39-7	6973-6984	connections	_	
39-8	6985-6988	for	_	
39-9	6989-6990	a	_	
39-10	6991-6996	given	_	
39-11	6997-7002	voxel	_	
39-12	7003-7005	in	_	
39-13	7006-7007	a	_	
39-14	7008-7015	network	_	
39-15	7016-7019	and	_	
39-16	7020-7028	reflects	_	
39-17	7029-7032	the	_	
39-18	7033-7043	functional	_	
39-19	7044-7056	connectivity	_	
39-20	7057-7063	within	_	
39-21	7064-7067	the	_	
39-22	7068-7073	brain	_	
39-23	7074-7081	network	_	
39-24	7081-7082	.	_	

#Text=It is one of the more reliable and compelling measures among several nodal network metrics and measures the centrality or importance of individual elements in the brain (for example, brain regions) by capturing their relationships with the entire brain network at the voxel level.
40-1	7083-7085	It	_	
40-2	7086-7088	is	_	
40-3	7089-7092	one	_	
40-4	7093-7095	of	_	
40-5	7096-7099	the	_	
40-6	7100-7104	more	_	
40-7	7105-7113	reliable	_	
40-8	7114-7117	and	_	
40-9	7118-7128	compelling	_	
40-10	7129-7137	measures	_	
40-11	7138-7143	among	_	
40-12	7144-7151	several	_	
40-13	7152-7157	nodal	_	
40-14	7158-7165	network	_	
40-15	7166-7173	metrics	_	
40-16	7174-7177	and	_	
40-17	7178-7186	measures	_	
40-18	7187-7190	the	_	
40-19	7191-7201	centrality	_	
40-20	7202-7204	or	_	
40-21	7205-7215	importance	_	
40-22	7216-7218	of	_	
40-23	7219-7229	individual	_	
40-24	7230-7238	elements	_	
40-25	7239-7241	in	_	
40-26	7242-7245	the	_	
40-27	7246-7251	brain	_	
40-28	7252-7253	(	_	
40-29	7253-7256	for	_	
40-30	7257-7264	example	_	
40-31	7264-7265	,	_	
40-32	7266-7271	brain	_	
40-33	7272-7279	regions	_	
40-34	7279-7280	)	_	
40-35	7281-7283	by	_	
40-36	7284-7293	capturing	_	
40-37	7294-7299	their	_	
40-38	7300-7313	relationships	_	
40-39	7314-7318	with	_	
40-40	7319-7322	the	_	
40-41	7323-7329	entire	_	
40-42	7330-7335	brain	_	
40-43	7336-7343	network	_	
40-44	7344-7346	at	_	
40-45	7347-7350	the	_	
40-46	7351-7356	voxel	_	
40-47	7357-7362	level	_	
40-48	7362-7363	.	_	

#Text=Furthermore, DC has been used in several studies where the dorsal and ventral precuneus, anterior and posterior cingulate gyrus, ventromedial prefrontal cortex, and inferior parietal lobes showed high DC values in normal individuals, which was found to be in agreement with DMN.
41-1	7364-7375	Furthermore	_	
41-2	7375-7376	,	_	
41-3	7377-7379	DC	_	
41-4	7380-7383	has	_	
41-5	7384-7388	been	_	
41-6	7389-7393	used	_	
41-7	7394-7396	in	_	
41-8	7397-7404	several	_	
41-9	7405-7412	studies	_	
41-10	7413-7418	where	_	
41-11	7419-7422	the	_	
41-12	7423-7429	dorsal	_	
41-13	7430-7433	and	_	
41-14	7434-7441	ventral	_	
41-15	7442-7451	precuneus	_	
41-16	7451-7452	,	_	
41-17	7453-7461	anterior	_	
41-18	7462-7465	and	_	
41-19	7466-7475	posterior	_	
41-20	7476-7485	cingulate	_	
41-21	7486-7491	gyrus	_	
41-22	7491-7492	,	_	
41-23	7493-7505	ventromedial	_	
41-24	7506-7516	prefrontal	_	
41-25	7517-7523	cortex	_	
41-26	7523-7524	,	_	
41-27	7525-7528	and	_	
41-28	7529-7537	inferior	_	
41-29	7538-7546	parietal	_	
41-30	7547-7552	lobes	_	
41-31	7553-7559	showed	_	
41-32	7560-7564	high	_	
41-33	7565-7567	DC	_	
41-34	7568-7574	values	_	
41-35	7575-7577	in	_	
41-36	7578-7584	normal	_	
41-37	7585-7596	individuals	_	
41-38	7596-7597	,	_	
41-39	7598-7603	which	_	
41-40	7604-7607	was	_	
41-41	7608-7613	found	_	
41-42	7614-7616	to	_	
41-43	7617-7619	be	_	
41-44	7620-7622	in	_	
41-45	7623-7632	agreement	_	
41-46	7633-7637	with	_	
41-47	7638-7641	DMN	_	
41-48	7641-7642	.	_	

#Text=Voxel-wise centrality maps provided novel insights into the patterns and complexity of functional connectivity throughout the huge human functional network that has been widely used in brain network studies.
42-1	7643-7653	Voxel-wise	_	
42-2	7654-7664	centrality	_	
42-3	7665-7669	maps	_	
42-4	7670-7678	provided	_	
42-5	7679-7684	novel	_	
42-6	7685-7693	insights	_	
42-7	7694-7698	into	_	
42-8	7699-7702	the	_	
42-9	7703-7711	patterns	_	
42-10	7712-7715	and	_	
42-11	7716-7726	complexity	_	
42-12	7727-7729	of	_	
42-13	7730-7740	functional	_	
42-14	7741-7753	connectivity	_	
42-15	7754-7764	throughout	_	
42-16	7765-7768	the	_	
42-17	7769-7773	huge	_	
42-18	7774-7779	human	_	
42-19	7780-7790	functional	_	
42-20	7791-7798	network	_	
42-21	7799-7803	that	_	
42-22	7804-7807	has	_	
42-23	7808-7812	been	_	
42-24	7813-7819	widely	_	
42-25	7820-7824	used	_	
42-26	7825-7827	in	_	
42-27	7828-7833	brain	_	
42-28	7834-7841	network	_	
42-29	7842-7849	studies	_	
42-30	7849-7850	.	_	

#Text=In the other studies, the DC measure was not calculated in CCS-dependent individuals.
43-1	7851-7853	In	_	
43-2	7854-7857	the	_	
43-3	7858-7863	other	_	
43-4	7864-7871	studies	_	
43-5	7871-7872	,	_	
43-6	7873-7876	the	_	
43-7	7877-7879	DC	_	
43-8	7880-7887	measure	_	
43-9	7888-7891	was	_	
43-10	7892-7895	not	_	
43-11	7896-7906	calculated	_	
43-12	7907-7909	in	_	
43-13	7910-7923	CCS-dependent	_	
43-14	7924-7935	individuals	_	
43-15	7935-7936	.	_	

#Text=However, the analysis level in the present study using DC is based on voxels.
44-1	7937-7944	However	_	
44-2	7944-7945	,	_	
44-3	7946-7949	the	_	
44-4	7950-7958	analysis	_	
44-5	7959-7964	level	_	
44-6	7965-7967	in	_	
44-7	7968-7971	the	_	
44-8	7972-7979	present	_	
44-9	7980-7985	study	_	
44-10	7986-7991	using	_	
44-11	7992-7994	DC	_	
44-12	7995-7997	is	_	
44-13	7998-8003	based	_	
44-14	8004-8006	on	_	
44-15	8007-8013	voxels	_	
44-16	8013-8014	.	_	

#Text=Therefore, the present study aimed to depict the intrinsic dysconnectivity pattern of whole-brain functional networks at the voxel level, focusing on network architecture, in CCS-dependent individuals.
45-1	8015-8024	Therefore	_	
45-2	8024-8025	,	_	
45-3	8026-8029	the	_	
45-4	8030-8037	present	_	
45-5	8038-8043	study	_	
45-6	8044-8049	aimed	_	
45-7	8050-8052	to	_	
45-8	8053-8059	depict	_	
45-9	8060-8063	the	_	
45-10	8064-8073	intrinsic	_	
45-11	8074-8089	dysconnectivity	_	
45-12	8090-8097	pattern	_	
45-13	8098-8100	of	_	
45-14	8101-8112	whole-brain	_	
45-15	8113-8123	functional	_	
45-16	8124-8132	networks	_	
45-17	8133-8135	at	_	
45-18	8136-8139	the	_	
45-19	8140-8145	voxel	_	
45-20	8146-8151	level	_	
45-21	8151-8152	,	_	
45-22	8153-8161	focusing	_	
45-23	8162-8164	on	_	
45-24	8165-8172	network	_	
45-25	8173-8185	architecture	_	
45-26	8185-8186	,	_	
45-27	8187-8189	in	_	
45-28	8190-8203	CCS-dependent	_	
45-29	8204-8215	individuals	_	
45-30	8215-8216	.	_	

#Text=In addition, we also correlated the DC changes to the BIS-11 total score, dose, duration and the age at first use of CCS.
46-1	8217-8219	In	_	
46-2	8220-8228	addition	_	
46-3	8228-8229	,	_	
46-4	8230-8232	we	_	
46-5	8233-8237	also	_	
46-6	8238-8248	correlated	_	
46-7	8249-8252	the	_	
46-8	8253-8255	DC	_	
46-9	8256-8263	changes	_	
46-10	8264-8266	to	_	
46-11	8267-8270	the	_	
46-12	8271-8274	BIS	_	
46-13	8274-8275	-	_	
46-14	8275-8277	11	_	
46-15	8278-8283	total	_	
46-16	8284-8289	score	_	
46-17	8289-8290	,	_	
46-18	8291-8295	dose	_	
46-19	8295-8296	,	_	
46-20	8297-8305	duration	_	
46-21	8306-8309	and	_	
46-22	8310-8313	the	_	
46-23	8314-8317	age	_	
46-24	8318-8320	at	_	
46-25	8321-8326	first	_	
46-26	8327-8330	use	_	
46-27	8331-8333	of	_	
46-28	8334-8337	CCS	_	
46-29	8337-8338	.	_	

#Text=Therefore, we speculated that in CCS-dependent individuals, abnormal activity of some brain regions associated with learning, memory, and executive control might exist.
47-1	8339-8348	Therefore	_	
47-2	8348-8349	,	_	
47-3	8350-8352	we	_	
47-4	8353-8363	speculated	_	
47-5	8364-8368	that	_	
47-6	8369-8371	in	_	
47-7	8372-8385	CCS-dependent	_	
47-8	8386-8397	individuals	_	
47-9	8397-8398	,	_	
47-10	8399-8407	abnormal	_	
47-11	8408-8416	activity	_	
47-12	8417-8419	of	_	
47-13	8420-8424	some	_	
47-14	8425-8430	brain	_	
47-15	8431-8438	regions	_	
47-16	8439-8449	associated	_	
47-17	8450-8454	with	_	
47-18	8455-8463	learning	_	
47-19	8463-8464	,	_	
47-20	8465-8471	memory	_	
47-21	8471-8472	,	_	
47-22	8473-8476	and	_	
47-23	8477-8486	executive	_	
47-24	8487-8494	control	_	
47-25	8495-8500	might	_	
47-26	8501-8506	exist	_	
47-27	8506-8507	.	_	

#Text=The potential brain changes in impaired cognition provided an in-depth insight of the level of functional integration.
48-1	8508-8511	The	_	
48-2	8512-8521	potential	_	
48-3	8522-8527	brain	_	
48-4	8528-8535	changes	_	
48-5	8536-8538	in	_	
48-6	8539-8547	impaired	_	
48-7	8548-8557	cognition	_	
48-8	8558-8566	provided	_	
48-9	8567-8569	an	_	
48-10	8570-8578	in-depth	_	
48-11	8579-8586	insight	_	
48-12	8587-8589	of	_	
48-13	8590-8593	the	_	
48-14	8594-8599	level	_	
48-15	8600-8602	of	_	
48-16	8603-8613	functional	_	
48-17	8614-8625	integration	_	
48-18	8625-8626	.	_	

#Text=Materials and methods
#Text=Participants
#Text=This prospective study was approved by the Ethics Committee of Guangdong Second Provincial General Hospital.
49-1	8627-8636	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]	
49-2	8637-8640	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]	
49-3	8641-8648	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[7]	
49-4	8649-8661	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-5	8662-8666	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-6	8667-8678	prospective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-7	8679-8684	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-8	8685-8688	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-9	8689-8697	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-10	8698-8700	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-11	8701-8704	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-12	8705-8711	Ethics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-13	8712-8721	Committee	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-14	8722-8724	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-15	8725-8734	Guangdong	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-16	8735-8741	Second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-17	8742-8752	Provincial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-18	8753-8760	General	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-19	8761-8769	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
49-20	8769-8770	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=Written informed consent was obtained from all subjects.
50-1	8771-8778	Written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
50-2	8779-8787	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
50-3	8788-8795	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
50-4	8796-8799	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
50-5	8800-8808	obtained	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
50-6	8809-8813	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
50-7	8814-8817	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
50-8	8818-8826	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	
50-9	8826-8827	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[8]	

#Text=A total of 72 right-handed participants, including 34 control subjects and 38 CCS-dependent individuals, were enrolled in this study.
51-1	8828-8829	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-2	8830-8835	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-3	8836-8838	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-4	8839-8841	72	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-5	8842-8854	right-handed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-6	8855-8867	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-7	8867-8868	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-8	8869-8878	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-9	8879-8881	34	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-10	8882-8889	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
51-11	8890-8898	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[10]	
51-12	8899-8902	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-13	8903-8905	38	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-14	8906-8919	CCS-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus[11]	
51-15	8920-8931	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus[11]	
51-16	8931-8932	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-17	8933-8937	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-18	8938-8946	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-19	8947-8949	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-20	8950-8954	this	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-21	8955-8960	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
51-22	8960-8961	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=The CCS-dependent individuals were recruited from the patients seeking treatment at the Addiction Medicine Division of the Guangdong Second Provincial General Hospital.
52-1	8962-8965	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-2	8966-8979	CCS-dependent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus[12]	
52-3	8980-8991	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus[12]	
52-4	8992-8996	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-5	8997-9006	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-6	9007-9011	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-7	9012-9015	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-8	9016-9024	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-9	9025-9032	seeking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-10	9033-9042	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-11	9043-9045	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-12	9046-9049	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-13	9050-9059	Addiction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-14	9060-9068	Medicine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-15	9069-9077	Division	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-16	9078-9080	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-17	9081-9084	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-18	9085-9094	Guangdong	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-19	9095-9101	Second	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-20	9102-9112	Provincial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-21	9113-9120	General	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-22	9121-9129	Hospital	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
52-23	9129-9130	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=All the patients were screened based on the DSM-IV criteria from medical history and underwent a urine test and an interview on the same day.
53-1	9131-9134	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-2	9135-9138	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-3	9139-9147	patients	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-4	9148-9152	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-5	9153-9161	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-6	9162-9167	based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-7	9168-9170	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-8	9171-9174	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-9	9175-9181	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-10	9182-9190	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-11	9191-9195	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-12	9196-9203	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-13	9204-9211	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-14	9212-9215	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-15	9216-9225	underwent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-16	9226-9227	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-17	9228-9233	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-18	9234-9238	test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-19	9239-9242	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-20	9243-9245	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-21	9246-9255	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-22	9256-9258	on	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-23	9259-9262	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-24	9263-9267	same	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-25	9268-9271	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
53-26	9271-9272	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=All participants regularly smoked cigarettes but did not use any type of psychotropic agents prior to the rs-fMRI scan.
54-1	9273-9276	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-2	9277-9289	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-3	9290-9299	regularly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-4	9300-9306	smoked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-5	9307-9317	cigarettes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-6	9318-9321	but	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-7	9322-9325	did	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-8	9326-9329	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-9	9330-9333	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-10	9334-9337	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-11	9338-9342	type	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-12	9343-9345	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-13	9346-9358	psychotropic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-14	9359-9365	agents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-15	9366-9371	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-16	9372-9374	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-17	9375-9378	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	
54-18	9379-9386	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[14]	
54-19	9387-9391	scan	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]|http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[14]	
54-20	9391-9392	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[13]	

#Text=The exclusion criteria for all participants included central nervous system diseases, schizophrenia, bipolar disorder, prior significant head trauma, positive human immunodeficiency virus (HIV) status, diabetes, hepatitis C, other major medical illness, and left-handedness.
55-1	9393-9396	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-2	9397-9406	exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-3	9407-9415	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-4	9416-9419	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-5	9420-9423	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-6	9424-9436	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-7	9437-9445	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-8	9446-9453	central	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-9	9454-9461	nervous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-10	9462-9468	system	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-11	9469-9477	diseases	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-12	9477-9478	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-13	9479-9492	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-14	9492-9493	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-15	9494-9501	bipolar	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-16	9502-9510	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-17	9510-9511	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-18	9512-9517	prior	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-19	9518-9529	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-20	9530-9534	head	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-21	9535-9541	trauma	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-22	9541-9542	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-23	9543-9551	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-24	9552-9557	human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-25	9558-9574	immunodeficiency	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-26	9575-9580	virus	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-27	9581-9582	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-28	9582-9585	HIV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-29	9585-9586	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-30	9587-9593	status	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-31	9593-9594	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-32	9595-9603	diabetes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-33	9603-9604	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-34	9605-9614	hepatitis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-35	9615-9616	C	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-36	9616-9617	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-37	9618-9623	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-38	9624-9629	major	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-39	9630-9637	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-40	9638-9645	illness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-41	9645-9646	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-42	9647-9650	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-43	9651-9666	left-handedness	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
55-44	9666-9667	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=The inclusion criteria for the control subjects was the absence of diagnosis of any type of substance abuse or dependence.
56-1	9668-9671	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-2	9672-9681	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-3	9682-9690	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-4	9691-9694	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-5	9695-9698	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-6	9699-9706	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-7	9707-9715	subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-8	9716-9719	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-9	9720-9723	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-10	9724-9731	absence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-11	9732-9734	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-12	9735-9744	diagnosis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-13	9745-9747	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-14	9748-9751	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-15	9752-9756	type	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-16	9757-9759	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-17	9760-9769	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-18	9770-9775	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-19	9776-9778	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-20	9779-9789	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
56-21	9789-9790	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=Impulsivity assessment
#Text=BIS-11 was used for assessing the impulsivity.
57-1	9791-9802	Impulsivity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[16]	
57-2	9803-9813	assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[16]	
57-3	9814-9817	BIS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[16]	
57-4	9817-9818	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[16]	
57-5	9818-9820	11	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]|http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[16]	
57-6	9821-9824	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-7	9825-9829	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-8	9830-9833	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-9	9834-9843	assessing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-10	9844-9847	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-11	9848-9859	impulsivity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-12	9859-9860	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	

#Text=This 30-item self-rated scale has three oblique factors: attentional/cognitive that measures the toleration for cognitive complexity and persistence; motor that estimates the tendency to act on the spur of the moment; and non-planning impulsivity, which evaluates the lack of sense of the future.
58-1	9861-9865	This	_	
58-2	9866-9868	30	_	
58-3	9868-9869	-	_	
58-4	9869-9873	item	_	
58-5	9874-9884	self-rated	_	
58-6	9885-9890	scale	_	
58-7	9891-9894	has	_	
58-8	9895-9900	three	_	
58-9	9901-9908	oblique	_	
58-10	9909-9916	factors	_	
58-11	9916-9917	:	_	
58-12	9918-9929	attentional	_	
58-13	9929-9930	/	_	
58-14	9930-9939	cognitive	_	
58-15	9940-9944	that	_	
58-16	9945-9953	measures	_	
58-17	9954-9957	the	_	
58-18	9958-9968	toleration	_	
58-19	9969-9972	for	_	
58-20	9973-9982	cognitive	_	
58-21	9983-9993	complexity	_	
58-22	9994-9997	and	_	
58-23	9998-10009	persistence	_	
58-24	10009-10010	;	_	
58-25	10011-10016	motor	_	
58-26	10017-10021	that	_	
58-27	10022-10031	estimates	_	
58-28	10032-10035	the	_	
58-29	10036-10044	tendency	_	
58-30	10045-10047	to	_	
58-31	10048-10051	act	_	
58-32	10052-10054	on	_	
58-33	10055-10058	the	_	
58-34	10059-10063	spur	_	
58-35	10064-10066	of	_	
58-36	10067-10070	the	_	
58-37	10071-10077	moment	_	
58-38	10077-10078	;	_	
58-39	10079-10082	and	_	
58-40	10083-10095	non-planning	_	
58-41	10096-10107	impulsivity	_	
58-42	10107-10108	,	_	
58-43	10109-10114	which	_	
58-44	10115-10124	evaluates	_	
58-45	10125-10128	the	_	
58-46	10129-10133	lack	_	
58-47	10134-10136	of	_	
58-48	10137-10142	sense	_	
58-49	10143-10145	of	_	
58-50	10146-10149	the	_	
58-51	10150-10156	future	_	
58-52	10156-10157	.	_	

#Text=Items are rated from 1 (rarely/never) to 4 (almost always/always).
59-1	10158-10163	Items	_	
59-2	10164-10167	are	_	
59-3	10168-10173	rated	_	
59-4	10174-10178	from	_	
59-5	10179-10180	1	_	
59-6	10181-10182	(	_	
59-7	10182-10188	rarely	_	
59-8	10188-10189	/	_	
59-9	10189-10194	never	_	
59-10	10194-10195	)	_	
59-11	10196-10198	to	_	
59-12	10199-10200	4	_	
59-13	10201-10202	(	_	
59-14	10202-10208	almost	_	
59-15	10209-10215	always	_	
59-16	10215-10216	/	_	
59-17	10216-10222	always	_	
59-18	10222-10223	)	_	
59-19	10223-10224	.	_	

#Text=To determine the overall impulsiveness scores, all items are summed; high scores indicate remarkable impulsivity.
60-1	10225-10227	To	_	
60-2	10228-10237	determine	_	
60-3	10238-10241	the	_	
60-4	10242-10249	overall	_	
60-5	10250-10263	impulsiveness	_	
60-6	10264-10270	scores	_	
60-7	10270-10271	,	_	
60-8	10272-10275	all	_	
60-9	10276-10281	items	_	
60-10	10282-10285	are	_	
60-11	10286-10292	summed	_	
60-12	10292-10293	;	_	
60-13	10294-10298	high	_	
60-14	10299-10305	scores	_	
60-15	10306-10314	indicate	_	
60-16	10315-10325	remarkable	_	
60-17	10326-10337	impulsivity	_	
60-18	10337-10338	.	_	

#Text=BIS-11 is a valid and reliable instrument for healthy Chinese and psychiatric populations.
61-1	10339-10342	BIS	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[17]	
61-2	10342-10343	-	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[17]	
61-3	10343-10345	11	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire[17]	
61-4	10346-10348	is	_	
61-5	10349-10350	a	_	
61-6	10351-10356	valid	_	
61-7	10357-10360	and	_	
61-8	10361-10369	reliable	_	
61-9	10370-10380	instrument	_	
61-10	10381-10384	for	_	
61-11	10385-10392	healthy	_	
61-12	10393-10400	Chinese	_	
61-13	10401-10404	and	_	
61-14	10405-10416	psychiatric	_	
61-15	10417-10428	populations	_	
61-16	10428-10429	.	_	

#Text=Data acquisition
#Text=All MRI datasets were obtained using a Philips Achieva 1.5 T Nova dual MR scanner at the Department of Medical Imaging, Guangdong Second Provincial General Hospital.
62-1	10430-10434	Data	_	
62-2	10435-10446	acquisition	_	
62-3	10447-10450	All	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
62-4	10451-10454	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
62-5	10455-10463	datasets	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[18]	
62-6	10464-10468	were	_	
62-7	10469-10477	obtained	_	
62-8	10478-10483	using	_	
62-9	10484-10485	a	_	
62-10	10486-10493	Philips	_	
62-11	10494-10501	Achieva	_	
62-12	10502-10505	1.5	_	
62-13	10505-10506	 	_	
62-14	10506-10507	T	_	
62-15	10508-10512	Nova	_	
62-16	10513-10517	dual	_	
62-17	10518-10520	MR	_	
62-18	10521-10528	scanner	_	
62-19	10529-10531	at	_	
62-20	10532-10535	the	_	
62-21	10536-10546	Department	_	
62-22	10547-10549	of	_	
62-23	10550-10557	Medical	_	
62-24	10558-10565	Imaging	_	
62-25	10565-10566	,	_	
62-26	10567-10576	Guangdong	_	
62-27	10577-10583	Second	_	
62-28	10584-10594	Provincial	_	
62-29	10595-10602	General	_	
62-30	10603-10611	Hospital	_	
62-31	10611-10612	.	_	

#Text=These datasets included rs-fMRI dataset and T1-weighted structural images.
63-1	10613-10618	These	_	
63-2	10619-10627	datasets	_	
63-3	10628-10636	included	_	
63-4	10637-10644	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	
63-5	10645-10652	dataset	_	
63-6	10653-10656	and	_	
63-7	10657-10659	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]	
63-8	10659-10660	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]	
63-9	10660-10668	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]	
63-10	10669-10679	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]	
63-11	10680-10686	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[19]	
63-12	10686-10687	.	_	

#Text=The rs-fMRI dataset [22 axial slices, repetition time (TR)/echo time (TE) = 2000 ms/50 ms, matrix = 64 × 64, field of view (FOV) = 230 × 230 mm2, slice thickness = 4.5 mm without gap, flip angle = 90°] was acquired using an echo planar imaging (EPI) sequence.
64-1	10688-10691	The	_	
64-2	10692-10699	rs-fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[20]	
64-3	10700-10707	dataset	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[20]	
64-4	10708-10709	[	_	
64-5	10709-10711	22	_	
64-6	10712-10717	axial	_	
64-7	10718-10724	slices	_	
64-8	10724-10725	,	_	
64-9	10726-10736	repetition	_	
64-10	10737-10741	time	_	
64-11	10742-10743	(	_	
64-12	10743-10745	TR	_	
64-13	10745-10746	)	_	
64-14	10746-10747	/	_	
64-15	10747-10751	echo	_	
64-16	10752-10756	time	_	
64-17	10757-10758	(	_	
64-18	10758-10760	TE	_	
64-19	10760-10761	)	_	
64-20	10761-10762	 	_	
64-21	10762-10763	=	_	
64-22	10763-10764	 	_	
64-23	10764-10768	2000	_	
64-24	10768-10769	 	_	
64-25	10769-10771	ms	_	
64-26	10771-10772	/	_	
64-27	10772-10774	50	_	
64-28	10774-10775	 	_	
64-29	10775-10777	ms	_	
64-30	10777-10778	,	_	
64-31	10779-10785	matrix	_	
64-32	10785-10786	 	_	
64-33	10786-10787	=	_	
64-34	10787-10788	 	_	
64-35	10788-10790	64	_	
64-36	10790-10791	 	_	
64-37	10791-10792	×	_	
64-38	10792-10793	 	_	
64-39	10793-10795	64	_	
64-40	10795-10796	,	_	
64-41	10797-10802	field	_	
64-42	10803-10805	of	_	
64-43	10806-10810	view	_	
64-44	10811-10812	(	_	
64-45	10812-10815	FOV	_	
64-46	10815-10816	)	_	
64-47	10816-10817	 	_	
64-48	10817-10818	=	_	
64-49	10818-10819	 	_	
64-50	10819-10822	230	_	
64-51	10822-10823	 	_	
64-52	10823-10824	×	_	
64-53	10824-10825	 	_	
64-54	10825-10828	230	_	
64-55	10828-10829	 	_	
64-56	10829-10832	mm2	_	
64-57	10832-10833	,	_	
64-58	10834-10839	slice	_	
64-59	10840-10849	thickness	_	
64-60	10849-10850	 	_	
64-61	10850-10851	=	_	
64-62	10851-10852	 	_	
64-63	10852-10855	4.5	_	
64-64	10855-10856	 	_	
64-65	10856-10858	mm	_	
64-66	10859-10866	without	_	
64-67	10867-10870	gap	_	
64-68	10870-10871	,	_	
64-69	10872-10876	flip	_	
64-70	10877-10882	angle	_	
64-71	10882-10883	 	_	
64-72	10883-10884	=	_	
64-73	10884-10885	 	_	
64-74	10885-10887	90	_	
64-75	10887-10888	°	_	
64-76	10888-10889	]	_	
64-77	10890-10893	was	_	
64-78	10894-10902	acquired	_	
64-79	10903-10908	using	_	
64-80	10909-10911	an	_	
64-81	10912-10916	echo	_	
64-82	10917-10923	planar	_	
64-83	10924-10931	imaging	_	
64-84	10932-10933	(	_	
64-85	10933-10936	EPI	_	
64-86	10936-10937	)	_	
64-87	10938-10946	sequence	_	
64-88	10946-10947	.	_	

#Text=Each functional run contained 240 volumes (8 min) [the slices were approximately along the anterior commissure-posterior commissure (AC-PC) line and covered approximately 230 to 60 in the inferosuperior direction], and the subjects were asked to lie quietly with their eyes closed and avoid eye movement or thinking of anything specific or falling asleep while in the scanner, during the rs-fMRI data acquisition.
65-1	10948-10952	Each	_	
65-2	10953-10963	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
65-3	10964-10967	run	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[21]	
65-4	10968-10977	contained	_	
65-5	10978-10981	240	_	
65-6	10982-10989	volumes	_	
65-7	10990-10991	(	_	
65-8	10991-10992	8	_	
65-9	10992-10993	 	_	
65-10	10993-10996	min	_	
65-11	10996-10997	)	_	
65-12	10998-10999	[	_	
65-13	10999-11002	the	_	
65-14	11003-11009	slices	_	
65-15	11010-11014	were	_	
65-16	11015-11028	approximately	_	
65-17	11029-11034	along	_	
65-18	11035-11038	the	_	
65-19	11039-11047	anterior	_	
65-20	11048-11068	commissure-posterior	_	
65-21	11069-11079	commissure	_	
65-22	11080-11081	(	_	
65-23	11081-11086	AC-PC	_	
65-24	11086-11087	)	_	
65-25	11088-11092	line	_	
65-26	11093-11096	and	_	
65-27	11097-11104	covered	_	
65-28	11105-11118	approximately	_	
65-29	11119-11122	230	_	
65-30	11123-11125	to	_	
65-31	11126-11128	60	_	
65-32	11129-11131	in	_	
65-33	11132-11135	the	_	
65-34	11136-11150	inferosuperior	_	
65-35	11151-11160	direction	_	
65-36	11160-11161	]	_	
65-37	11161-11162	,	_	
65-38	11163-11166	and	_	
65-39	11167-11170	the	_	
65-40	11171-11179	subjects	_	
65-41	11180-11184	were	_	
65-42	11185-11190	asked	_	
65-43	11191-11193	to	_	
65-44	11194-11197	lie	_	
65-45	11198-11205	quietly	_	
65-46	11206-11210	with	_	
65-47	11211-11216	their	_	
65-48	11217-11221	eyes	_	
65-49	11222-11228	closed	_	
65-50	11229-11232	and	_	
65-51	11233-11238	avoid	_	
65-52	11239-11242	eye	_	
65-53	11243-11251	movement	_	
65-54	11252-11254	or	_	
65-55	11255-11263	thinking	_	
65-56	11264-11266	of	_	
65-57	11267-11275	anything	_	
65-58	11276-11284	specific	_	
65-59	11285-11287	or	_	
65-60	11288-11295	falling	_	
65-61	11296-11302	asleep	_	
65-62	11303-11308	while	_	
65-63	11309-11311	in	_	
65-64	11312-11315	the	_	
65-65	11316-11323	scanner	_	
65-66	11323-11324	,	_	
65-67	11325-11331	during	_	
65-68	11332-11335	the	_	
65-69	11336-11343	rs-fMRI	_	
65-70	11344-11348	data	_	
65-71	11349-11360	acquisition	_	
65-72	11360-11361	.	_	

#Text=Sagittal structural images (160 sagittal slices, TR/TE = 25 ms/4.1 ms, thickness = 1.0 mm, no gap, in-plane resolution = 231 × 232, FOV = 230 × 230 mm, flip angle = 30°) were acquired using a fast field echo (FFE) three-dimensional (3D) T1-weighted sequence.
66-1	11362-11370	Sagittal	_	
66-2	11371-11381	structural	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[22]	
66-3	11382-11388	images	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging[22]	
66-4	11389-11390	(	_	
66-5	11390-11393	160	_	
66-6	11394-11402	sagittal	_	
66-7	11403-11409	slices	_	
66-8	11409-11410	,	_	
66-9	11411-11413	TR	_	
66-10	11413-11414	/	_	
66-11	11414-11416	TE	_	
66-12	11416-11417	 	_	
66-13	11417-11418	=	_	
66-14	11418-11419	 	_	
66-15	11419-11421	25	_	
66-16	11421-11422	 	_	
66-17	11422-11424	ms	_	
66-18	11424-11425	/	_	
66-19	11425-11428	4.1	_	
66-20	11428-11429	 	_	
66-21	11429-11431	ms	_	
66-22	11431-11432	,	_	
66-23	11433-11442	thickness	_	
66-24	11442-11443	 	_	
66-25	11443-11444	=	_	
66-26	11444-11445	 	_	
66-27	11445-11448	1.0	_	
66-28	11448-11449	 	_	
66-29	11449-11451	mm	_	
66-30	11451-11452	,	_	
66-31	11453-11455	no	_	
66-32	11456-11459	gap	_	
66-33	11459-11460	,	_	
66-34	11461-11469	in-plane	_	
66-35	11470-11480	resolution	_	
66-36	11480-11481	 	_	
66-37	11481-11482	=	_	
66-38	11482-11483	 	_	
66-39	11483-11486	231	_	
66-40	11486-11487	 	_	
66-41	11487-11488	×	_	
66-42	11488-11489	 	_	
66-43	11489-11492	232	_	
66-44	11492-11493	,	_	
66-45	11494-11497	FOV	_	
66-46	11497-11498	 	_	
66-47	11498-11499	=	_	
66-48	11499-11500	 	_	
66-49	11500-11503	230	_	
66-50	11503-11504	 	_	
66-51	11504-11505	×	_	
66-52	11505-11506	 	_	
66-53	11506-11509	230	_	
66-54	11509-11510	 	_	
66-55	11510-11512	mm	_	
66-56	11512-11513	,	_	
66-57	11514-11518	flip	_	
66-58	11519-11524	angle	_	
66-59	11524-11525	 	_	
66-60	11525-11526	=	_	
66-61	11526-11527	 	_	
66-62	11527-11529	30	_	
66-63	11529-11530	°	_	
66-64	11530-11531	)	_	
66-65	11532-11536	were	_	
66-66	11537-11545	acquired	_	
66-67	11546-11551	using	_	
66-68	11552-11553	a	_	
66-69	11554-11558	fast	_	
66-70	11559-11564	field	_	
66-71	11565-11569	echo	_	
66-72	11570-11571	(	_	
66-73	11571-11574	FFE	_	
66-74	11574-11575	)	_	
66-75	11576-11593	three-dimensional	_	
66-76	11594-11595	(	_	
66-77	11595-11597	3D	_	
66-78	11597-11598	)	_	
66-79	11599-11601	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[23]	
66-80	11601-11602	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[23]	
66-81	11602-11610	weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[23]	
66-82	11611-11619	sequence	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[23]	
66-83	11619-11620	.	_	

#Text=Data pre-processing and DC calculation
#Text=Data Processing Assistant for Resting-State Functional MR Imaging toolbox (http://www.restfmri.net.sci-hub.cc/forum/DPARSF,) was used for the post-processing of the imaging data.
67-1	11621-11625	Data	_	
67-2	11626-11640	pre-processing	_	
67-3	11641-11644	and	_	
67-4	11645-11647	DC	_	
67-5	11648-11659	calculation	_	
67-6	11660-11664	Data	_	
67-7	11665-11675	Processing	_	
67-8	11676-11685	Assistant	_	
67-9	11686-11689	for	_	
67-10	11690-11703	Resting-State	_	
67-11	11704-11714	Functional	_	
67-12	11715-11717	MR	_	
67-13	11718-11725	Imaging	_	
67-14	11726-11733	toolbox	_	
67-15	11734-11735	(	_	
67-16	11735-11739	http	_	
67-17	11739-11740	:	_	
67-18	11740-11741	/	_	
67-19	11741-11742	/	_	
67-20	11742-11769	www.restfmri.net.sci-hub.cc	_	
67-21	11769-11770	/	_	
67-22	11770-11775	forum	_	
67-23	11775-11776	/	_	
67-24	11776-11782	DPARSF	_	
67-25	11782-11783	,	_	
67-26	11783-11784	)	_	
67-27	11785-11788	was	_	
67-28	11789-11793	used	_	
67-29	11794-11797	for	_	
67-30	11798-11801	the	_	
67-31	11802-11817	post-processing	_	
67-32	11818-11820	of	_	
67-33	11821-11824	the	_	
67-34	11825-11832	imaging	_	
67-35	11833-11837	data	_	
67-36	11837-11838	.	_	

#Text=Before pre-processing, the first 10 volumes were discarded for each subject so that magnetization reached a steady state and subjects adapted to the MRI scanning noise.
68-1	11839-11845	Before	_	
68-2	11846-11860	pre-processing	_	
68-3	11860-11861	,	_	
68-4	11862-11865	the	_	
68-5	11866-11871	first	_	
68-6	11872-11874	10	_	
68-7	11875-11882	volumes	_	
68-8	11883-11887	were	_	
68-9	11888-11897	discarded	_	
68-10	11898-11901	for	_	
68-11	11902-11906	each	_	
68-12	11907-11914	subject	_	
68-13	11915-11917	so	_	
68-14	11918-11922	that	_	
68-15	11923-11936	magnetization	_	
68-16	11937-11944	reached	_	
68-17	11945-11946	a	_	
68-18	11947-11953	steady	_	
68-19	11954-11959	state	_	
68-20	11960-11963	and	_	
68-21	11964-11972	subjects	_	
68-22	11973-11980	adapted	_	
68-23	11981-11983	to	_	
68-24	11984-11987	the	_	
68-25	11988-11991	MRI	_	
68-26	11992-12000	scanning	_	
68-27	12001-12006	noise	_	
68-28	12006-12007	.	_	

#Text=Then, the remaining 230 fMRI images were obtained with slice time correction for the acquisition time delay and realignment of the head motion correction.
69-1	12008-12012	Then	_	
69-2	12012-12013	,	_	
69-3	12014-12017	the	_	
69-4	12018-12027	remaining	_	
69-5	12028-12031	230	_	
69-6	12032-12036	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[24]	
69-7	12037-12043	images	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol[24]	
69-8	12044-12048	were	_	
69-9	12049-12057	obtained	_	
69-10	12058-12062	with	_	
69-11	12063-12068	slice	_	
69-12	12069-12073	time	_	
69-13	12074-12084	correction	_	
69-14	12085-12088	for	_	
69-15	12089-12092	the	_	
69-16	12093-12104	acquisition	_	
69-17	12105-12109	time	_	
69-18	12110-12115	delay	_	
69-19	12116-12119	and	_	
69-20	12120-12131	realignment	_	
69-21	12132-12134	of	_	
69-22	12135-12138	the	_	
69-23	12139-12143	head	_	
69-24	12144-12150	motion	_	
69-25	12151-12161	correction	_	
69-26	12161-12162	.	_	

#Text=One patient and two control subjects, who showed head motion >1.5 mm or 1.5° during image acquisition, were excluded in subsequent analysis.
70-1	12163-12166	One	_	
70-2	12167-12174	patient	_	
70-3	12175-12178	and	_	
70-4	12179-12182	two	_	
70-5	12183-12190	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]	
70-6	12191-12199	subjects	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder[25]	
70-7	12199-12200	,	_	
70-8	12201-12204	who	_	
70-9	12205-12211	showed	_	
70-10	12212-12216	head	_	
70-11	12217-12223	motion	_	
70-12	12224-12225	>	_	
70-13	12225-12228	1.5	_	
70-14	12228-12229	 	_	
70-15	12229-12231	mm	_	
70-16	12232-12234	or	_	
70-17	12235-12238	1.5	_	
70-18	12238-12239	°	_	
70-19	12240-12246	during	_	
70-20	12247-12252	image	_	
70-21	12253-12264	acquisition	_	
70-22	12264-12265	,	_	
70-23	12266-12270	were	_	
70-24	12271-12279	excluded	_	
70-25	12280-12282	in	_	
70-26	12283-12293	subsequent	_	
70-27	12294-12302	analysis	_	
70-28	12302-12303	.	_	

#Text=All realigned images were normalized to the standard Montreal Neurological Institute (MNI) template by applying the echo planar imaging (EPI) template at a 3 × 3 × 3 mm3 resolution.
71-1	12304-12307	All	_	
71-2	12308-12317	realigned	_	
71-3	12318-12324	images	_	
71-4	12325-12329	were	_	
71-5	12330-12340	normalized	_	
71-6	12341-12343	to	_	
71-7	12344-12347	the	_	
71-8	12348-12356	standard	_	
71-9	12357-12365	Montreal	_	
71-10	12366-12378	Neurological	_	
71-11	12379-12388	Institute	_	
71-12	12389-12390	(	_	
71-13	12390-12393	MNI	_	
71-14	12393-12394	)	_	
71-15	12395-12403	template	_	
71-16	12404-12406	by	_	
71-17	12407-12415	applying	_	
71-18	12416-12419	the	_	
71-19	12420-12424	echo	_	
71-20	12425-12431	planar	_	
71-21	12432-12439	imaging	_	
71-22	12440-12441	(	_	
71-23	12441-12444	EPI	_	
71-24	12444-12445	)	_	
71-25	12446-12454	template	_	
71-26	12455-12457	at	_	
71-27	12458-12459	a	_	
71-28	12460-12461	3	_	
71-29	12461-12462	 	_	
71-30	12462-12463	×	_	
71-31	12463-12464	 	_	
71-32	12464-12465	3	_	
71-33	12465-12466	 	_	
71-34	12466-12467	×	_	
71-35	12467-12468	 	_	
71-36	12468-12469	3	_	
71-37	12469-12470	 	_	
71-38	12470-12473	mm3	_	
71-39	12474-12484	resolution	_	
71-40	12484-12485	.	_	

#Text=The normalized functional image was subjected to spatial smoothing [6 mm half high full-width (FWHM) Gaussian kernel].
72-1	12486-12489	The	_	
72-2	12490-12500	normalized	_	
72-3	12501-12511	functional	_	
72-4	12512-12517	image	_	
72-5	12518-12521	was	_	
72-6	12522-12531	subjected	_	
72-7	12532-12534	to	_	
72-8	12535-12542	spatial	_	
72-9	12543-12552	smoothing	_	
72-10	12553-12554	[	_	
72-11	12554-12555	6	_	
72-12	12555-12556	 	_	
72-13	12556-12558	mm	_	
72-14	12559-12563	half	_	
72-15	12564-12568	high	_	
72-16	12569-12579	full-width	_	
72-17	12580-12581	(	_	
72-18	12581-12585	FWHM	_	
72-19	12585-12586	)	_	
72-20	12587-12595	Gaussian	_	
72-21	12596-12602	kernel	_	
72-22	12602-12603	]	_	
72-23	12603-12604	.	_	

#Text=Finally, the imaging data were processed to remove the linear trends and filtered using typical temporal bandpass (0.01–0.08 Hz) to reduce the low-frequency drift and high-frequency noise.
73-1	12605-12612	Finally	_	
73-2	12612-12613	,	_	
73-3	12614-12617	the	_	
73-4	12618-12625	imaging	_	
73-5	12626-12630	data	_	
73-6	12631-12635	were	_	
73-7	12636-12645	processed	_	
73-8	12646-12648	to	_	
73-9	12649-12655	remove	_	
73-10	12656-12659	the	_	
73-11	12660-12666	linear	_	
73-12	12667-12673	trends	_	
73-13	12674-12677	and	_	
73-14	12678-12686	filtered	_	
73-15	12687-12692	using	_	
73-16	12693-12700	typical	_	
73-17	12701-12709	temporal	_	
73-18	12710-12718	bandpass	_	
73-19	12719-12720	(	_	
73-20	12720-12724	0.01	_	
73-21	12724-12725	–	_	
73-22	12725-12729	0.08	_	
73-23	12729-12730	 	_	
73-24	12730-12732	Hz	_	
73-25	12732-12733	)	_	
73-26	12734-12736	to	_	
73-27	12737-12743	reduce	_	
73-28	12744-12747	the	_	
73-29	12748-12761	low-frequency	_	
73-30	12762-12767	drift	_	
73-31	12768-12771	and	_	
73-32	12772-12786	high-frequency	_	
73-33	12787-12792	noise	_	
73-34	12792-12793	.	_	

#Text=For calculating the DC, we performed voxel-wise voxel-based whole-brain correlation analysis on the pre-processed fMRI data, as described previously.
74-1	12794-12797	For	_	
74-2	12798-12809	calculating	_	
74-3	12810-12813	the	_	
74-4	12814-12816	DC	_	
74-5	12816-12817	,	_	
74-6	12818-12820	we	_	
74-7	12821-12830	performed	_	
74-8	12831-12841	voxel-wise	_	
74-9	12842-12853	voxel-based	_	
74-10	12854-12865	whole-brain	_	
74-11	12866-12877	correlation	_	
74-12	12878-12886	analysis	_	
74-13	12887-12889	on	_	
74-14	12890-12893	the	_	
74-15	12894-12907	pre-processed	_	
74-16	12908-12912	fMRI	_	
74-17	12913-12917	data	_	
74-18	12917-12918	,	_	
74-19	12919-12921	as	_	
74-20	12922-12931	described	_	
74-21	12932-12942	previously	_	
74-22	12942-12943	.	_	

#Text=The time course of each voxel in each brain was correlated to every other voxel time course in the GM mask.
75-1	12944-12947	The	_	
75-2	12948-12952	time	_	
75-3	12953-12959	course	_	
75-4	12960-12962	of	_	
75-5	12963-12967	each	_	
75-6	12968-12973	voxel	_	
75-7	12974-12976	in	_	
75-8	12977-12981	each	_	
75-9	12982-12987	brain	_	
75-10	12988-12991	was	_	
75-11	12992-13002	correlated	_	
75-12	13003-13005	to	_	
75-13	13006-13011	every	_	
75-14	13012-13017	other	_	
75-15	13018-13023	voxel	_	
75-16	13024-13028	time	_	
75-17	13029-13035	course	_	
75-18	13036-13038	in	_	
75-19	13039-13042	the	_	
75-20	13043-13045	GM	_	
75-21	13046-13050	mask	_	
75-22	13050-13051	.	_	

#Text=Thus, we could acquire a n × n matrix of Pearson's correlation coefficients between any pair of voxels, where n is the voxel number of the GM mask.
76-1	13052-13056	Thus	_	
76-2	13056-13057	,	_	
76-3	13058-13060	we	_	
76-4	13061-13066	could	_	
76-5	13067-13074	acquire	_	
76-6	13075-13076	a	_	
76-7	13077-13078	n	_	
76-8	13078-13079	 	_	
76-9	13079-13080	×	_	
76-10	13080-13081	 	_	
76-11	13081-13082	n	_	
76-12	13083-13089	matrix	_	
76-13	13090-13092	of	_	
76-14	13093-13102	Pearson's	_	
76-15	13103-13114	correlation	_	
76-16	13115-13127	coefficients	_	
76-17	13128-13135	between	_	
76-18	13136-13139	any	_	
76-19	13140-13144	pair	_	
76-20	13145-13147	of	_	
76-21	13148-13154	voxels	_	
76-22	13154-13155	,	_	
76-23	13156-13161	where	_	
76-24	13162-13163	n	_	
76-25	13164-13166	is	_	
76-26	13167-13170	the	_	
76-27	13171-13176	voxel	_	
76-28	13177-13183	number	_	
76-29	13184-13186	of	_	
76-30	13187-13190	the	_	
76-31	13191-13193	GM	_	
76-32	13194-13198	mask	_	
76-33	13198-13199	.	_	

#Text=Next, we transformed the Pearson's correlation data into normally distributed Fisher Z-scores and constructed the whole-brain functional network by thresholding each correlation at r > 0.25.
77-1	13200-13204	Next	_	
77-2	13204-13205	,	_	
77-3	13206-13208	we	_	
77-4	13209-13220	transformed	_	
77-5	13221-13224	the	_	
77-6	13225-13234	Pearson's	_	
77-7	13235-13246	correlation	_	
77-8	13247-13251	data	_	
77-9	13252-13256	into	_	
77-10	13257-13265	normally	_	
77-11	13266-13277	distributed	_	
77-12	13278-13284	Fisher	_	
77-13	13285-13293	Z-scores	_	
77-14	13294-13297	and	_	
77-15	13298-13309	constructed	_	
77-16	13310-13313	the	_	
77-17	13314-13325	whole-brain	_	
77-18	13326-13336	functional	_	
77-19	13337-13344	network	_	
77-20	13345-13347	by	_	
77-21	13348-13360	thresholding	_	
77-22	13361-13365	each	_	
77-23	13366-13377	correlation	_	
77-24	13378-13380	at	_	
77-25	13381-13382	r	_	
77-26	13382-13383	 	_	
77-27	13383-13384	>	_	
77-28	13384-13385	 	_	
77-29	13385-13389	0.25	_	
77-30	13389-13390	.	_	

#Text=The threshold was the default setting while constructing the DC map.
78-1	13391-13394	The	_	
78-2	13395-13404	threshold	_	
78-3	13405-13408	was	_	
78-4	13409-13412	the	_	
78-5	13413-13420	default	_	
78-6	13421-13428	setting	_	
78-7	13429-13434	while	_	
78-8	13435-13447	constructing	_	
78-9	13448-13451	the	_	
78-10	13452-13454	DC	_	
78-11	13455-13458	map	_	
78-12	13458-13459	.	_	

#Text=Only positive Pearson's correlation coefficients were considered in the present study.
79-1	13460-13464	Only	_	
79-2	13465-13473	positive	_	
79-3	13474-13483	Pearson's	_	
79-4	13484-13495	correlation	_	
79-5	13496-13508	coefficients	_	
79-6	13509-13513	were	_	
79-7	13514-13524	considered	_	
79-8	13525-13527	in	_	
79-9	13528-13531	the	_	
79-10	13532-13539	present	_	
79-11	13540-13545	study	_	
79-12	13545-13546	.	_	

#Text=For a given voxel, the DC was calculated as the sum of the significant connections at the individual level.
80-1	13547-13550	For	_	
80-2	13551-13552	a	_	
80-3	13553-13558	given	_	
80-4	13559-13564	voxel	_	
80-5	13564-13565	,	_	
80-6	13566-13569	the	_	
80-7	13570-13572	DC	_	
80-8	13573-13576	was	_	
80-9	13577-13587	calculated	_	
80-10	13588-13590	as	_	
80-11	13591-13594	the	_	
80-12	13595-13598	sum	_	
80-13	13599-13601	of	_	
80-14	13602-13605	the	_	
80-15	13606-13617	significant	_	
80-16	13618-13629	connections	_	
80-17	13630-13632	at	_	
80-18	13633-13636	the	_	
80-19	13637-13647	individual	_	
80-20	13648-13653	level	_	
80-21	13653-13654	.	_	

#Text=As described by previous studies, DC represents the number of direct connections for a given voxel in the voxel-based graphs.
81-1	13655-13657	As	_	
81-2	13658-13667	described	_	
81-3	13668-13670	by	_	
81-4	13671-13679	previous	_	
81-5	13680-13687	studies	_	
81-6	13687-13688	,	_	
81-7	13689-13691	DC	_	
81-8	13692-13702	represents	_	
81-9	13703-13706	the	_	
81-10	13707-13713	number	_	
81-11	13714-13716	of	_	
81-12	13717-13723	direct	_	
81-13	13724-13735	connections	_	
81-14	13736-13739	for	_	
81-15	13740-13741	a	_	
81-16	13742-13747	given	_	
81-17	13748-13753	voxel	_	
81-18	13754-13756	in	_	
81-19	13757-13760	the	_	
81-20	13761-13772	voxel-based	_	
81-21	13773-13779	graphs	_	
81-22	13779-13780	.	_	

#Text=It has been widely used to represent the node characteristics of large-scale brain intrinsic connectivity networks.
82-1	13781-13783	It	_	
82-2	13784-13787	has	_	
82-3	13788-13792	been	_	
82-4	13793-13799	widely	_	
82-5	13800-13804	used	_	
82-6	13805-13807	to	_	
82-7	13808-13817	represent	_	
82-8	13818-13821	the	_	
82-9	13822-13826	node	_	
82-10	13827-13842	characteristics	_	
82-11	13843-13845	of	_	
82-12	13846-13857	large-scale	_	
82-13	13858-13863	brain	_	
82-14	13864-13873	intrinsic	_	
82-15	13874-13886	connectivity	_	
82-16	13887-13895	networks	_	
82-17	13895-13896	.	_	

#Text=Statistical analysis
#Text=The differences in age, education, and nicotine use between the CCS-dependent and control groups were assessed by two-sample two-tailed t-tests using SPSS statistical software.
83-1	13897-13908	Statistical	_	
83-2	13909-13917	analysis	_	
83-3	13918-13921	The	_	
83-4	13922-13933	differences	_	
83-5	13934-13936	in	_	
83-6	13937-13940	age	_	
83-7	13940-13941	,	_	
83-8	13942-13951	education	_	
83-9	13951-13952	,	_	
83-10	13953-13956	and	_	
83-11	13957-13965	nicotine	_	
83-12	13966-13969	use	_	
83-13	13970-13977	between	_	
83-14	13978-13981	the	_	
83-15	13982-13995	CCS-dependent	_	
83-16	13996-13999	and	_	
83-17	14000-14007	control	_	
83-18	14008-14014	groups	_	
83-19	14015-14019	were	_	
83-20	14020-14028	assessed	_	
83-21	14029-14031	by	_	
83-22	14032-14042	two-sample	_	
83-23	14043-14053	two-tailed	_	
83-24	14054-14061	t-tests	_	
83-25	14062-14067	using	_	
83-26	14068-14072	SPSS	_	
83-27	14073-14084	statistical	_	
83-28	14085-14093	software	_	
83-29	14093-14094	.	_	

#Text=A two-tailed Pearson's chi-square test was performed to determine the differences in the gender between the two groups.
84-1	14095-14096	A	_	
84-2	14097-14107	two-tailed	_	
84-3	14108-14117	Pearson's	_	
84-4	14118-14128	chi-square	_	
84-5	14129-14133	test	_	
84-6	14134-14137	was	_	
84-7	14138-14147	performed	_	
84-8	14148-14150	to	_	
84-9	14151-14160	determine	_	
84-10	14161-14164	the	_	
84-11	14165-14176	differences	_	
84-12	14177-14179	in	_	
84-13	14180-14183	the	_	
84-14	14184-14190	gender	_	
84-15	14191-14198	between	_	
84-16	14199-14202	the	_	
84-17	14203-14206	two	_	
84-18	14207-14213	groups	_	
84-19	14213-14214	.	_	

#Text=To examine the between-group differences in the DC using zDC maps, a two-sample t-test was performed between the two groups using REST.
85-1	14215-14217	To	_	
85-2	14218-14225	examine	_	
85-3	14226-14229	the	_	
85-4	14230-14243	between-group	_	
85-5	14244-14255	differences	_	
85-6	14256-14258	in	_	
85-7	14259-14262	the	_	
85-8	14263-14265	DC	_	
85-9	14266-14271	using	_	
85-10	14272-14275	zDC	_	
85-11	14276-14280	maps	_	
85-12	14280-14281	,	_	
85-13	14282-14283	a	_	
85-14	14284-14294	two-sample	_	
85-15	14295-14301	t-test	_	
85-16	14302-14305	was	_	
85-17	14306-14315	performed	_	
85-18	14316-14323	between	_	
85-19	14324-14327	the	_	
85-20	14328-14331	two	_	
85-21	14332-14338	groups	_	
85-22	14339-14344	using	_	
85-23	14345-14349	REST	_	
85-24	14349-14350	.	_	

#Text=A correction for multiple comparisons was performed by Monte Carlo simulation using the AlphaSim program, (http://afni.nimh.nih.gov).
86-1	14351-14352	A	_	
86-2	14353-14363	correction	_	
86-3	14364-14367	for	_	
86-4	14368-14376	multiple	_	
86-5	14377-14388	comparisons	_	
86-6	14389-14392	was	_	
86-7	14393-14402	performed	_	
86-8	14403-14405	by	_	
86-9	14406-14411	Monte	_	
86-10	14412-14417	Carlo	_	
86-11	14418-14428	simulation	_	
86-12	14429-14434	using	_	
86-13	14435-14438	the	_	
86-14	14439-14447	AlphaSim	_	
86-15	14448-14455	program	_	
86-16	14455-14456	,	_	
86-17	14457-14458	(	_	
86-18	14458-14462	http	_	
86-19	14462-14463	:	_	
86-20	14463-14464	/	_	
86-21	14464-14465	/	_	
86-22	14465-14482	afni.nimh.nih.gov	_	
86-23	14482-14483	)	_	
86-24	14483-14484	.	_	

#Text=The AlphaSim program was implemented in the REST software by combining the height threshold of P < 0.001 and an extent threshold of P < 0.01, which corresponded to a corrected P < 0.01.
87-1	14485-14488	The	_	
87-2	14489-14497	AlphaSim	_	
87-3	14498-14505	program	_	
87-4	14506-14509	was	_	
87-5	14510-14521	implemented	_	
87-6	14522-14524	in	_	
87-7	14525-14528	the	_	
87-8	14529-14533	REST	_	
87-9	14534-14542	software	_	
87-10	14543-14545	by	_	
87-11	14546-14555	combining	_	
87-12	14556-14559	the	_	
87-13	14560-14566	height	_	
87-14	14567-14576	threshold	_	
87-15	14577-14579	of	_	
87-16	14580-14581	P	_	
87-17	14581-14582	 	_	
87-18	14582-14583	<	_	
87-19	14583-14584	 	_	
87-20	14584-14589	0.001	_	
87-21	14590-14593	and	_	
87-22	14594-14596	an	_	
87-23	14597-14603	extent	_	
87-24	14604-14613	threshold	_	
87-25	14614-14616	of	_	
87-26	14617-14618	P	_	
87-27	14618-14619	 	_	
87-28	14619-14620	<	_	
87-29	14620-14621	 	_	
87-30	14621-14625	0.01	_	
87-31	14625-14626	,	_	
87-32	14627-14632	which	_	
87-33	14633-14645	corresponded	_	
87-34	14646-14648	to	_	
87-35	14649-14650	a	_	
87-36	14651-14660	corrected	_	
87-37	14661-14662	P	_	
87-38	14662-14663	 	_	
87-39	14663-14664	<	_	
87-40	14664-14665	 	_	
87-41	14665-14669	0.01	_	
87-42	14669-14670	.	_	

#Text=The average DC values of all voxels in the significantly different regions demonstrated by voxel-based analysis were extracted independently using the extract time series in REST and entered into SPSS.
88-1	14671-14674	The	_	
88-2	14675-14682	average	_	
88-3	14683-14685	DC	_	
88-4	14686-14692	values	_	
88-5	14693-14695	of	_	
88-6	14696-14699	all	_	
88-7	14700-14706	voxels	_	
88-8	14707-14709	in	_	
88-9	14710-14713	the	_	
88-10	14714-14727	significantly	_	
88-11	14728-14737	different	_	
88-12	14738-14745	regions	_	
88-13	14746-14758	demonstrated	_	
88-14	14759-14761	by	_	
88-15	14762-14773	voxel-based	_	
88-16	14774-14782	analysis	_	
88-17	14783-14787	were	_	
88-18	14788-14797	extracted	_	
88-19	14798-14811	independently	_	
88-20	14812-14817	using	_	
88-21	14818-14821	the	_	
88-22	14822-14829	extract	_	
88-23	14830-14834	time	_	
88-24	14835-14841	series	_	
88-25	14842-14844	in	_	
88-26	14845-14849	REST	_	
88-27	14850-14853	and	_	
88-28	14854-14861	entered	_	
88-29	14862-14866	into	_	
88-30	14867-14871	SPSS	_	
88-31	14871-14872	.	_	

#Text=Then, a Pearson's correlation analysis was performed to clarify the relationships between abnormal DC values of significantly different regions and clinical characteristics in CCS-dependent patients, including the duration of CCS usage, age at first CCS use, and BIS-11 scores; the significance levels were set at P < 0.05 (two-tailed).
89-1	14873-14877	Then	_	
89-2	14877-14878	,	_	
89-3	14879-14880	a	_	
89-4	14881-14890	Pearson's	_	
89-5	14891-14902	correlation	_	
89-6	14903-14911	analysis	_	
89-7	14912-14915	was	_	
89-8	14916-14925	performed	_	
89-9	14926-14928	to	_	
89-10	14929-14936	clarify	_	
89-11	14937-14940	the	_	
89-12	14941-14954	relationships	_	
89-13	14955-14962	between	_	
89-14	14963-14971	abnormal	_	
89-15	14972-14974	DC	_	
89-16	14975-14981	values	_	
89-17	14982-14984	of	_	
89-18	14985-14998	significantly	_	
89-19	14999-15008	different	_	
89-20	15009-15016	regions	_	
89-21	15017-15020	and	_	
89-22	15021-15029	clinical	_	
89-23	15030-15045	characteristics	_	
89-24	15046-15048	in	_	
89-25	15049-15062	CCS-dependent	_	
89-26	15063-15071	patients	_	
89-27	15071-15072	,	_	
89-28	15073-15082	including	_	
89-29	15083-15086	the	_	
89-30	15087-15095	duration	_	
89-31	15096-15098	of	_	
89-32	15099-15102	CCS	_	
89-33	15103-15108	usage	_	
89-34	15108-15109	,	_	
89-35	15110-15113	age	_	
89-36	15114-15116	at	_	
89-37	15117-15122	first	_	
89-38	15123-15126	CCS	_	
89-39	15127-15130	use	_	
89-40	15130-15131	,	_	
89-41	15132-15135	and	_	
89-42	15136-15139	BIS	_	
89-43	15139-15140	-	_	
89-44	15140-15142	11	_	
89-45	15143-15149	scores	_	
89-46	15149-15150	;	_	
89-47	15151-15154	the	_	
89-48	15155-15167	significance	_	
89-49	15168-15174	levels	_	
89-50	15175-15179	were	_	
89-51	15180-15183	set	_	
89-52	15184-15186	at	_	
89-53	15187-15188	P	_	
89-54	15188-15189	 	_	
89-55	15189-15190	<	_	
89-56	15190-15191	 	_	
89-57	15191-15195	0.05	_	
89-58	15196-15197	(	_	
89-59	15197-15207	two-tailed	_	
89-60	15207-15208	)	_	
89-61	15208-15209	.	_	

#Text=Results
#Text=Demographics and clinical characteristics
#Text=Demographic and clinical characteristics of the Codeine-containing Cough Syrup (CCS)-dependent individuals and control subjects.
90-1	15210-15217	Results	_	
90-2	15218-15230	Demographics	_	
90-3	15231-15234	and	_	
90-4	15235-15243	clinical	_	
90-5	15244-15259	characteristics	_	
90-6	15260-15271	Demographic	_	
90-7	15272-15275	and	_	
90-8	15276-15284	clinical	_	
90-9	15285-15300	characteristics	_	
90-10	15301-15303	of	_	
90-11	15304-15307	the	_	
90-12	15308-15326	Codeine-containing	_	
90-13	15327-15332	Cough	_	
90-14	15333-15338	Syrup	_	
90-15	15339-15340	(	_	
90-16	15340-15343	CCS	_	
90-17	15343-15344	)	_	
90-18	15344-15345	-	_	
90-19	15345-15354	dependent	_	
90-20	15355-15366	individuals	_	
90-21	15367-15370	and	_	
90-22	15371-15378	control	_	
90-23	15379-15387	subjects	_	
90-24	15387-15388	.	_	

#Text=Table 1\t \t
#Text=Characteristic\tCCS-dependent individuals (n = 37)\tControls (n = 32)\tP-value\t \tAge (years)\t24.081 (3.252)\t26.218 (6.131)\t0.084\t \tEducation (years)\t12.432 (3.287)\t13.250 (4.557)\t0.392\t \tNicotine (no. of cigarettes/day)\t16.243 (8.597)\t13.218 (6.926)\t0.116\t \tCough syrups use (years)\t5.872 (range: 1–15)\tN/A\t–\t \tAge at the first use of cough syrups\t18.148 (range: 13–24)\tN/A\t–\t \tMean dose (mL/d)\t446.486 (range: 60–1800)\tN/A\t–\t \tTotal BIS scores\t71.621 (4.872)\t58.812 (5.127)\t0.000⁎\t \tAttentional impulsivity\t18.487 (5.670)\t16.469 (1.502)\t0.044\t \tMotor impulsivity\t23.838 (5.781)\t21.188 (3.533)\t0.023\t \tNonplan impulsivity\t29.297 (2.644)\t20.812 (2.620)\t0.000⁎\t \tHead motion (mean FD_Power)\t0.203166 (0.115205)\t0.159498 (0.072997)\t0.061\t \t
#Text=Unless otherwise indicated, data are means ± standard deviations.
91-1	15389-15394	Table	_	
91-2	15395-15396	1	_	
91-3	15400-15414	Characteristic	_	
91-4	15415-15428	CCS-dependent	_	
91-5	15429-15440	individuals	_	
91-6	15441-15442	(	_	
91-7	15442-15443	n	_	
91-8	15443-15444	 	_	
91-9	15444-15445	=	_	
91-10	15445-15446	 	_	
91-11	15446-15448	37	_	
91-12	15448-15449	)	_	
91-13	15450-15458	Controls	_	
91-14	15459-15460	(	_	
91-15	15460-15461	n	_	
91-16	15461-15462	 	_	
91-17	15462-15463	=	_	
91-18	15463-15464	 	_	
91-19	15464-15466	32	_	
91-20	15466-15467	)	_	
91-21	15468-15475	P-value	_	
91-22	15478-15481	Age	_	
91-23	15482-15483	(	_	
91-24	15483-15488	years	_	
91-25	15488-15489	)	_	
91-26	15490-15496	24.081	_	
91-27	15497-15498	(	_	
91-28	15498-15503	3.252	_	
91-29	15503-15504	)	_	
91-30	15505-15511	26.218	_	
91-31	15512-15513	(	_	
91-32	15513-15518	6.131	_	
91-33	15518-15519	)	_	
91-34	15520-15525	0.084	_	
91-35	15528-15537	Education	_	
91-36	15538-15539	(	_	
91-37	15539-15544	years	_	
91-38	15544-15545	)	_	
91-39	15546-15552	12.432	_	
91-40	15553-15554	(	_	
91-41	15554-15559	3.287	_	
91-42	15559-15560	)	_	
91-43	15561-15567	13.250	_	
91-44	15568-15569	(	_	
91-45	15569-15574	4.557	_	
91-46	15574-15575	)	_	
91-47	15576-15581	0.392	_	
91-48	15584-15592	Nicotine	_	
91-49	15593-15594	(	_	
91-50	15594-15596	no	_	
91-51	15596-15597	.	_	
91-52	15598-15600	of	_	
91-53	15601-15611	cigarettes	_	
91-54	15611-15612	/	_	
91-55	15612-15615	day	_	
91-56	15615-15616	)	_	
91-57	15617-15623	16.243	_	
91-58	15624-15625	(	_	
91-59	15625-15630	8.597	_	
91-60	15630-15631	)	_	
91-61	15632-15638	13.218	_	
91-62	15639-15640	(	_	
91-63	15640-15645	6.926	_	
91-64	15645-15646	)	_	
91-65	15647-15652	0.116	_	
91-66	15655-15660	Cough	_	
91-67	15661-15667	syrups	_	
91-68	15668-15671	use	_	
91-69	15672-15673	(	_	
91-70	15673-15678	years	_	
91-71	15678-15679	)	_	
91-72	15680-15685	5.872	_	
91-73	15686-15687	(	_	
91-74	15687-15692	range	_	
91-75	15692-15693	:	_	
91-76	15694-15695	1	_	
91-77	15695-15696	–	_	
91-78	15696-15698	15	_	
91-79	15698-15699	)	_	
91-80	15700-15701	N	_	
91-81	15701-15702	/	_	
91-82	15702-15703	A	_	
91-83	15704-15705	–	_	
91-84	15708-15711	Age	_	
91-85	15712-15714	at	_	
91-86	15715-15718	the	_	
91-87	15719-15724	first	_	
91-88	15725-15728	use	_	
91-89	15729-15731	of	_	
91-90	15732-15737	cough	_	
91-91	15738-15744	syrups	_	
91-92	15745-15751	18.148	_	
91-93	15752-15753	(	_	
91-94	15753-15758	range	_	
91-95	15758-15759	:	_	
91-96	15760-15762	13	_	
91-97	15762-15763	–	_	
91-98	15763-15765	24	_	
91-99	15765-15766	)	_	
91-100	15767-15768	N	_	
91-101	15768-15769	/	_	
91-102	15769-15770	A	_	
91-103	15771-15772	–	_	
91-104	15775-15779	Mean	_	
91-105	15780-15784	dose	_	
91-106	15785-15786	(	_	
91-107	15786-15788	mL	_	
91-108	15788-15789	/	_	
91-109	15789-15790	d	_	
91-110	15790-15791	)	_	
91-111	15792-15799	446.486	_	
91-112	15800-15801	(	_	
91-113	15801-15806	range	_	
91-114	15806-15807	:	_	
91-115	15808-15810	60	_	
91-116	15810-15811	–	_	
91-117	15811-15815	1800	_	
91-118	15815-15816	)	_	
91-119	15817-15818	N	_	
91-120	15818-15819	/	_	
91-121	15819-15820	A	_	
91-122	15821-15822	–	_	
91-123	15825-15830	Total	_	
91-124	15831-15834	BIS	_	
91-125	15835-15841	scores	_	
91-126	15842-15848	71.621	_	
91-127	15849-15850	(	_	
91-128	15850-15855	4.872	_	
91-129	15855-15856	)	_	
91-130	15857-15863	58.812	_	
91-131	15864-15865	(	_	
91-132	15865-15870	5.127	_	
91-133	15870-15871	)	_	
91-134	15872-15877	0.000	_	
91-135	15877-15878	⁎	_	
91-136	15881-15892	Attentional	_	
91-137	15893-15904	impulsivity	_	
91-138	15905-15911	18.487	_	
91-139	15912-15913	(	_	
91-140	15913-15918	5.670	_	
91-141	15918-15919	)	_	
91-142	15920-15926	16.469	_	
91-143	15927-15928	(	_	
91-144	15928-15933	1.502	_	
91-145	15933-15934	)	_	
91-146	15935-15940	0.044	_	
91-147	15943-15948	Motor	_	
91-148	15949-15960	impulsivity	_	
91-149	15961-15967	23.838	_	
91-150	15968-15969	(	_	
91-151	15969-15974	5.781	_	
91-152	15974-15975	)	_	
91-153	15976-15982	21.188	_	
91-154	15983-15984	(	_	
91-155	15984-15989	3.533	_	
91-156	15989-15990	)	_	
91-157	15991-15996	0.023	_	
91-158	15999-16006	Nonplan	_	
91-159	16007-16018	impulsivity	_	
91-160	16019-16025	29.297	_	
91-161	16026-16027	(	_	
91-162	16027-16032	2.644	_	
91-163	16032-16033	)	_	
91-164	16034-16040	20.812	_	
91-165	16041-16042	(	_	
91-166	16042-16047	2.620	_	
91-167	16047-16048	)	_	
91-168	16049-16054	0.000	_	
91-169	16054-16055	⁎	_	
91-170	16058-16062	Head	_	
91-171	16063-16069	motion	_	
91-172	16070-16071	(	_	
91-173	16071-16075	mean	_	
91-174	16076-16084	FD_Power	_	
91-175	16084-16085	)	_	
91-176	16086-16094	0.203166	_	
91-177	16095-16096	(	_	
91-178	16096-16104	0.115205	_	
91-179	16104-16105	)	_	
91-180	16106-16114	0.159498	_	
91-181	16115-16116	(	_	
91-182	16116-16124	0.072997	_	
91-183	16124-16125	)	_	
91-184	16126-16131	0.061	_	
91-185	16135-16141	Unless	_	
91-186	16142-16151	otherwise	_	
91-187	16152-16161	indicated	_	
91-188	16161-16162	,	_	
91-189	16163-16167	data	_	
91-190	16168-16171	are	_	
91-191	16172-16177	means	_	
91-192	16177-16178	 	_	
91-193	16178-16179	±	_	
91-194	16179-16180	 	_	
91-195	16180-16188	standard	_	
91-196	16189-16199	deviations	_	
91-197	16199-16200	.	_	

#Text=NA, not applicable.
92-1	16201-16203	NA	_	
92-2	16203-16204	,	_	
92-3	16205-16208	not	_	
92-4	16209-16219	applicable	_	
92-5	16219-16220	.	_	

#Text=P < 0.05.
93-1	16221-16222	P	_	
93-2	16222-16223	 	_	
93-3	16223-16224	<	_	
93-4	16224-16225	 	_	
93-5	16225-16229	0.05	_	
93-6	16229-16230	.	_	

#Text=No significant differences were observed in age (t = 4.232, P = 0.084), gender distribution (χ2 = 0.842, P = 0.359), formal years of education (t = 0.862, P = 0.392), number of cigarettes smoked per day (t = −1.592, P = 0.116), and head motion (t = 1.905, P = 0.061) between the CCS-dependent individuals and the control subjects.
94-1	16231-16233	No	_	
94-2	16234-16245	significant	_	
94-3	16246-16257	differences	_	
94-4	16258-16262	were	_	
94-5	16263-16271	observed	_	
94-6	16272-16274	in	_	
94-7	16275-16278	age	_	
94-8	16279-16280	(	_	
94-9	16280-16281	t	_	
94-10	16281-16282	 	_	
94-11	16282-16283	=	_	
94-12	16283-16284	 	_	
94-13	16284-16289	4.232	_	
94-14	16289-16290	,	_	
94-15	16291-16292	P	_	
94-16	16292-16293	 	_	
94-17	16293-16294	=	_	
94-18	16294-16295	 	_	
94-19	16295-16300	0.084	_	
94-20	16300-16301	)	_	
94-21	16301-16302	,	_	
94-22	16303-16309	gender	_	
94-23	16310-16322	distribution	_	
94-24	16323-16324	(	_	
94-25	16324-16326	χ2	_	
94-26	16326-16327	 	_	
94-27	16327-16328	=	_	
94-28	16328-16329	 	_	
94-29	16329-16334	0.842	_	
94-30	16334-16335	,	_	
94-31	16336-16337	P	_	
94-32	16337-16338	 	_	
94-33	16338-16339	=	_	
94-34	16339-16340	 	_	
94-35	16340-16345	0.359	_	
94-36	16345-16346	)	_	
94-37	16346-16347	,	_	
94-38	16348-16354	formal	_	
94-39	16355-16360	years	_	
94-40	16361-16363	of	_	
94-41	16364-16373	education	_	
94-42	16374-16375	(	_	
94-43	16375-16376	t	_	
94-44	16376-16377	 	_	
94-45	16377-16378	=	_	
94-46	16378-16379	 	_	
94-47	16379-16384	0.862	_	
94-48	16384-16385	,	_	
94-49	16386-16387	P	_	
94-50	16387-16388	 	_	
94-51	16388-16389	=	_	
94-52	16389-16390	 	_	
94-53	16390-16395	0.392	_	
94-54	16395-16396	)	_	
94-55	16396-16397	,	_	
94-56	16398-16404	number	_	
94-57	16405-16407	of	_	
94-58	16408-16418	cigarettes	_	
94-59	16419-16425	smoked	_	
94-60	16426-16429	per	_	
94-61	16430-16433	day	_	
94-62	16434-16435	(	_	
94-63	16435-16436	t	_	
94-64	16436-16437	 	_	
94-65	16437-16438	=	_	
94-66	16438-16439	 	_	
94-67	16439-16440	−	_	
94-68	16440-16445	1.592	_	
94-69	16445-16446	,	_	
94-70	16447-16448	P	_	
94-71	16448-16449	 	_	
94-72	16449-16450	=	_	
94-73	16450-16451	 	_	
94-74	16451-16456	0.116	_	
94-75	16456-16457	)	_	
94-76	16457-16458	,	_	
94-77	16459-16462	and	_	
94-78	16463-16467	head	_	
94-79	16468-16474	motion	_	
94-80	16475-16476	(	_	
94-81	16476-16477	t	_	
94-82	16477-16478	 	_	
94-83	16478-16479	=	_	
94-84	16479-16480	 	_	
94-85	16480-16485	1.905	_	
94-86	16485-16486	,	_	
94-87	16487-16488	P	_	
94-88	16488-16489	 	_	
94-89	16489-16490	=	_	
94-90	16490-16491	 	_	
94-91	16491-16496	0.061	_	
94-92	16496-16497	)	_	
94-93	16498-16505	between	_	
94-94	16506-16509	the	_	
94-95	16510-16523	CCS-dependent	_	
94-96	16524-16535	individuals	_	
94-97	16536-16539	and	_	
94-98	16540-16543	the	_	
94-99	16544-16551	control	_	
94-100	16552-16560	subjects	_	
94-101	16560-16561	.	_	

#Text=Details of the demographic data and corresponding clinical characteristics are presented in Table 1.
95-1	16562-16569	Details	_	
95-2	16570-16572	of	_	
95-3	16573-16576	the	_	
95-4	16577-16588	demographic	_	
95-5	16589-16593	data	_	
95-6	16594-16597	and	_	
95-7	16598-16611	corresponding	_	
95-8	16612-16620	clinical	_	
95-9	16621-16636	characteristics	_	
95-10	16637-16640	are	_	
95-11	16641-16650	presented	_	
95-12	16651-16653	in	_	
95-13	16654-16659	Table	_	
95-14	16660-16661	1	_	
95-15	16661-16662	.	_	

#Text=The comparison of average BIS-11 scores from the chronic CCS-dependent individuals and control group is shown in Table 1.
96-1	16663-16666	The	_	
96-2	16667-16677	comparison	_	
96-3	16678-16680	of	_	
96-4	16681-16688	average	_	
96-5	16689-16692	BIS	_	
96-6	16692-16693	-	_	
96-7	16693-16695	11	_	
96-8	16696-16702	scores	_	
96-9	16703-16707	from	_	
96-10	16708-16711	the	_	
96-11	16712-16719	chronic	_	
96-12	16720-16733	CCS-dependent	_	
96-13	16734-16745	individuals	_	
96-14	16746-16749	and	_	
96-15	16750-16757	control	_	
96-16	16758-16763	group	_	
96-17	16764-16766	is	_	
96-18	16767-16772	shown	_	
96-19	16773-16775	in	_	
96-20	16776-16781	Table	_	
96-21	16782-16783	1	_	
96-22	16783-16784	.	_	

#Text=We observed that the CCS-dependent individuals had significantly higher total scores, attentional impulsivity, motor impulsivity, and non-plan impulsivity than the control group (P < 0.05).
97-1	16785-16787	We	_	
97-2	16788-16796	observed	_	
97-3	16797-16801	that	_	
97-4	16802-16805	the	_	
97-5	16806-16819	CCS-dependent	_	
97-6	16820-16831	individuals	_	
97-7	16832-16835	had	_	
97-8	16836-16849	significantly	_	
97-9	16850-16856	higher	_	
97-10	16857-16862	total	_	
97-11	16863-16869	scores	_	
97-12	16869-16870	,	_	
97-13	16871-16882	attentional	_	
97-14	16883-16894	impulsivity	_	
97-15	16894-16895	,	_	
97-16	16896-16901	motor	_	
97-17	16902-16913	impulsivity	_	
97-18	16913-16914	,	_	
97-19	16915-16918	and	_	
97-20	16919-16927	non-plan	_	
97-21	16928-16939	impulsivity	_	
97-22	16940-16944	than	_	
97-23	16945-16948	the	_	
97-24	16949-16956	control	_	
97-25	16957-16962	group	_	
97-26	16963-16964	(	_	
97-27	16964-16965	P	_	
97-28	16965-16966	 	_	
97-29	16966-16967	<	_	
97-30	16967-16968	 	_	
97-31	16968-16972	0.05	_	
97-32	16972-16973	)	_	
97-33	16973-16974	.	_	

#Text=DC analysis
#Text=Brain regions showing differences in the degree between control subjects and CCS-dependent patients.
98-1	16975-16977	DC	_	
98-2	16978-16986	analysis	_	
98-3	16987-16992	Brain	_	
98-4	16993-17000	regions	_	
98-5	17001-17008	showing	_	
98-6	17009-17020	differences	_	
98-7	17021-17023	in	_	
98-8	17024-17027	the	_	
98-9	17028-17034	degree	_	
98-10	17035-17042	between	_	
98-11	17043-17050	control	_	
98-12	17051-17059	subjects	_	
98-13	17060-17063	and	_	
98-14	17064-17077	CCS-dependent	_	
98-15	17078-17086	patients	_	
98-16	17086-17087	.	_	

#Text=Table 2\t \t
#Text=Brain regions\tMNI coordinates\tNumber of Voxels\tT value\t \t\tX\tY\tZ\t\t\t \tHippocampus_R\t33\t−15\t−27\t19\t4.0148\t \tTemporal_Mid_L\t−63\t−36\t−12\t37\t−3.856\t \tPallidum_R\t21\t−3\t−3\t24\t4.2402\t \tParietal_Inf_L\t−27\t−69\t42\t35\t−3.853\t \t
#Text=Brain regions showing decreased degree of differences in CCS-dependent group as compared to the HC group.
99-1	17088-17093	Table	_	
99-2	17094-17095	2	_	
99-3	17099-17104	Brain	_	
99-4	17105-17112	regions	_	
99-5	17113-17116	MNI	_	
99-6	17117-17128	coordinates	_	
99-7	17129-17135	Number	_	
99-8	17136-17138	of	_	
99-9	17139-17145	Voxels	_	
99-10	17146-17147	T	_	
99-11	17148-17153	value	_	
99-12	17157-17158	X	_	
99-13	17159-17160	Y	_	
99-14	17161-17162	Z	_	
99-15	17167-17180	Hippocampus_R	_	
99-16	17181-17183	33	_	
99-17	17184-17185	−	_	
99-18	17185-17187	15	_	
99-19	17188-17189	−	_	
99-20	17189-17191	27	_	
99-21	17192-17194	19	_	
99-22	17195-17201	4.0148	_	
99-23	17204-17218	Temporal_Mid_L	_	
99-24	17219-17220	−	_	
99-25	17220-17222	63	_	
99-26	17223-17224	−	_	
99-27	17224-17226	36	_	
99-28	17227-17228	−	_	
99-29	17228-17230	12	_	
99-30	17231-17233	37	_	
99-31	17234-17235	−	_	
99-32	17235-17240	3.856	_	
99-33	17243-17253	Pallidum_R	_	
99-34	17254-17256	21	_	
99-35	17257-17258	−	_	
99-36	17258-17259	3	_	
99-37	17260-17261	−	_	
99-38	17261-17262	3	_	
99-39	17263-17265	24	_	
99-40	17266-17272	4.2402	_	
99-41	17275-17289	Parietal_Inf_L	_	
99-42	17290-17291	−	_	
99-43	17291-17293	27	_	
99-44	17294-17295	−	_	
99-45	17295-17297	69	_	
99-46	17298-17300	42	_	
99-47	17301-17303	35	_	
99-48	17304-17305	−	_	
99-49	17305-17310	3.853	_	
99-50	17314-17319	Brain	_	
99-51	17320-17327	regions	_	
99-52	17328-17335	showing	_	
99-53	17336-17345	decreased	_	
99-54	17346-17352	degree	_	
99-55	17353-17355	of	_	
99-56	17356-17367	differences	_	
99-57	17368-17370	in	_	
99-58	17371-17384	CCS-dependent	_	
99-59	17385-17390	group	_	
99-60	17391-17393	as	_	
99-61	17394-17402	compared	_	
99-62	17403-17405	to	_	
99-63	17406-17409	the	_	
99-64	17410-17412	HC	_	
99-65	17413-17418	group	_	
99-66	17418-17419	.	_	

#Text=The regions showing decreased degree of differences in axial (Z = −12, Z = 42 mm), coronal (X = −63, X = −27), and sagittal maps (Y = −36, Y = −69).
100-1	17420-17423	The	_	
100-2	17424-17431	regions	_	
100-3	17432-17439	showing	_	
100-4	17440-17449	decreased	_	
100-5	17450-17456	degree	_	
100-6	17457-17459	of	_	
100-7	17460-17471	differences	_	
100-8	17472-17474	in	_	
100-9	17475-17480	axial	_	
100-10	17481-17482	(	_	
100-11	17482-17483	Z	_	
100-12	17483-17484	 	_	
100-13	17484-17485	=	_	
100-14	17485-17486	 	_	
100-15	17486-17487	−	_	
100-16	17487-17489	12	_	
100-17	17489-17490	,	_	
100-18	17491-17492	Z	_	
100-19	17492-17493	 	_	
100-20	17493-17494	=	_	
100-21	17494-17495	 	_	
100-22	17495-17497	42	_	
100-23	17497-17498	 	_	
100-24	17498-17500	mm	_	
100-25	17500-17501	)	_	
100-26	17501-17502	,	_	
100-27	17503-17510	coronal	_	
100-28	17511-17512	(	_	
100-29	17512-17513	X	_	
100-30	17513-17514	 	_	
100-31	17514-17515	=	_	
100-32	17515-17516	 	_	
100-33	17516-17517	−	_	
100-34	17517-17519	63	_	
100-35	17519-17520	,	_	
100-36	17521-17522	X	_	
100-37	17522-17523	 	_	
100-38	17523-17524	=	_	
100-39	17524-17525	 	_	
100-40	17525-17526	−	_	
100-41	17526-17528	27	_	
100-42	17528-17529	)	_	
100-43	17529-17530	,	_	
100-44	17531-17534	and	_	
100-45	17535-17543	sagittal	_	
100-46	17544-17548	maps	_	
100-47	17549-17550	(	_	
100-48	17550-17551	Y	_	
100-49	17551-17552	 	_	
100-50	17552-17553	=	_	
100-51	17553-17554	 	_	
100-52	17554-17555	−	_	
100-53	17555-17557	36	_	
100-54	17557-17558	,	_	
100-55	17559-17560	Y	_	
100-56	17560-17561	 	_	
100-57	17561-17562	=	_	
100-58	17562-17563	 	_	
100-59	17563-17564	−	_	
100-60	17564-17566	69	_	
100-61	17566-17567	)	_	
100-62	17567-17568	.	_	

#Text=Fig. 1
#Text=Brain regions showing increased degree of differences in CCS-dependent group as compared to the HC group.
101-1	17569-17572	Fig	_	
101-2	17572-17573	.	_	
101-3	17574-17575	1	_	
101-4	17576-17581	Brain	_	
101-5	17582-17589	regions	_	
101-6	17590-17597	showing	_	
101-7	17598-17607	increased	_	
101-8	17608-17614	degree	_	
101-9	17615-17617	of	_	
101-10	17618-17629	differences	_	
101-11	17630-17632	in	_	
101-12	17633-17646	CCS-dependent	_	
101-13	17647-17652	group	_	
101-14	17653-17655	as	_	
101-15	17656-17664	compared	_	
101-16	17665-17667	to	_	
101-17	17668-17671	the	_	
101-18	17672-17674	HC	_	
101-19	17675-17680	group	_	
101-20	17680-17681	.	_	

#Text=The regions showing increased degree of differences in axial (Z = −3, Z = −27 mm), coronal (X = 21, X = 33), and sagittal maps (Y = −3, Y = −15).
102-1	17682-17685	The	_	
102-2	17686-17693	regions	_	
102-3	17694-17701	showing	_	
102-4	17702-17711	increased	_	
102-5	17712-17718	degree	_	
102-6	17719-17721	of	_	
102-7	17722-17733	differences	_	
102-8	17734-17736	in	_	
102-9	17737-17742	axial	_	
102-10	17743-17744	(	_	
102-11	17744-17745	Z	_	
102-12	17745-17746	 	_	
102-13	17746-17747	=	_	
102-14	17747-17748	 	_	
102-15	17748-17749	−	_	
102-16	17749-17750	3	_	
102-17	17750-17751	,	_	
102-18	17752-17753	Z	_	
102-19	17753-17754	 	_	
102-20	17754-17755	=	_	
102-21	17755-17756	 	_	
102-22	17756-17757	−	_	
102-23	17757-17759	27	_	
102-24	17759-17760	 	_	
102-25	17760-17762	mm	_	
102-26	17762-17763	)	_	
102-27	17763-17764	,	_	
102-28	17765-17772	coronal	_	
102-29	17773-17774	(	_	
102-30	17774-17775	X	_	
102-31	17775-17776	 	_	
102-32	17776-17777	=	_	
102-33	17777-17778	 	_	
102-34	17778-17780	21	_	
102-35	17780-17781	,	_	
102-36	17782-17783	X	_	
102-37	17783-17784	 	_	
102-38	17784-17785	=	_	
102-39	17785-17786	 	_	
102-40	17786-17788	33	_	
102-41	17788-17789	)	_	
102-42	17789-17790	,	_	
102-43	17791-17794	and	_	
102-44	17795-17803	sagittal	_	
102-45	17804-17808	maps	_	
102-46	17809-17810	(	_	
102-47	17810-17811	Y	_	
102-48	17811-17812	 	_	
102-49	17812-17813	=	_	
102-50	17813-17814	 	_	
102-51	17814-17815	−	_	
102-52	17815-17816	3	_	
102-53	17816-17817	,	_	
102-54	17818-17819	Y	_	
102-55	17819-17820	 	_	
102-56	17820-17821	=	_	
102-57	17821-17822	 	_	
102-58	17822-17823	−	_	
102-59	17823-17825	15	_	
102-60	17825-17826	)	_	
102-61	17826-17827	.	_	

#Text=Fig. 2
#Text=The two-sample t-test analysis revealed significantly increased DC values within the right hippocampus and right pallidum and significantly decreased DC values within the left IPL and left middle temporal gyrus in CCS-dependent individuals as compared to the control group (P < 0.01, AlphaSim corrected) (Table 2 and Fig. 1, Fig. 2).
103-1	17828-17831	Fig	_	
103-2	17831-17832	.	_	
103-3	17833-17834	2	_	
103-4	17835-17838	The	_	
103-5	17839-17849	two-sample	_	
103-6	17850-17856	t-test	_	
103-7	17857-17865	analysis	_	
103-8	17866-17874	revealed	_	
103-9	17875-17888	significantly	_	
103-10	17889-17898	increased	_	
103-11	17899-17901	DC	_	
103-12	17902-17908	values	_	
103-13	17909-17915	within	_	
103-14	17916-17919	the	_	
103-15	17920-17925	right	_	
103-16	17926-17937	hippocampus	_	
103-17	17938-17941	and	_	
103-18	17942-17947	right	_	
103-19	17948-17956	pallidum	_	
103-20	17957-17960	and	_	
103-21	17961-17974	significantly	_	
103-22	17975-17984	decreased	_	
103-23	17985-17987	DC	_	
103-24	17988-17994	values	_	
103-25	17995-18001	within	_	
103-26	18002-18005	the	_	
103-27	18006-18010	left	_	
103-28	18011-18014	IPL	_	
103-29	18015-18018	and	_	
103-30	18019-18023	left	_	
103-31	18024-18030	middle	_	
103-32	18031-18039	temporal	_	
103-33	18040-18045	gyrus	_	
103-34	18046-18048	in	_	
103-35	18049-18062	CCS-dependent	_	
103-36	18063-18074	individuals	_	
103-37	18075-18077	as	_	
103-38	18078-18086	compared	_	
103-39	18087-18089	to	_	
103-40	18090-18093	the	_	
103-41	18094-18101	control	_	
103-42	18102-18107	group	_	
103-43	18108-18109	(	_	
103-44	18109-18110	P	_	
103-45	18110-18111	 	_	
103-46	18111-18112	<	_	
103-47	18112-18113	 	_	
103-48	18113-18117	0.01	_	
103-49	18117-18118	,	_	
103-50	18119-18127	AlphaSim	_	
103-51	18128-18137	corrected	_	
103-52	18137-18138	)	_	
103-53	18139-18140	(	_	
103-54	18140-18145	Table	_	
103-55	18146-18147	2	_	
103-56	18148-18151	and	_	
103-57	18152-18155	Fig	_	
103-58	18155-18156	.	_	
103-59	18157-18158	1	_	
103-60	18158-18159	,	_	
103-61	18160-18163	Fig	_	
103-62	18163-18164	.	_	
103-63	18165-18166	2	_	
103-64	18166-18167	)	_	
103-65	18167-18168	.	_	

#Text=Correlation results
#Text=Scatter plot of the mean DC values in the left inferior parietal lobule changing with the age at first use of codeine-containing cough syrups and attentional impulsivity scores, respectively.
104-1	18169-18180	Correlation	_	
104-2	18181-18188	results	_	
104-3	18189-18196	Scatter	_	
104-4	18197-18201	plot	_	
104-5	18202-18204	of	_	
104-6	18205-18208	the	_	
104-7	18209-18213	mean	_	
104-8	18214-18216	DC	_	
104-9	18217-18223	values	_	
104-10	18224-18226	in	_	
104-11	18227-18230	the	_	
104-12	18231-18235	left	_	
104-13	18236-18244	inferior	_	
104-14	18245-18253	parietal	_	
104-15	18254-18260	lobule	_	
104-16	18261-18269	changing	_	
104-17	18270-18274	with	_	
104-18	18275-18278	the	_	
104-19	18279-18282	age	_	
104-20	18283-18285	at	_	
104-21	18286-18291	first	_	
104-22	18292-18295	use	_	
104-23	18296-18298	of	_	
104-24	18299-18317	codeine-containing	_	
104-25	18318-18323	cough	_	
104-26	18324-18330	syrups	_	
104-27	18331-18334	and	_	
104-28	18335-18346	attentional	_	
104-29	18347-18358	impulsivity	_	
104-30	18359-18365	scores	_	
104-31	18365-18366	,	_	
104-32	18367-18379	respectively	_	
104-33	18379-18380	.	_	

#Text=Fig. 3
#Text=A decreased average DC value of the left IPL observed in CCS-dependent individuals correlated negatively with the subscale of attentional impulsivity (P = 0.002, PBonferroni < 0.0021) and positively with age at the first use of CCS (Fig. 3).
105-1	18381-18384	Fig	_	
105-2	18384-18385	.	_	
105-3	18386-18387	3	_	
105-4	18388-18389	A	_	
105-5	18390-18399	decreased	_	
105-6	18400-18407	average	_	
105-7	18408-18410	DC	_	
105-8	18411-18416	value	_	
105-9	18417-18419	of	_	
105-10	18420-18423	the	_	
105-11	18424-18428	left	_	
105-12	18429-18432	IPL	_	
105-13	18433-18441	observed	_	
105-14	18442-18444	in	_	
105-15	18445-18458	CCS-dependent	_	
105-16	18459-18470	individuals	_	
105-17	18471-18481	correlated	_	
105-18	18482-18492	negatively	_	
105-19	18493-18497	with	_	
105-20	18498-18501	the	_	
105-21	18502-18510	subscale	_	
105-22	18511-18513	of	_	
105-23	18514-18525	attentional	_	
105-24	18526-18537	impulsivity	_	
105-25	18538-18539	(	_	
105-26	18539-18540	P	_	
105-27	18540-18541	 	_	
105-28	18541-18542	=	_	
105-29	18542-18543	 	_	
105-30	18543-18548	0.002	_	
105-31	18548-18549	,	_	
105-32	18550-18561	PBonferroni	_	
105-33	18561-18562	 	_	
105-34	18562-18563	<	_	
105-35	18563-18564	 	_	
105-36	18564-18570	0.0021	_	
105-37	18570-18571	)	_	
105-38	18572-18575	and	_	
105-39	18576-18586	positively	_	
105-40	18587-18591	with	_	
105-41	18592-18595	age	_	
105-42	18596-18598	at	_	
105-43	18599-18602	the	_	
105-44	18603-18608	first	_	
105-45	18609-18612	use	_	
105-46	18613-18615	of	_	
105-47	18616-18619	CCS	_	
105-48	18620-18621	(	_	
105-49	18621-18624	Fig	_	
105-50	18624-18625	.	_	
105-51	18626-18627	3	_	
105-52	18627-18628	)	_	
105-53	18628-18629	.	_	

#Text=Discussion
#Text=In the present study, we used the DC analysis method to depict the intrinsic dysconnectivity pattern of the whole-brain functional networks at the voxel level in CCS-dependent individuals.
106-1	18630-18640	Discussion	_	
106-2	18641-18643	In	_	
106-3	18644-18647	the	_	
106-4	18648-18655	present	_	
106-5	18656-18661	study	_	
106-6	18661-18662	,	_	
106-7	18663-18665	we	_	
106-8	18666-18670	used	_	
106-9	18671-18674	the	_	
106-10	18675-18677	DC	_	
106-11	18678-18686	analysis	_	
106-12	18687-18693	method	_	
106-13	18694-18696	to	_	
106-14	18697-18703	depict	_	
106-15	18704-18707	the	_	
106-16	18708-18717	intrinsic	_	
106-17	18718-18733	dysconnectivity	_	
106-18	18734-18741	pattern	_	
106-19	18742-18744	of	_	
106-20	18745-18748	the	_	
106-21	18749-18760	whole-brain	_	
106-22	18761-18771	functional	_	
106-23	18772-18780	networks	_	
106-24	18781-18783	at	_	
106-25	18784-18787	the	_	
106-26	18788-18793	voxel	_	
106-27	18794-18799	level	_	
106-28	18800-18802	in	_	
106-29	18803-18816	CCS-dependent	_	
106-30	18817-18828	individuals	_	
106-31	18828-18829	.	_	

#Text=An increased degree value represents an increased number of direct connections and also reflects the increased centrality or importance of a specific voxel in the brain network.
107-1	18830-18832	An	_	
107-2	18833-18842	increased	_	
107-3	18843-18849	degree	_	
107-4	18850-18855	value	_	
107-5	18856-18866	represents	_	
107-6	18867-18869	an	_	
107-7	18870-18879	increased	_	
107-8	18880-18886	number	_	
107-9	18887-18889	of	_	
107-10	18890-18896	direct	_	
107-11	18897-18908	connections	_	
107-12	18909-18912	and	_	
107-13	18913-18917	also	_	
107-14	18918-18926	reflects	_	
107-15	18927-18930	the	_	
107-16	18931-18940	increased	_	
107-17	18941-18951	centrality	_	
107-18	18952-18954	or	_	
107-19	18955-18965	importance	_	
107-20	18966-18968	of	_	
107-21	18969-18970	a	_	
107-22	18971-18979	specific	_	
107-23	18980-18985	voxel	_	
107-24	18986-18988	in	_	
107-25	18989-18992	the	_	
107-26	18993-18998	brain	_	
107-27	18999-19006	network	_	
107-28	19006-19007	.	_	

#Text=However, significantly increased DC values within the right hippocampus and the right pallidum and significantly decreased DC values within the left IPL and the left middle temporal lobe were found in CCS-dependent individuals as compared to the control group.
108-1	19008-19015	However	_	
108-2	19015-19016	,	_	
108-3	19017-19030	significantly	_	
108-4	19031-19040	increased	_	
108-5	19041-19043	DC	_	
108-6	19044-19050	values	_	
108-7	19051-19057	within	_	
108-8	19058-19061	the	_	
108-9	19062-19067	right	_	
108-10	19068-19079	hippocampus	_	
108-11	19080-19083	and	_	
108-12	19084-19087	the	_	
108-13	19088-19093	right	_	
108-14	19094-19102	pallidum	_	
108-15	19103-19106	and	_	
108-16	19107-19120	significantly	_	
108-17	19121-19130	decreased	_	
108-18	19131-19133	DC	_	
108-19	19134-19140	values	_	
108-20	19141-19147	within	_	
108-21	19148-19151	the	_	
108-22	19152-19156	left	_	
108-23	19157-19160	IPL	_	
108-24	19161-19164	and	_	
108-25	19165-19168	the	_	
108-26	19169-19173	left	_	
108-27	19174-19180	middle	_	
108-28	19181-19189	temporal	_	
108-29	19190-19194	lobe	_	
108-30	19195-19199	were	_	
108-31	19200-19205	found	_	
108-32	19206-19208	in	_	
108-33	19209-19222	CCS-dependent	_	
108-34	19223-19234	individuals	_	
108-35	19235-19237	as	_	
108-36	19238-19246	compared	_	
108-37	19247-19249	to	_	
108-38	19250-19253	the	_	
108-39	19254-19261	control	_	
108-40	19262-19267	group	_	
108-41	19267-19268	.	_	

#Text=Furthermore, a significantly negative correlation was established between the decreased average DC value of the left IPL and the subscale of attentional impulsivity, and a positive correlation between the decreased average DC value of the left IPL and the age at the first use of CCS.
109-1	19269-19280	Furthermore	_	
109-2	19280-19281	,	_	
109-3	19282-19283	a	_	
109-4	19284-19297	significantly	_	
109-5	19298-19306	negative	_	
109-6	19307-19318	correlation	_	
109-7	19319-19322	was	_	
109-8	19323-19334	established	_	
109-9	19335-19342	between	_	
109-10	19343-19346	the	_	
109-11	19347-19356	decreased	_	
109-12	19357-19364	average	_	
109-13	19365-19367	DC	_	
109-14	19368-19373	value	_	
109-15	19374-19376	of	_	
109-16	19377-19380	the	_	
109-17	19381-19385	left	_	
109-18	19386-19389	IPL	_	
109-19	19390-19393	and	_	
109-20	19394-19397	the	_	
109-21	19398-19406	subscale	_	
109-22	19407-19409	of	_	
109-23	19410-19421	attentional	_	
109-24	19422-19433	impulsivity	_	
109-25	19433-19434	,	_	
109-26	19435-19438	and	_	
109-27	19439-19440	a	_	
109-28	19441-19449	positive	_	
109-29	19450-19461	correlation	_	
109-30	19462-19469	between	_	
109-31	19470-19473	the	_	
109-32	19474-19483	decreased	_	
109-33	19484-19491	average	_	
109-34	19492-19494	DC	_	
109-35	19495-19500	value	_	
109-36	19501-19503	of	_	
109-37	19504-19507	the	_	
109-38	19508-19512	left	_	
109-39	19513-19516	IPL	_	
109-40	19517-19520	and	_	
109-41	19521-19524	the	_	
109-42	19525-19528	age	_	
109-43	19529-19531	at	_	
109-44	19532-19535	the	_	
109-45	19536-19541	first	_	
109-46	19542-19545	use	_	
109-47	19546-19548	of	_	
109-48	19549-19552	CCS	_	
109-49	19552-19553	.	_	

#Text=An important finding in the current study was that CCS-dependent individuals showed increased degree values in the right globus pallidus (ventral pallidum includes the portions of the globus pallidus), which is a key region involved in the reward circuit.
110-1	19554-19556	An	_	
110-2	19557-19566	important	_	
110-3	19567-19574	finding	_	
110-4	19575-19577	in	_	
110-5	19578-19581	the	_	
110-6	19582-19589	current	_	
110-7	19590-19595	study	_	
110-8	19596-19599	was	_	
110-9	19600-19604	that	_	
110-10	19605-19618	CCS-dependent	_	
110-11	19619-19630	individuals	_	
110-12	19631-19637	showed	_	
110-13	19638-19647	increased	_	
110-14	19648-19654	degree	_	
110-15	19655-19661	values	_	
110-16	19662-19664	in	_	
110-17	19665-19668	the	_	
110-18	19669-19674	right	_	
110-19	19675-19681	globus	_	
110-20	19682-19690	pallidus	_	
110-21	19691-19692	(	_	
110-22	19692-19699	ventral	_	
110-23	19700-19708	pallidum	_	
110-24	19709-19717	includes	_	
110-25	19718-19721	the	_	
110-26	19722-19730	portions	_	
110-27	19731-19733	of	_	
110-28	19734-19737	the	_	
110-29	19738-19744	globus	_	
110-30	19745-19753	pallidus	_	
110-31	19753-19754	)	_	
110-32	19754-19755	,	_	
110-33	19756-19761	which	_	
110-34	19762-19764	is	_	
110-35	19765-19766	a	_	
110-36	19767-19770	key	_	
110-37	19771-19777	region	_	
110-38	19778-19786	involved	_	
110-39	19787-19789	in	_	
110-40	19790-19793	the	_	
110-41	19794-19800	reward	_	
110-42	19801-19808	circuit	_	
110-43	19808-19809	.	_	

#Text=Previous studies have demonstrated that rats can eliminate a preference for the food reward, craving, and learning ability by the selective destruction of the ventral pallidum (VP), whereas to excite or disinhibit the VP neuron activity, they could promote food craving.
111-1	19810-19818	Previous	_	
111-2	19819-19826	studies	_	
111-3	19827-19831	have	_	
111-4	19832-19844	demonstrated	_	
111-5	19845-19849	that	_	
111-6	19850-19854	rats	_	
111-7	19855-19858	can	_	
111-8	19859-19868	eliminate	_	
111-9	19869-19870	a	_	
111-10	19871-19881	preference	_	
111-11	19882-19885	for	_	
111-12	19886-19889	the	_	
111-13	19890-19894	food	_	
111-14	19895-19901	reward	_	
111-15	19901-19902	,	_	
111-16	19903-19910	craving	_	
111-17	19910-19911	,	_	
111-18	19912-19915	and	_	
111-19	19916-19924	learning	_	
111-20	19925-19932	ability	_	
111-21	19933-19935	by	_	
111-22	19936-19939	the	_	
111-23	19940-19949	selective	_	
111-24	19950-19961	destruction	_	
111-25	19962-19964	of	_	
111-26	19965-19968	the	_	
111-27	19969-19976	ventral	_	
111-28	19977-19985	pallidum	_	
111-29	19986-19987	(	_	
111-30	19987-19989	VP	_	
111-31	19989-19990	)	_	
111-32	19990-19991	,	_	
111-33	19992-19999	whereas	_	
111-34	20000-20002	to	_	
111-35	20003-20009	excite	_	
111-36	20010-20012	or	_	
111-37	20013-20023	disinhibit	_	
111-38	20024-20027	the	_	
111-39	20028-20030	VP	_	
111-40	20031-20037	neuron	_	
111-41	20038-20046	activity	_	
111-42	20046-20047	,	_	
111-43	20048-20052	they	_	
111-44	20053-20058	could	_	
111-45	20059-20066	promote	_	
111-46	20067-20071	food	_	
111-47	20072-20079	craving	_	
111-48	20079-20080	.	_	

#Text=The current results suggested that the number of direct connections of the right globus pallidus increased within the brain network in CCS-dependent individuals, indicating the increased activity of the brain region.
112-1	20081-20084	The	_	
112-2	20085-20092	current	_	
112-3	20093-20100	results	_	
112-4	20101-20110	suggested	_	
112-5	20111-20115	that	_	
112-6	20116-20119	the	_	
112-7	20120-20126	number	_	
112-8	20127-20129	of	_	
112-9	20130-20136	direct	_	
112-10	20137-20148	connections	_	
112-11	20149-20151	of	_	
112-12	20152-20155	the	_	
112-13	20156-20161	right	_	
112-14	20162-20168	globus	_	
112-15	20169-20177	pallidus	_	
112-16	20178-20187	increased	_	
112-17	20188-20194	within	_	
112-18	20195-20198	the	_	
112-19	20199-20204	brain	_	
112-20	20205-20212	network	_	
112-21	20213-20215	in	_	
112-22	20216-20229	CCS-dependent	_	
112-23	20230-20241	individuals	_	
112-24	20241-20242	,	_	
112-25	20243-20253	indicating	_	
112-26	20254-20257	the	_	
112-27	20258-20267	increased	_	
112-28	20268-20276	activity	_	
112-29	20277-20279	of	_	
112-30	20280-20283	the	_	
112-31	20284-20289	brain	_	
112-32	20290-20296	region	_	
112-33	20296-20297	.	_	

#Text=Thus the increased DC value of the globus pallidus is speculated to promote the craving for addictive drugs in CCS-dependent individuals.
113-1	20298-20302	Thus	_	
113-2	20303-20306	the	_	
113-3	20307-20316	increased	_	
113-4	20317-20319	DC	_	
113-5	20320-20325	value	_	
113-6	20326-20328	of	_	
113-7	20329-20332	the	_	
113-8	20333-20339	globus	_	
113-9	20340-20348	pallidus	_	
113-10	20349-20351	is	_	
113-11	20352-20362	speculated	_	
113-12	20363-20365	to	_	
113-13	20366-20373	promote	_	
113-14	20374-20377	the	_	
113-15	20378-20385	craving	_	
113-16	20386-20389	for	_	
113-17	20390-20399	addictive	_	
113-18	20400-20405	drugs	_	
113-19	20406-20408	in	_	
113-20	20409-20422	CCS-dependent	_	
113-21	20423-20434	individuals	_	
113-22	20434-20435	.	_	

#Text=Consecutively, the dysfunction of the globus pallidus may indicate the dysfunction of the striatum in CCS-dependent individuals as it is a part of the striatum.
114-1	20436-20449	Consecutively	_	
114-2	20449-20450	,	_	
114-3	20451-20454	the	_	
114-4	20455-20466	dysfunction	_	
114-5	20467-20469	of	_	
114-6	20470-20473	the	_	
114-7	20474-20480	globus	_	
114-8	20481-20489	pallidus	_	
114-9	20490-20493	may	_	
114-10	20494-20502	indicate	_	
114-11	20503-20506	the	_	
114-12	20507-20518	dysfunction	_	
114-13	20519-20521	of	_	
114-14	20522-20525	the	_	
114-15	20526-20534	striatum	_	
114-16	20535-20537	in	_	
114-17	20538-20551	CCS-dependent	_	
114-18	20552-20563	individuals	_	
114-19	20564-20566	as	_	
114-20	20567-20569	it	_	
114-21	20570-20572	is	_	
114-22	20573-20574	a	_	
114-23	20575-20579	part	_	
114-24	20580-20582	of	_	
114-25	20583-20586	the	_	
114-26	20587-20595	striatum	_	
114-27	20595-20596	.	_	

#Text=The striatum is considered to be associated with stressful experiences.
115-1	20597-20600	The	_	
115-2	20601-20609	striatum	_	
115-3	20610-20612	is	_	
115-4	20613-20623	considered	_	
115-5	20624-20626	to	_	
115-6	20627-20629	be	_	
115-7	20630-20640	associated	_	
115-8	20641-20645	with	_	
115-9	20646-20655	stressful	_	
115-10	20656-20667	experiences	_	
115-11	20667-20668	.	_	

#Text=The PET studies revealed that acute stress exposure increased the amount of dopamine release in the striatum.
116-1	20669-20672	The	_	
116-2	20673-20676	PET	_	
116-3	20677-20684	studies	_	
116-4	20685-20693	revealed	_	
116-5	20694-20698	that	_	
116-6	20699-20704	acute	_	
116-7	20705-20711	stress	_	
116-8	20712-20720	exposure	_	
116-9	20721-20730	increased	_	
116-10	20731-20734	the	_	
116-11	20735-20741	amount	_	
116-12	20742-20744	of	_	
116-13	20745-20753	dopamine	_	
116-14	20754-20761	release	_	
116-15	20762-20764	in	_	
116-16	20765-20768	the	_	
116-17	20769-20777	striatum	_	
116-18	20777-20778	.	_	

#Text=Furthermore, found that stress could induce reinstatement of heroin-seeking behavior following a test for food deprivation-induced reinstatement in rats. employed rs-fMRI and found that the connectivity strength was overall high in the striatum in heroin-addicted patients.
117-1	20779-20790	Furthermore	_	
117-2	20790-20791	,	_	
117-3	20792-20797	found	_	
117-4	20798-20802	that	_	
117-5	20803-20809	stress	_	
117-6	20810-20815	could	_	
117-7	20816-20822	induce	_	
117-8	20823-20836	reinstatement	_	
117-9	20837-20839	of	_	
117-10	20840-20854	heroin-seeking	_	
117-11	20855-20863	behavior	_	
117-12	20864-20873	following	_	
117-13	20874-20875	a	_	
117-14	20876-20880	test	_	
117-15	20881-20884	for	_	
117-16	20885-20889	food	_	
117-17	20890-20909	deprivation-induced	_	
117-18	20910-20923	reinstatement	_	
117-19	20924-20926	in	_	
117-20	20927-20931	rats	_	
117-21	20931-20932	.	_	
117-22	20933-20941	employed	_	
117-23	20942-20949	rs-fMRI	_	
117-24	20950-20953	and	_	
117-25	20954-20959	found	_	
117-26	20960-20964	that	_	
117-27	20965-20968	the	_	
117-28	20969-20981	connectivity	_	
117-29	20982-20990	strength	_	
117-30	20991-20994	was	_	
117-31	20995-21002	overall	_	
117-32	21003-21007	high	_	
117-33	21008-21010	in	_	
117-34	21011-21014	the	_	
117-35	21015-21023	striatum	_	
117-36	21024-21026	in	_	
117-37	21027-21042	heroin-addicted	_	
117-38	21043-21051	patients	_	
117-39	21051-21052	.	_	

#Text=Furthermore, the study considered that such a dysregulation of the brain regions might lead to a deficit in stress regulatory processes during the resting state.
118-1	21053-21064	Furthermore	_	
118-2	21064-21065	,	_	
118-3	21066-21069	the	_	
118-4	21070-21075	study	_	
118-5	21076-21086	considered	_	
118-6	21087-21091	that	_	
118-7	21092-21096	such	_	
118-8	21097-21098	a	_	
118-9	21099-21112	dysregulation	_	
118-10	21113-21115	of	_	
118-11	21116-21119	the	_	
118-12	21120-21125	brain	_	
118-13	21126-21133	regions	_	
118-14	21134-21139	might	_	
118-15	21140-21144	lead	_	
118-16	21145-21147	to	_	
118-17	21148-21149	a	_	
118-18	21150-21157	deficit	_	
118-19	21158-21160	in	_	
118-20	21161-21167	stress	_	
118-21	21168-21178	regulatory	_	
118-22	21179-21188	processes	_	
118-23	21189-21195	during	_	
118-24	21196-21199	the	_	
118-25	21200-21207	resting	_	
118-26	21208-21213	state	_	
118-27	21213-21214	.	_	

#Text=Thus, increased degree values in the globus pallidus in the current study could be correlated to a deficit in stress regulatory processes in drug-addicted patients during the resting state; this postulate can probably provide novel approaches for customized therapies for the treatment of CCS-dependent patients.
119-1	21215-21219	Thus	_	
119-2	21219-21220	,	_	
119-3	21221-21230	increased	_	
119-4	21231-21237	degree	_	
119-5	21238-21244	values	_	
119-6	21245-21247	in	_	
119-7	21248-21251	the	_	
119-8	21252-21258	globus	_	
119-9	21259-21267	pallidus	_	
119-10	21268-21270	in	_	
119-11	21271-21274	the	_	
119-12	21275-21282	current	_	
119-13	21283-21288	study	_	
119-14	21289-21294	could	_	
119-15	21295-21297	be	_	
119-16	21298-21308	correlated	_	
119-17	21309-21311	to	_	
119-18	21312-21313	a	_	
119-19	21314-21321	deficit	_	
119-20	21322-21324	in	_	
119-21	21325-21331	stress	_	
119-22	21332-21342	regulatory	_	
119-23	21343-21352	processes	_	
119-24	21353-21355	in	_	
119-25	21356-21369	drug-addicted	_	
119-26	21370-21378	patients	_	
119-27	21379-21385	during	_	
119-28	21386-21389	the	_	
119-29	21390-21397	resting	_	
119-30	21398-21403	state	_	
119-31	21403-21404	;	_	
119-32	21405-21409	this	_	
119-33	21410-21419	postulate	_	
119-34	21420-21423	can	_	
119-35	21424-21432	probably	_	
119-36	21433-21440	provide	_	
119-37	21441-21446	novel	_	
119-38	21447-21457	approaches	_	
119-39	21458-21461	for	_	
119-40	21462-21472	customized	_	
119-41	21473-21482	therapies	_	
119-42	21483-21486	for	_	
119-43	21487-21490	the	_	
119-44	21491-21500	treatment	_	
119-45	21501-21503	of	_	
119-46	21504-21517	CCS-dependent	_	
119-47	21518-21526	patients	_	
119-48	21526-21527	.	_	

#Text=Moreover, the increased average DC value of the right globus pallidus in CCS-dependent individuals did not show a distinct correlation with the BIS-11 total score.
120-1	21528-21536	Moreover	_	
120-2	21536-21537	,	_	
120-3	21538-21541	the	_	
120-4	21542-21551	increased	_	
120-5	21552-21559	average	_	
120-6	21560-21562	DC	_	
120-7	21563-21568	value	_	
120-8	21569-21571	of	_	
120-9	21572-21575	the	_	
120-10	21576-21581	right	_	
120-11	21582-21588	globus	_	
120-12	21589-21597	pallidus	_	
120-13	21598-21600	in	_	
120-14	21601-21614	CCS-dependent	_	
120-15	21615-21626	individuals	_	
120-16	21627-21630	did	_	
120-17	21631-21634	not	_	
120-18	21635-21639	show	_	
120-19	21640-21641	a	_	
120-20	21642-21650	distinct	_	
120-21	21651-21662	correlation	_	
120-22	21663-21667	with	_	
120-23	21668-21671	the	_	
120-24	21672-21675	BIS	_	
120-25	21675-21676	-	_	
120-26	21676-21678	11	_	
120-27	21679-21684	total	_	
120-28	21685-21690	score	_	
120-29	21690-21691	.	_	

#Text=However, found that BIS-11 total scores were correlated with the functional connectivity of the bilateral striatum within the DMN in CCS-dependent individuals as assessed by the independent component analysis method.
121-1	21692-21699	However	_	
121-2	21699-21700	,	_	
121-3	21701-21706	found	_	
121-4	21707-21711	that	_	
121-5	21712-21715	BIS	_	
121-6	21715-21716	-	_	
121-7	21716-21718	11	_	
121-8	21719-21724	total	_	
121-9	21725-21731	scores	_	
121-10	21732-21736	were	_	
121-11	21737-21747	correlated	_	
121-12	21748-21752	with	_	
121-13	21753-21756	the	_	
121-14	21757-21767	functional	_	
121-15	21768-21780	connectivity	_	
121-16	21781-21783	of	_	
121-17	21784-21787	the	_	
121-18	21788-21797	bilateral	_	
121-19	21798-21806	striatum	_	
121-20	21807-21813	within	_	
121-21	21814-21817	the	_	
121-22	21818-21821	DMN	_	
121-23	21822-21824	in	_	
121-24	21825-21838	CCS-dependent	_	
121-25	21839-21850	individuals	_	
121-26	21851-21853	as	_	
121-27	21854-21862	assessed	_	
121-28	21863-21865	by	_	
121-29	21866-21869	the	_	
121-30	21870-21881	independent	_	
121-31	21882-21891	component	_	
121-32	21892-21900	analysis	_	
121-33	21901-21907	method	_	
121-34	21907-21908	.	_	

#Text=The opposite result may be attributed to the differences arising due to the selected subjects and processing methods.
122-1	21909-21912	The	_	
122-2	21913-21921	opposite	_	
122-3	21922-21928	result	_	
122-4	21929-21932	may	_	
122-5	21933-21935	be	_	
122-6	21936-21946	attributed	_	
122-7	21947-21949	to	_	
122-8	21950-21953	the	_	
122-9	21954-21965	differences	_	
122-10	21966-21973	arising	_	
122-11	21974-21977	due	_	
122-12	21978-21980	to	_	
122-13	21981-21984	the	_	
122-14	21985-21993	selected	_	
122-15	21994-22002	subjects	_	
122-16	22003-22006	and	_	
122-17	22007-22017	processing	_	
122-18	22018-22025	methods	_	
122-19	22025-22026	.	_	

#Text=In the present study, increased degree values in the right hippocampus were found in CCS-dependent individuals.
123-1	22027-22029	In	_	
123-2	22030-22033	the	_	
123-3	22034-22041	present	_	
123-4	22042-22047	study	_	
123-5	22047-22048	,	_	
123-6	22049-22058	increased	_	
123-7	22059-22065	degree	_	
123-8	22066-22072	values	_	
123-9	22073-22075	in	_	
123-10	22076-22079	the	_	
123-11	22080-22085	right	_	
123-12	22086-22097	hippocampus	_	
123-13	22098-22102	were	_	
123-14	22103-22108	found	_	
123-15	22109-22111	in	_	
123-16	22112-22125	CCS-dependent	_	
123-17	22126-22137	individuals	_	
123-18	22137-22138	.	_	

#Text=The hippocampus plays a critical role in the formation of the pathological memory of addiction.
124-1	22139-22142	The	_	
124-2	22143-22154	hippocampus	_	
124-3	22155-22160	plays	_	
124-4	22161-22162	a	_	
124-5	22163-22171	critical	_	
124-6	22172-22176	role	_	
124-7	22177-22179	in	_	
124-8	22180-22183	the	_	
124-9	22184-22193	formation	_	
124-10	22194-22196	of	_	
124-11	22197-22200	the	_	
124-12	22201-22213	pathological	_	
124-13	22214-22220	memory	_	
124-14	22221-22223	of	_	
124-15	22224-22233	addiction	_	
124-16	22233-22234	.	_	

#Text=In the case of long-term withdrawal of addiction patients, drug-related stimulus conditions could still strongly recall the experience of using drugs, which is known as “addiction memory”.
125-1	22235-22237	In	_	
125-2	22238-22241	the	_	
125-3	22242-22246	case	_	
125-4	22247-22249	of	_	
125-5	22250-22259	long-term	_	
125-6	22260-22270	withdrawal	_	
125-7	22271-22273	of	_	
125-8	22274-22283	addiction	_	
125-9	22284-22292	patients	_	
125-10	22292-22293	,	_	
125-11	22294-22306	drug-related	_	
125-12	22307-22315	stimulus	_	
125-13	22316-22326	conditions	_	
125-14	22327-22332	could	_	
125-15	22333-22338	still	_	
125-16	22339-22347	strongly	_	
125-17	22348-22354	recall	_	
125-18	22355-22358	the	_	
125-19	22359-22369	experience	_	
125-20	22370-22372	of	_	
125-21	22373-22378	using	_	
125-22	22379-22384	drugs	_	
125-23	22384-22385	,	_	
125-24	22386-22391	which	_	
125-25	22392-22394	is	_	
125-26	22395-22400	known	_	
125-27	22401-22403	as	_	
125-28	22404-22405	“	_	
125-29	22405-22414	addiction	_	
125-30	22415-22421	memory	_	
125-31	22421-22422	”	_	
125-32	22422-22423	.	_	

#Text=The pathological memory is closely related to acquiring drug addiction.
126-1	22424-22427	The	_	
126-2	22428-22440	pathological	_	
126-3	22441-22447	memory	_	
126-4	22448-22450	is	_	
126-5	22451-22458	closely	_	
126-6	22459-22466	related	_	
126-7	22467-22469	to	_	
126-8	22470-22479	acquiring	_	
126-9	22480-22484	drug	_	
126-10	22485-22494	addiction	_	
126-11	22494-22495	.	_	

#Text=In an experimental mouse model of addiction, found that stimulating the hippocampus could lead to a strong craving for drugs.
127-1	22496-22498	In	_	
127-2	22499-22501	an	_	
127-3	22502-22514	experimental	_	
127-4	22515-22520	mouse	_	
127-5	22521-22526	model	_	
127-6	22527-22529	of	_	
127-7	22530-22539	addiction	_	
127-8	22539-22540	,	_	
127-9	22541-22546	found	_	
127-10	22547-22551	that	_	
127-11	22552-22563	stimulating	_	
127-12	22564-22567	the	_	
127-13	22568-22579	hippocampus	_	
127-14	22580-22585	could	_	
127-15	22586-22590	lead	_	
127-16	22591-22593	to	_	
127-17	22594-22595	a	_	
127-18	22596-22602	strong	_	
127-19	22603-22610	craving	_	
127-20	22611-22614	for	_	
127-21	22615-22620	drugs	_	
127-22	22620-22621	.	_	

#Text=The blockade of beta-adrenergic receptors in the dorsal hippocampus of the rats would reduce drug seeking and induce the relapse of the cue.
128-1	22622-22625	The	_	
128-2	22626-22634	blockade	_	
128-3	22635-22637	of	_	
128-4	22638-22653	beta-adrenergic	_	
128-5	22654-22663	receptors	_	
128-6	22664-22666	in	_	
128-7	22667-22670	the	_	
128-8	22671-22677	dorsal	_	
128-9	22678-22689	hippocampus	_	
128-10	22690-22692	of	_	
128-11	22693-22696	the	_	
128-12	22697-22701	rats	_	
128-13	22702-22707	would	_	
128-14	22708-22714	reduce	_	
128-15	22715-22719	drug	_	
128-16	22720-22727	seeking	_	
128-17	22728-22731	and	_	
128-18	22732-22738	induce	_	
128-19	22739-22742	the	_	
128-20	22743-22750	relapse	_	
128-21	22751-22753	of	_	
128-22	22754-22757	the	_	
128-23	22758-22761	cue	_	
128-24	22761-22762	.	_	

#Text=Several studies associated with cocaine-dependent participants noted that participants exposed to cocaine cues showed strong craving for drugs while an increased activity of the hippocampus was observed. used a fallypride (18F) tracer with a high-resolution PET to assess the ability of drug cues in order to induce dopamine (DA) release in the hippocampus of cocaine-dependent participants, and the results showed a dopaminergic response to cocaine cues in the hippocampus.
129-1	22763-22770	Several	_	
129-2	22771-22778	studies	_	
129-3	22779-22789	associated	_	
129-4	22790-22794	with	_	
129-5	22795-22812	cocaine-dependent	_	
129-6	22813-22825	participants	_	
129-7	22826-22831	noted	_	
129-8	22832-22836	that	_	
129-9	22837-22849	participants	_	
129-10	22850-22857	exposed	_	
129-11	22858-22860	to	_	
129-12	22861-22868	cocaine	_	
129-13	22869-22873	cues	_	
129-14	22874-22880	showed	_	
129-15	22881-22887	strong	_	
129-16	22888-22895	craving	_	
129-17	22896-22899	for	_	
129-18	22900-22905	drugs	_	
129-19	22906-22911	while	_	
129-20	22912-22914	an	_	
129-21	22915-22924	increased	_	
129-22	22925-22933	activity	_	
129-23	22934-22936	of	_	
129-24	22937-22940	the	_	
129-25	22941-22952	hippocampus	_	
129-26	22953-22956	was	_	
129-27	22957-22965	observed	_	
129-28	22965-22966	.	_	
129-29	22967-22971	used	_	
129-30	22972-22973	a	_	
129-31	22974-22984	fallypride	_	
129-32	22985-22986	(	_	
129-33	22986-22989	18F	_	
129-34	22989-22990	)	_	
129-35	22991-22997	tracer	_	
129-36	22998-23002	with	_	
129-37	23003-23004	a	_	
129-38	23005-23020	high-resolution	_	
129-39	23021-23024	PET	_	
129-40	23025-23027	to	_	
129-41	23028-23034	assess	_	
129-42	23035-23038	the	_	
129-43	23039-23046	ability	_	
129-44	23047-23049	of	_	
129-45	23050-23054	drug	_	
129-46	23055-23059	cues	_	
129-47	23060-23062	in	_	
129-48	23063-23068	order	_	
129-49	23069-23071	to	_	
129-50	23072-23078	induce	_	
129-51	23079-23087	dopamine	_	
129-52	23088-23089	(	_	
129-53	23089-23091	DA	_	
129-54	23091-23092	)	_	
129-55	23093-23100	release	_	
129-56	23101-23103	in	_	
129-57	23104-23107	the	_	
129-58	23108-23119	hippocampus	_	
129-59	23120-23122	of	_	
129-60	23123-23140	cocaine-dependent	_	
129-61	23141-23153	participants	_	
129-62	23153-23154	,	_	
129-63	23155-23158	and	_	
129-64	23159-23162	the	_	
129-65	23163-23170	results	_	
129-66	23171-23177	showed	_	
129-67	23178-23179	a	_	
129-68	23180-23192	dopaminergic	_	
129-69	23193-23201	response	_	
129-70	23202-23204	to	_	
129-71	23205-23212	cocaine	_	
129-72	23213-23217	cues	_	
129-73	23218-23220	in	_	
129-74	23221-23224	the	_	
129-75	23225-23236	hippocampus	_	
129-76	23236-23237	.	_	

#Text=Importantly, these cocaine-dependent participants showed a high degree of desire, leading the investigators to speculate that increased hippocampal activity was related to the memory pathways of cocaine stimulation.
130-1	23238-23249	Importantly	_	
130-2	23249-23250	,	_	
130-3	23251-23256	these	_	
130-4	23257-23274	cocaine-dependent	_	
130-5	23275-23287	participants	_	
130-6	23288-23294	showed	_	
130-7	23295-23296	a	_	
130-8	23297-23301	high	_	
130-9	23302-23308	degree	_	
130-10	23309-23311	of	_	
130-11	23312-23318	desire	_	
130-12	23318-23319	,	_	
130-13	23320-23327	leading	_	
130-14	23328-23331	the	_	
130-15	23332-23345	investigators	_	
130-16	23346-23348	to	_	
130-17	23349-23358	speculate	_	
130-18	23359-23363	that	_	
130-19	23364-23373	increased	_	
130-20	23374-23385	hippocampal	_	
130-21	23386-23394	activity	_	
130-22	23395-23398	was	_	
130-23	23399-23406	related	_	
130-24	23407-23409	to	_	
130-25	23410-23413	the	_	
130-26	23414-23420	memory	_	
130-27	23421-23429	pathways	_	
130-28	23430-23432	of	_	
130-29	23433-23440	cocaine	_	
130-30	23441-23452	stimulation	_	
130-31	23452-23453	.	_	

#Text=Furthermore, in the current study, the abnormal degree values in the right hippocampus demonstrated that the vitality of this region of the brain was increased among learning and memory circuits in CCS-dependent individuals, which contributed to the formation of the addiction memory.
131-1	23454-23465	Furthermore	_	
131-2	23465-23466	,	_	
131-3	23467-23469	in	_	
131-4	23470-23473	the	_	
131-5	23474-23481	current	_	
131-6	23482-23487	study	_	
131-7	23487-23488	,	_	
131-8	23489-23492	the	_	
131-9	23493-23501	abnormal	_	
131-10	23502-23508	degree	_	
131-11	23509-23515	values	_	
131-12	23516-23518	in	_	
131-13	23519-23522	the	_	
131-14	23523-23528	right	_	
131-15	23529-23540	hippocampus	_	
131-16	23541-23553	demonstrated	_	
131-17	23554-23558	that	_	
131-18	23559-23562	the	_	
131-19	23563-23571	vitality	_	
131-20	23572-23574	of	_	
131-21	23575-23579	this	_	
131-22	23580-23586	region	_	
131-23	23587-23589	of	_	
131-24	23590-23593	the	_	
131-25	23594-23599	brain	_	
131-26	23600-23603	was	_	
131-27	23604-23613	increased	_	
131-28	23614-23619	among	_	
131-29	23620-23628	learning	_	
131-30	23629-23632	and	_	
131-31	23633-23639	memory	_	
131-32	23640-23648	circuits	_	
131-33	23649-23651	in	_	
131-34	23652-23665	CCS-dependent	_	
131-35	23666-23677	individuals	_	
131-36	23677-23678	,	_	
131-37	23679-23684	which	_	
131-38	23685-23696	contributed	_	
131-39	23697-23699	to	_	
131-40	23700-23703	the	_	
131-41	23704-23713	formation	_	
131-42	23714-23716	of	_	
131-43	23717-23720	the	_	
131-44	23721-23730	addiction	_	
131-45	23731-23737	memory	_	
131-46	23737-23738	.	_	

#Text=However, any significant correlations of the mean degree values in the right hippocampus with the BIS-11 total scores and the duration of CCS use were not observed.
132-1	23739-23746	However	_	
132-2	23746-23747	,	_	
132-3	23748-23751	any	_	
132-4	23752-23763	significant	_	
132-5	23764-23776	correlations	_	
132-6	23777-23779	of	_	
132-7	23780-23783	the	_	
132-8	23784-23788	mean	_	
132-9	23789-23795	degree	_	
132-10	23796-23802	values	_	
132-11	23803-23805	in	_	
132-12	23806-23809	the	_	
132-13	23810-23815	right	_	
132-14	23816-23827	hippocampus	_	
132-15	23828-23832	with	_	
132-16	23833-23836	the	_	
132-17	23837-23840	BIS	_	
132-18	23840-23841	-	_	
132-19	23841-23843	11	_	
132-20	23844-23849	total	_	
132-21	23850-23856	scores	_	
132-22	23857-23860	and	_	
132-23	23861-23864	the	_	
132-24	23865-23873	duration	_	
132-25	23874-23876	of	_	
132-26	23877-23880	CCS	_	
132-27	23881-23884	use	_	
132-28	23885-23889	were	_	
132-29	23890-23893	not	_	
132-30	23894-23902	observed	_	
132-31	23902-23903	.	_	

#Text=In addition, we also found decreased degree values in the left inferior parietal lobule and left middle temporal gyrus were related to the cognitive function in the CCS-dependent individuals.
133-1	23904-23906	In	_	
133-2	23907-23915	addition	_	
133-3	23915-23916	,	_	
133-4	23917-23919	we	_	
133-5	23920-23924	also	_	
133-6	23925-23930	found	_	
133-7	23931-23940	decreased	_	
133-8	23941-23947	degree	_	
133-9	23948-23954	values	_	
133-10	23955-23957	in	_	
133-11	23958-23961	the	_	
133-12	23962-23966	left	_	
133-13	23967-23975	inferior	_	
133-14	23976-23984	parietal	_	
133-15	23985-23991	lobule	_	
133-16	23992-23995	and	_	
133-17	23996-24000	left	_	
133-18	24001-24007	middle	_	
133-19	24008-24016	temporal	_	
133-20	24017-24022	gyrus	_	
133-21	24023-24027	were	_	
133-22	24028-24035	related	_	
133-23	24036-24038	to	_	
133-24	24039-24042	the	_	
133-25	24043-24052	cognitive	_	
133-26	24053-24061	function	_	
133-27	24062-24064	in	_	
133-28	24065-24068	the	_	
133-29	24069-24082	CCS-dependent	_	
133-30	24083-24094	individuals	_	
133-31	24094-24095	.	_	

#Text=A previous study demonstrated that the left inferior parietal lobule, one of the crucial brain regions of the attentional control network, was involved in executive function.
134-1	24096-24097	A	_	
134-2	24098-24106	previous	_	
134-3	24107-24112	study	_	
134-4	24113-24125	demonstrated	_	
134-5	24126-24130	that	_	
134-6	24131-24134	the	_	
134-7	24135-24139	left	_	
134-8	24140-24148	inferior	_	
134-9	24149-24157	parietal	_	
134-10	24158-24164	lobule	_	
134-11	24164-24165	,	_	
134-12	24166-24169	one	_	
134-13	24170-24172	of	_	
134-14	24173-24176	the	_	
134-15	24177-24184	crucial	_	
134-16	24185-24190	brain	_	
134-17	24191-24198	regions	_	
134-18	24199-24201	of	_	
134-19	24202-24205	the	_	
134-20	24206-24217	attentional	_	
134-21	24218-24225	control	_	
134-22	24226-24233	network	_	
134-23	24233-24234	,	_	
134-24	24235-24238	was	_	
134-25	24239-24247	involved	_	
134-26	24248-24250	in	_	
134-27	24251-24260	executive	_	
134-28	24261-24269	function	_	
134-29	24269-24270	.	_	

#Text=The current results suggested that such abnormal intrinsic connectivity may indicate cognitive and executive deficits in CCS-dependent individuals. demonstrated that the frontal-parietal working memory circuits in the cocaine-dependent participants were involved in the enhancement of attention towards drug cues, which were related to the initiation and maintenance of craving.
135-1	24271-24274	The	_	
135-2	24275-24282	current	_	
135-3	24283-24290	results	_	
135-4	24291-24300	suggested	_	
135-5	24301-24305	that	_	
135-6	24306-24310	such	_	
135-7	24311-24319	abnormal	_	
135-8	24320-24329	intrinsic	_	
135-9	24330-24342	connectivity	_	
135-10	24343-24346	may	_	
135-11	24347-24355	indicate	_	
135-12	24356-24365	cognitive	_	
135-13	24366-24369	and	_	
135-14	24370-24379	executive	_	
135-15	24380-24388	deficits	_	
135-16	24389-24391	in	_	
135-17	24392-24405	CCS-dependent	_	
135-18	24406-24417	individuals	_	
135-19	24417-24418	.	_	
135-20	24419-24431	demonstrated	_	
135-21	24432-24436	that	_	
135-22	24437-24440	the	_	
135-23	24441-24457	frontal-parietal	_	
135-24	24458-24465	working	_	
135-25	24466-24472	memory	_	
135-26	24473-24481	circuits	_	
135-27	24482-24484	in	_	
135-28	24485-24488	the	_	
135-29	24489-24506	cocaine-dependent	_	
135-30	24507-24519	participants	_	
135-31	24520-24524	were	_	
135-32	24525-24533	involved	_	
135-33	24534-24536	in	_	
135-34	24537-24540	the	_	
135-35	24541-24552	enhancement	_	
135-36	24553-24555	of	_	
135-37	24556-24565	attention	_	
135-38	24566-24573	towards	_	
135-39	24574-24578	drug	_	
135-40	24579-24583	cues	_	
135-41	24583-24584	,	_	
135-42	24585-24590	which	_	
135-43	24591-24595	were	_	
135-44	24596-24603	related	_	
135-45	24604-24606	to	_	
135-46	24607-24610	the	_	
135-47	24611-24621	initiation	_	
135-48	24622-24625	and	_	
135-49	24626-24637	maintenance	_	
135-50	24638-24640	of	_	
135-51	24641-24648	craving	_	
135-52	24648-24649	.	_	

#Text=Previous studies also found that the mirror-neuron of the inferior parietal cortex in monkeys was activated during the execution and observation of the identical actions.
136-1	24650-24658	Previous	_	
136-2	24659-24666	studies	_	
136-3	24667-24671	also	_	
136-4	24672-24677	found	_	
136-5	24678-24682	that	_	
136-6	24683-24686	the	_	
136-7	24687-24700	mirror-neuron	_	
136-8	24701-24703	of	_	
136-9	24704-24707	the	_	
136-10	24708-24716	inferior	_	
136-11	24717-24725	parietal	_	
136-12	24726-24732	cortex	_	
136-13	24733-24735	in	_	
136-14	24736-24743	monkeys	_	
136-15	24744-24747	was	_	
136-16	24748-24757	activated	_	
136-17	24758-24764	during	_	
136-18	24765-24768	the	_	
136-19	24769-24778	execution	_	
136-20	24779-24782	and	_	
136-21	24783-24794	observation	_	
136-22	24795-24797	of	_	
136-23	24798-24801	the	_	
136-24	24802-24811	identical	_	
136-25	24812-24819	actions	_	
136-26	24819-24820	.	_	

#Text=This finding provided new evidence in order to elucidate the mechanism underlying craving formation and the role of IPL in the process.
137-1	24821-24825	This	_	
137-2	24826-24833	finding	_	
137-3	24834-24842	provided	_	
137-4	24843-24846	new	_	
137-5	24847-24855	evidence	_	
137-6	24856-24858	in	_	
137-7	24859-24864	order	_	
137-8	24865-24867	to	_	
137-9	24868-24877	elucidate	_	
137-10	24878-24881	the	_	
137-11	24882-24891	mechanism	_	
137-12	24892-24902	underlying	_	
137-13	24903-24910	craving	_	
137-14	24911-24920	formation	_	
137-15	24921-24924	and	_	
137-16	24925-24928	the	_	
137-17	24929-24933	role	_	
137-18	24934-24936	of	_	
137-19	24937-24940	IPL	_	
137-20	24941-24943	in	_	
137-21	24944-24947	the	_	
137-22	24948-24955	process	_	
137-23	24955-24956	.	_	

#Text=Therefore, decreased degree values in the left inferior parietal lobule and the left middle temporal gyrus in our study may be related to the deficit of attention and cognition in drug cue response in the addicts.
138-1	24957-24966	Therefore	_	
138-2	24966-24967	,	_	
138-3	24968-24977	decreased	_	
138-4	24978-24984	degree	_	
138-5	24985-24991	values	_	
138-6	24992-24994	in	_	
138-7	24995-24998	the	_	
138-8	24999-25003	left	_	
138-9	25004-25012	inferior	_	
138-10	25013-25021	parietal	_	
138-11	25022-25028	lobule	_	
138-12	25029-25032	and	_	
138-13	25033-25036	the	_	
138-14	25037-25041	left	_	
138-15	25042-25048	middle	_	
138-16	25049-25057	temporal	_	
138-17	25058-25063	gyrus	_	
138-18	25064-25066	in	_	
138-19	25067-25070	our	_	
138-20	25071-25076	study	_	
138-21	25077-25080	may	_	
138-22	25081-25083	be	_	
138-23	25084-25091	related	_	
138-24	25092-25094	to	_	
138-25	25095-25098	the	_	
138-26	25099-25106	deficit	_	
138-27	25107-25109	of	_	
138-28	25110-25119	attention	_	
138-29	25120-25123	and	_	
138-30	25124-25133	cognition	_	
138-31	25134-25136	in	_	
138-32	25137-25141	drug	_	
138-33	25142-25145	cue	_	
138-34	25146-25154	response	_	
138-35	25155-25157	in	_	
138-36	25158-25161	the	_	
138-37	25162-25169	addicts	_	
138-38	25169-25170	.	_	

#Text=Thus, decreased degree values in both the regions in CCS-dependent patients, based on the functional network integrity perspective, postulate that the function of cognitive control-related regions was weakening.
139-1	25171-25175	Thus	_	
139-2	25175-25176	,	_	
139-3	25177-25186	decreased	_	
139-4	25187-25193	degree	_	
139-5	25194-25200	values	_	
139-6	25201-25203	in	_	
139-7	25204-25208	both	_	
139-8	25209-25212	the	_	
139-9	25213-25220	regions	_	
139-10	25221-25223	in	_	
139-11	25224-25237	CCS-dependent	_	
139-12	25238-25246	patients	_	
139-13	25246-25247	,	_	
139-14	25248-25253	based	_	
139-15	25254-25256	on	_	
139-16	25257-25260	the	_	
139-17	25261-25271	functional	_	
139-18	25272-25279	network	_	
139-19	25280-25289	integrity	_	
139-20	25290-25301	perspective	_	
139-21	25301-25302	,	_	
139-22	25303-25312	postulate	_	
139-23	25313-25317	that	_	
139-24	25318-25321	the	_	
139-25	25322-25330	function	_	
139-26	25331-25333	of	_	
139-27	25334-25343	cognitive	_	
139-28	25344-25359	control-related	_	
139-29	25360-25367	regions	_	
139-30	25368-25371	was	_	
139-31	25372-25381	weakening	_	
139-32	25381-25382	.	_	

#Text=Then, a significantly negative correlation was observed between the decreased average DC value of the left IPL and the subscale of the attentional impulsivity.
140-1	25383-25387	Then	_	
140-2	25387-25388	,	_	
140-3	25389-25390	a	_	
140-4	25391-25404	significantly	_	
140-5	25405-25413	negative	_	
140-6	25414-25425	correlation	_	
140-7	25426-25429	was	_	
140-8	25430-25438	observed	_	
140-9	25439-25446	between	_	
140-10	25447-25450	the	_	
140-11	25451-25460	decreased	_	
140-12	25461-25468	average	_	
140-13	25469-25471	DC	_	
140-14	25472-25477	value	_	
140-15	25478-25480	of	_	
140-16	25481-25484	the	_	
140-17	25485-25489	left	_	
140-18	25490-25493	IPL	_	
140-19	25494-25497	and	_	
140-20	25498-25501	the	_	
140-21	25502-25510	subscale	_	
140-22	25511-25513	of	_	
140-23	25514-25517	the	_	
140-24	25518-25529	attentional	_	
140-25	25530-25541	impulsivity	_	
140-26	25541-25542	.	_	

#Text=Thus, we hypothesized that a deficit in cognitive control regulatory processes might occur in CCS-dependent patients during the resting state.
141-1	25543-25547	Thus	_	
141-2	25547-25548	,	_	
141-3	25549-25551	we	_	
141-4	25552-25564	hypothesized	_	
141-5	25565-25569	that	_	
141-6	25570-25571	a	_	
141-7	25572-25579	deficit	_	
141-8	25580-25582	in	_	
141-9	25583-25592	cognitive	_	
141-10	25593-25600	control	_	
141-11	25601-25611	regulatory	_	
141-12	25612-25621	processes	_	
141-13	25622-25627	might	_	
141-14	25628-25633	occur	_	
141-15	25634-25636	in	_	
141-16	25637-25650	CCS-dependent	_	
141-17	25651-25659	patients	_	
141-18	25660-25666	during	_	
141-19	25667-25670	the	_	
141-20	25671-25678	resting	_	
141-21	25679-25684	state	_	
141-22	25684-25685	.	_	

#Text=When the patients were influenced by drug-related cues, they exhibit a rather intense craving, putatively leading to poor decision making and repeated drug use. also found that the attentional impulsivity correlated with the right IPL within the ECN in CCS-dependent patients; this finding coincides with our results.
142-1	25686-25690	When	_	
142-2	25691-25694	the	_	
142-3	25695-25703	patients	_	
142-4	25704-25708	were	_	
142-5	25709-25719	influenced	_	
142-6	25720-25722	by	_	
142-7	25723-25735	drug-related	_	
142-8	25736-25740	cues	_	
142-9	25740-25741	,	_	
142-10	25742-25746	they	_	
142-11	25747-25754	exhibit	_	
142-12	25755-25756	a	_	
142-13	25757-25763	rather	_	
142-14	25764-25771	intense	_	
142-15	25772-25779	craving	_	
142-16	25779-25780	,	_	
142-17	25781-25791	putatively	_	
142-18	25792-25799	leading	_	
142-19	25800-25802	to	_	
142-20	25803-25807	poor	_	
142-21	25808-25816	decision	_	
142-22	25817-25823	making	_	
142-23	25824-25827	and	_	
142-24	25828-25836	repeated	_	
142-25	25837-25841	drug	_	
142-26	25842-25845	use	_	
142-27	25845-25846	.	_	
142-28	25847-25851	also	_	
142-29	25852-25857	found	_	
142-30	25858-25862	that	_	
142-31	25863-25866	the	_	
142-32	25867-25878	attentional	_	
142-33	25879-25890	impulsivity	_	
142-34	25891-25901	correlated	_	
142-35	25902-25906	with	_	
142-36	25907-25910	the	_	
142-37	25911-25916	right	_	
142-38	25917-25920	IPL	_	
142-39	25921-25927	within	_	
142-40	25928-25931	the	_	
142-41	25932-25935	ECN	_	
142-42	25936-25938	in	_	
142-43	25939-25952	CCS-dependent	_	
142-44	25953-25961	patients	_	
142-45	25961-25962	;	_	
142-46	25963-25967	this	_	
142-47	25968-25975	finding	_	
142-48	25976-25985	coincides	_	
142-49	25986-25990	with	_	
142-50	25991-25994	our	_	
142-51	25995-26002	results	_	
142-52	26002-26003	.	_	

#Text=We also found a significantly positive correlation between the decreased average DC value of the left IPL and the age at the first use of CCS.
143-1	26004-26006	We	_	
143-2	26007-26011	also	_	
143-3	26012-26017	found	_	
143-4	26018-26019	a	_	
143-5	26020-26033	significantly	_	
143-6	26034-26042	positive	_	
143-7	26043-26054	correlation	_	
143-8	26055-26062	between	_	
143-9	26063-26066	the	_	
143-10	26067-26076	decreased	_	
143-11	26077-26084	average	_	
143-12	26085-26087	DC	_	
143-13	26088-26093	value	_	
143-14	26094-26096	of	_	
143-15	26097-26100	the	_	
143-16	26101-26105	left	_	
143-17	26106-26109	IPL	_	
143-18	26110-26113	and	_	
143-19	26114-26117	the	_	
143-20	26118-26121	age	_	
143-21	26122-26124	at	_	
143-22	26125-26128	the	_	
143-23	26129-26134	first	_	
143-24	26135-26138	use	_	
143-25	26139-26141	of	_	
143-26	26142-26145	CCS	_	
143-27	26145-26146	.	_	

#Text=Previous studies have shown that longer duration of heroin use was associated with more damage to the brain and that these changes might be cumulative.
144-1	26147-26155	Previous	_	
144-2	26156-26163	studies	_	
144-3	26164-26168	have	_	
144-4	26169-26174	shown	_	
144-5	26175-26179	that	_	
144-6	26180-26186	longer	_	
144-7	26187-26195	duration	_	
144-8	26196-26198	of	_	
144-9	26199-26205	heroin	_	
144-10	26206-26209	use	_	
144-11	26210-26213	was	_	
144-12	26214-26224	associated	_	
144-13	26225-26229	with	_	
144-14	26230-26234	more	_	
144-15	26235-26241	damage	_	
144-16	26242-26244	to	_	
144-17	26245-26248	the	_	
144-18	26249-26254	brain	_	
144-19	26255-26258	and	_	
144-20	26259-26263	that	_	
144-21	26264-26269	these	_	
144-22	26270-26277	changes	_	
144-23	26278-26283	might	_	
144-24	26284-26286	be	_	
144-25	26287-26297	cumulative	_	
144-26	26297-26298	.	_	

#Text=Nevertheless, the current results might further confirm the presence of brain damage in CCS-dependent individuals.
145-1	26299-26311	Nevertheless	_	
145-2	26311-26312	,	_	
145-3	26313-26316	the	_	
145-4	26317-26324	current	_	
145-5	26325-26332	results	_	
145-6	26333-26338	might	_	
145-7	26339-26346	further	_	
145-8	26347-26354	confirm	_	
145-9	26355-26358	the	_	
145-10	26359-26367	presence	_	
145-11	26368-26370	of	_	
145-12	26371-26376	brain	_	
145-13	26377-26383	damage	_	
145-14	26384-26386	in	_	
145-15	26387-26400	CCS-dependent	_	
145-16	26401-26412	individuals	_	
145-17	26412-26413	.	_	

#Text=Since the causes of CCS abuse are complex, we cannot absolutely assert the mechanisms underlying these changes.
146-1	26414-26419	Since	_	
146-2	26420-26423	the	_	
146-3	26424-26430	causes	_	
146-4	26431-26433	of	_	
146-5	26434-26437	CCS	_	
146-6	26438-26443	abuse	_	
146-7	26444-26447	are	_	
146-8	26448-26455	complex	_	
146-9	26455-26456	,	_	
146-10	26457-26459	we	_	
146-11	26460-26466	cannot	_	
146-12	26467-26477	absolutely	_	
146-13	26478-26484	assert	_	
146-14	26485-26488	the	_	
146-15	26489-26499	mechanisms	_	
146-16	26500-26510	underlying	_	
146-17	26511-26516	these	_	
146-18	26517-26524	changes	_	
146-19	26524-26525	.	_	

#Text=Thus, additional rigorous experimental designs are essential in future studies.
147-1	26526-26530	Thus	_	
147-2	26530-26531	,	_	
147-3	26532-26542	additional	_	
147-4	26543-26551	rigorous	_	
147-5	26552-26564	experimental	_	
147-6	26565-26572	designs	_	
147-7	26573-26576	are	_	
147-8	26577-26586	essential	_	
147-9	26587-26589	in	_	
147-10	26590-26596	future	_	
147-11	26597-26604	studies	_	
147-12	26604-26605	.	_	

#Text=Nonetheless, the present study had several limitations.
148-1	26606-26617	Nonetheless	_	
148-2	26617-26618	,	_	
148-3	26619-26622	the	_	
148-4	26623-26630	present	_	
148-5	26631-26636	study	_	
148-6	26637-26640	had	_	
148-7	26641-26648	several	_	
148-8	26649-26660	limitations	_	
148-9	26660-26661	.	_	

#Text=First, as a cross-sectional study, DC can only find the brain regions showing abnormal functional connectivities and is unable to provide detailed information about the functional connection.
149-1	26662-26667	First	_	
149-2	26667-26668	,	_	
149-3	26669-26671	as	_	
149-4	26672-26673	a	_	
149-5	26674-26689	cross-sectional	_	
149-6	26690-26695	study	_	
149-7	26695-26696	,	_	
149-8	26697-26699	DC	_	
149-9	26700-26703	can	_	
149-10	26704-26708	only	_	
149-11	26709-26713	find	_	
149-12	26714-26717	the	_	
149-13	26718-26723	brain	_	
149-14	26724-26731	regions	_	
149-15	26732-26739	showing	_	
149-16	26740-26748	abnormal	_	
149-17	26749-26759	functional	_	
149-18	26760-26774	connectivities	_	
149-19	26775-26778	and	_	
149-20	26779-26781	is	_	
149-21	26782-26788	unable	_	
149-22	26789-26791	to	_	
149-23	26792-26799	provide	_	
149-24	26800-26808	detailed	_	
149-25	26809-26820	information	_	
149-26	26821-26826	about	_	
149-27	26827-26830	the	_	
149-28	26831-26841	functional	_	
149-29	26842-26852	connection	_	
149-30	26852-26853	.	_	

#Text=Thus, in future studies, it will be interesting to trace the brain regions to which the abnormal functional connectivities are linked.
150-1	26854-26858	Thus	_	
150-2	26858-26859	,	_	
150-3	26860-26862	in	_	
150-4	26863-26869	future	_	
150-5	26870-26877	studies	_	
150-6	26877-26878	,	_	
150-7	26879-26881	it	_	
150-8	26882-26886	will	_	
150-9	26887-26889	be	_	
150-10	26890-26901	interesting	_	
150-11	26902-26904	to	_	
150-12	26905-26910	trace	_	
150-13	26911-26914	the	_	
150-14	26915-26920	brain	_	
150-15	26921-26928	regions	_	
150-16	26929-26931	to	_	
150-17	26932-26937	which	_	
150-18	26938-26941	the	_	
150-19	26942-26950	abnormal	_	
150-20	26951-26961	functional	_	
150-21	26962-26976	connectivities	_	
150-22	26977-26980	are	_	
150-23	26981-26987	linked	_	
150-24	26987-26988	.	_	

#Text=Second, the sample size was relatively small in the present study, which might influence the statistical power to detect specific effects.
151-1	26989-26995	Second	_	
151-2	26995-26996	,	_	
151-3	26997-27000	the	_	
151-4	27001-27007	sample	_	
151-5	27008-27012	size	_	
151-6	27013-27016	was	_	
151-7	27017-27027	relatively	_	
151-8	27028-27033	small	_	
151-9	27034-27036	in	_	
151-10	27037-27040	the	_	
151-11	27041-27048	present	_	
151-12	27049-27054	study	_	
151-13	27054-27055	,	_	
151-14	27056-27061	which	_	
151-15	27062-27067	might	_	
151-16	27068-27077	influence	_	
151-17	27078-27081	the	_	
151-18	27082-27093	statistical	_	
151-19	27094-27099	power	_	
151-20	27100-27102	to	_	
151-21	27103-27109	detect	_	
151-22	27110-27118	specific	_	
151-23	27119-27126	effects	_	
151-24	27126-27127	.	_	

#Text=Thus, additional studies with a large sample size of CCS-dependent patients are needed to improve the power of the statistical analysis of our results.
152-1	27128-27132	Thus	_	
152-2	27132-27133	,	_	
152-3	27134-27144	additional	_	
152-4	27145-27152	studies	_	
152-5	27153-27157	with	_	
152-6	27158-27159	a	_	
152-7	27160-27165	large	_	
152-8	27166-27172	sample	_	
152-9	27173-27177	size	_	
152-10	27178-27180	of	_	
152-11	27181-27194	CCS-dependent	_	
152-12	27195-27203	patients	_	
152-13	27204-27207	are	_	
152-14	27208-27214	needed	_	
152-15	27215-27217	to	_	
152-16	27218-27225	improve	_	
152-17	27226-27229	the	_	
152-18	27230-27235	power	_	
152-19	27236-27238	of	_	
152-20	27239-27242	the	_	
152-21	27243-27254	statistical	_	
152-22	27255-27263	analysis	_	
152-23	27264-27266	of	_	
152-24	27267-27270	our	_	
152-25	27271-27278	results	_	
152-26	27278-27279	.	_	

#Text=Third, there were 10 brands of CCS reported to be used by volunteers enrolled in the present study, and for one volunteer, one to three brands of CCS were used simultaneously.
153-1	27280-27285	Third	_	
153-2	27285-27286	,	_	
153-3	27287-27292	there	_	
153-4	27293-27297	were	_	
153-5	27298-27300	10	_	
153-6	27301-27307	brands	_	
153-7	27308-27310	of	_	
153-8	27311-27314	CCS	_	
153-9	27315-27323	reported	_	
153-10	27324-27326	to	_	
153-11	27327-27329	be	_	
153-12	27330-27334	used	_	
153-13	27335-27337	by	_	
153-14	27338-27348	volunteers	_	
153-15	27349-27357	enrolled	_	
153-16	27358-27360	in	_	
153-17	27361-27364	the	_	
153-18	27365-27372	present	_	
153-19	27373-27378	study	_	
153-20	27378-27379	,	_	
153-21	27380-27383	and	_	
153-22	27384-27387	for	_	
153-23	27388-27391	one	_	
153-24	27392-27401	volunteer	_	
153-25	27401-27402	,	_	
153-26	27403-27406	one	_	
153-27	27407-27409	to	_	
153-28	27410-27415	three	_	
153-29	27416-27422	brands	_	
153-30	27423-27425	of	_	
153-31	27426-27429	CCS	_	
153-32	27430-27434	were	_	
153-33	27435-27439	used	_	
153-34	27440-27454	simultaneously	_	
153-35	27454-27455	.	_	

#Text=Therefore, a rigorous experimental study is imperative to exclude the influence of different CCS brands.
154-1	27456-27465	Therefore	_	
154-2	27465-27466	,	_	
154-3	27467-27468	a	_	
154-4	27469-27477	rigorous	_	
154-5	27478-27490	experimental	_	
154-6	27491-27496	study	_	
154-7	27497-27499	is	_	
154-8	27500-27510	imperative	_	
154-9	27511-27513	to	_	
154-10	27514-27521	exclude	_	
154-11	27522-27525	the	_	
154-12	27526-27535	influence	_	
154-13	27536-27538	of	_	
154-14	27539-27548	different	_	
154-15	27549-27552	CCS	_	
154-16	27553-27559	brands	_	
154-17	27559-27560	.	_	

#Text=Conclusion
#Text=In the current study, we applied the DC approach, derived from the rs-fMRI technique, to examine the intrinsic dysconnectivity pattern of the whole-brain functional networks in CCS-dependent patients.
155-1	27561-27571	Conclusion	_	
155-2	27572-27574	In	_	
155-3	27575-27578	the	_	
155-4	27579-27586	current	_	
155-5	27587-27592	study	_	
155-6	27592-27593	,	_	
155-7	27594-27596	we	_	
155-8	27597-27604	applied	_	
155-9	27605-27608	the	_	
155-10	27609-27611	DC	_	
155-11	27612-27620	approach	_	
155-12	27620-27621	,	_	
155-13	27622-27629	derived	_	
155-14	27630-27634	from	_	
155-15	27635-27638	the	_	
155-16	27639-27646	rs-fMRI	_	
155-17	27647-27656	technique	_	
155-18	27656-27657	,	_	
155-19	27658-27660	to	_	
155-20	27661-27668	examine	_	
155-21	27669-27672	the	_	
155-22	27673-27682	intrinsic	_	
155-23	27683-27698	dysconnectivity	_	
155-24	27699-27706	pattern	_	
155-25	27707-27709	of	_	
155-26	27710-27713	the	_	
155-27	27714-27725	whole-brain	_	
155-28	27726-27736	functional	_	
155-29	27737-27745	networks	_	
155-30	27746-27748	in	_	
155-31	27749-27762	CCS-dependent	_	
155-32	27763-27771	patients	_	
155-33	27771-27772	.	_	

#Text=We also correlated the DC changes to the BIS-11 total score, dose, duration of CCS use, and the age at first CCS administration.
156-1	27773-27775	We	_	
156-2	27776-27780	also	_	
156-3	27781-27791	correlated	_	
156-4	27792-27795	the	_	
156-5	27796-27798	DC	_	
156-6	27799-27806	changes	_	
156-7	27807-27809	to	_	
156-8	27810-27813	the	_	
156-9	27814-27817	BIS	_	
156-10	27817-27818	-	_	
156-11	27818-27820	11	_	
156-12	27821-27826	total	_	
156-13	27827-27832	score	_	
156-14	27832-27833	,	_	
156-15	27834-27838	dose	_	
156-16	27838-27839	,	_	
156-17	27840-27848	duration	_	
156-18	27849-27851	of	_	
156-19	27852-27855	CCS	_	
156-20	27856-27859	use	_	
156-21	27859-27860	,	_	
156-22	27861-27864	and	_	
156-23	27865-27868	the	_	
156-24	27869-27872	age	_	
156-25	27873-27875	at	_	
156-26	27876-27881	first	_	
156-27	27882-27885	CCS	_	
156-28	27886-27900	administration	_	
156-29	27900-27901	.	_	

#Text=The current results showed increased connectivity in the reward, learning, and memory circuit-related regions in the right hippocampus and the right pallidum.
157-1	27902-27905	The	_	
157-2	27906-27913	current	_	
157-3	27914-27921	results	_	
157-4	27922-27928	showed	_	
157-5	27929-27938	increased	_	
157-6	27939-27951	connectivity	_	
157-7	27952-27954	in	_	
157-8	27955-27958	the	_	
157-9	27959-27965	reward	_	
157-10	27965-27966	,	_	
157-11	27967-27975	learning	_	
157-12	27975-27976	,	_	
157-13	27977-27980	and	_	
157-14	27981-27987	memory	_	
157-15	27988-28003	circuit-related	_	
157-16	28004-28011	regions	_	
157-17	28012-28014	in	_	
157-18	28015-28018	the	_	
157-19	28019-28024	right	_	
157-20	28025-28036	hippocampus	_	
157-21	28037-28040	and	_	
157-22	28041-28044	the	_	
157-23	28045-28050	right	_	
157-24	28051-28059	pallidum	_	
157-25	28059-28060	.	_	

#Text=In addition, decreased functional connectivities were found in the cognitive control of circuit-related regions, including the left inferior parietal lobule and the left middle temporal gyrus.
158-1	28061-28063	In	_	
158-2	28064-28072	addition	_	
158-3	28072-28073	,	_	
158-4	28074-28083	decreased	_	
158-5	28084-28094	functional	_	
158-6	28095-28109	connectivities	_	
158-7	28110-28114	were	_	
158-8	28115-28120	found	_	
158-9	28121-28123	in	_	
158-10	28124-28127	the	_	
158-11	28128-28137	cognitive	_	
158-12	28138-28145	control	_	
158-13	28146-28148	of	_	
158-14	28149-28164	circuit-related	_	
158-15	28165-28172	regions	_	
158-16	28172-28173	,	_	
158-17	28174-28183	including	_	
158-18	28184-28187	the	_	
158-19	28188-28192	left	_	
158-20	28193-28201	inferior	_	
158-21	28202-28210	parietal	_	
158-22	28211-28217	lobule	_	
158-23	28218-28221	and	_	
158-24	28222-28225	the	_	
158-25	28226-28230	left	_	
158-26	28231-28237	middle	_	
158-27	28238-28246	temporal	_	
158-28	28247-28252	gyrus	_	
158-29	28252-28253	.	_	

#Text=Moreover, a significant correlation was established between the average DC value in the left inferior parietal and the subscale of attentional impulsivity, dose, duration and the age at the first CCS use.
159-1	28254-28262	Moreover	_	
159-2	28262-28263	,	_	
159-3	28264-28265	a	_	
159-4	28266-28277	significant	_	
159-5	28278-28289	correlation	_	
159-6	28290-28293	was	_	
159-7	28294-28305	established	_	
159-8	28306-28313	between	_	
159-9	28314-28317	the	_	
159-10	28318-28325	average	_	
159-11	28326-28328	DC	_	
159-12	28329-28334	value	_	
159-13	28335-28337	in	_	
159-14	28338-28341	the	_	
159-15	28342-28346	left	_	
159-16	28347-28355	inferior	_	
159-17	28356-28364	parietal	_	
159-18	28365-28368	and	_	
159-19	28369-28372	the	_	
159-20	28373-28381	subscale	_	
159-21	28382-28384	of	_	
159-22	28385-28396	attentional	_	
159-23	28397-28408	impulsivity	_	
159-24	28408-28409	,	_	
159-25	28410-28414	dose	_	
159-26	28414-28415	,	_	
159-27	28416-28424	duration	_	
159-28	28425-28428	and	_	
159-29	28429-28432	the	_	
159-30	28433-28436	age	_	
159-31	28437-28439	at	_	
159-32	28440-28443	the	_	
159-33	28444-28449	first	_	
159-34	28450-28453	CCS	_	
159-35	28454-28457	use	_	
159-36	28457-28458	.	_	

#Text=Taken together, these results suggested a novel approach for exploring the complex disorder of addiction.
160-1	28459-28464	Taken	_	
160-2	28465-28473	together	_	
160-3	28473-28474	,	_	
160-4	28475-28480	these	_	
160-5	28481-28488	results	_	
160-6	28489-28498	suggested	_	
160-7	28499-28500	a	_	
160-8	28501-28506	novel	_	
160-9	28507-28515	approach	_	
160-10	28516-28519	for	_	
160-11	28520-28529	exploring	_	
160-12	28530-28533	the	_	
160-13	28534-28541	complex	_	
160-14	28542-28550	disorder	_	
160-15	28551-28553	of	_	
160-16	28554-28563	addiction	_	
160-17	28563-28564	.	_	

#Text=This rs-fMRI study advanced our understanding of CCS dependency towards an intrinsic dysconnectivity pattern of whole-brain functional networks.
161-1	28565-28569	This	_	
161-2	28570-28577	rs-fMRI	_	
161-3	28578-28583	study	_	
161-4	28584-28592	advanced	_	
161-5	28593-28596	our	_	
161-6	28597-28610	understanding	_	
161-7	28611-28613	of	_	
161-8	28614-28617	CCS	_	
161-9	28618-28628	dependency	_	
161-10	28629-28636	towards	_	
161-11	28637-28639	an	_	
161-12	28640-28649	intrinsic	_	
161-13	28650-28665	dysconnectivity	_	
161-14	28666-28673	pattern	_	
161-15	28674-28676	of	_	
161-16	28677-28688	whole-brain	_	
161-17	28689-28699	functional	_	
161-18	28700-28708	networks	_	
161-19	28708-28709	.	_	

#Text=Conflict of interest
#Text=The authors have no relevant conflicts of interest to disclose.
162-1	28710-28718	Conflict	_	
162-2	28719-28721	of	_	
162-3	28722-28730	interest	_	
162-4	28731-28734	The	_	
162-5	28735-28742	authors	_	
162-6	28743-28747	have	_	
162-7	28748-28750	no	_	
162-8	28751-28759	relevant	_	
162-9	28760-28769	conflicts	_	
162-10	28770-28772	of	_	
162-11	28773-28781	interest	_	
162-12	28782-28784	to	_	
162-13	28785-28793	disclose	_	
162-14	28793-28794	.	_	

#Text=References
#Text=Purple drank prevalence and characteristics of misusers of codeine cough syrup mixtures
#Text=Brain blood flow SPET imaging in heroin abusers
#Text=Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease
#Text=A place for the hippocampus in the cocaine addiction circuit: potential roles for adult hippocampal neurogenesis
#Text=Network hubs in the human brain[J]
#Text=Shared and distinct intrinsic functional network centrality in autism and attention-deficit/hyperactivity disorder
#Text=Inhibition of protein synthesis but not β-adrenergic receptors blocks reconsolidation of a cocaine-associated cue memory
#Text=Cluster failure: why fMRI inferences for spatial extent have inflated false-positive rates
#Text=Cocaine cue-induced dopamine release in amygdala and hippocampus: a high-resolution PET [18F]fallypride study in cocaine dependent participants
#Text=Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli
#Text=Drug addiction and its underlying neurobiological basis: neuroimaging evidence for the involvement of the frontal cortex
#Text=Different neural correlates of reward expectation and reward expectation error in the putamen and caudate nucleus during stimulus-action-reward association learning
#Text=The ventral pallidum plays a role in mediating cocaine and heroin self-administration in the rat
#Text=Neural mechanisms of addiction: the role of reward—related learning and memory
#Text=Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies
#Text=Amplitude low-frequency oscillation abnormalities in the heroin users: a resting state fMRI study
#Text=Estimation of the probabilities of 3D clusters in functional brain images
#Text=Increased global and local efficiency of human brain anatomical networks detected with FLAIR-DTI compared to non-FLAIR-DTI
#Text=Abnormal degree centrality in neurologically asymptomatic patients with end-stage renal disease: a resting-state fMRI study
#Text=Dysfunctional connectivity patterns in chronic heroin users: an fMRI study
#Text=Addiction related alteration in resting-state brain connectivity
#Text=Abnormal brain default-mode network functional connectivity in drug addicts
#Text=Birth-cohort trends in lifetime and past-year prescription opioid-use disorder resulting from nonmedical use: results from two national surveys
#Text=Abuse of codeine-containing cough syrups: a report from India
#Text=Brain regions with mirror properties: a meta-analysis of 125 human FMRI studies
#Text=Functional modular architecture underlying attentional control in aging
#Text=Infralimbic BDNF/TrkB enhancement of GluN2B currents facilitates extinction of a cocaine-conditioned place preference
#Text=Factor structure of the Barratt impulsiveness scale
#Text=The mirror neuron system also rests
#Text=Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C] raclopride
#Text=Reduced regional homogeneity in bilateral frontostriatal system relates to higher impulsivity behavior in codeine-containing cough syrups dependent individuals
#Text=Reduced ventral medial prefrontal cortex (vmPFC) volume and impaired vmPFC-default mode network integration in codeine-containing cough syrups users
#Text=Abnormal white matter integrity in chronic users of codeine-containing cough syrups: a tract-based spatial statistics study
#Text=Intrinsic brain network abnormalities in codeine-containing cough syrup-dependent male individuals revealed in resting-state fMRI
#Text=Stress-induced relapse to heroin and cocaine seeking in rats: a review
#Text=Selective induction of c-Fos immunoreactivity in the prelimbic cortex during reinstatement of heroin seeking induced by acute food deprivation in rats
#Text=Adolescent cough medicine abuse in Hong Kong: implications for the design of positive youth development programs in Hong Kong
#Text=Prenatal methamphetamine exposure induces long-lasting alterations in memory and development of NMDA receptors in the hippocampus
#Text=Functional connectivity density mapping
#Text=Aberrant learning and memory in addiction[J]
#Text=Activation of orbital and medial prefrontal cortex by methylphenidate in cocaine-addicted subjects but not in controls: relevance to addiction
#Text=Codeine analgesia is due to codeine-6-glucuronide, not morphine
#Text=Graph theoretical analysis of functional brain networks: test-retest evaluation on short- and long-term resting-state functional MRI data
#Text=Brain anatomical networks in world class gymnasts: a DTI tractography study
#Text=DPARSF: a MATLAB toolbox for “pipeline” data analysis of resting-state fMRI
#Text=Investigation and analysis on personalities of male-codeine phosphate addicts by MMPI
#Text=An examination of the psychometric properties of the Chinese version of the Barratt impulsiveness scale, 11th version in a sample of Chinese adolescents
#Text=Gray matter density negatively correlates with duration of heroin use in young lifetime heroin-dependent individuals
#Text=Altered small-world brain functional networks and duration of heroin use in male abstinent heroin-dependent individuals
#Text=Distinct resting-state brain activities in heroin-dependent individuals
#Text=Abnormal white matter structural networks characterize heroin-dependent individuals: a network analysis
#Text=
#Text=Network centrality in the human functional connectome
163-1	28795-28805	References	_	
163-2	28806-28812	Purple	_	
163-3	28813-28818	drank	_	
163-4	28819-28829	prevalence	_	
163-5	28830-28833	and	_	
163-6	28834-28849	characteristics	_	
163-7	28850-28852	of	_	
163-8	28853-28861	misusers	_	
163-9	28862-28864	of	_	
163-10	28865-28872	codeine	_	
163-11	28873-28878	cough	_	
163-12	28879-28884	syrup	_	
163-13	28885-28893	mixtures	_	
163-14	28894-28899	Brain	_	
163-15	28900-28905	blood	_	
163-16	28906-28910	flow	_	
163-17	28911-28915	SPET	_	
163-18	28916-28923	imaging	_	
163-19	28924-28926	in	_	
163-20	28927-28933	heroin	_	
163-21	28934-28941	abusers	_	
163-22	28942-28950	Cortical	_	
163-23	28951-28955	hubs	_	
163-24	28956-28964	revealed	_	
163-25	28965-28967	by	_	
163-26	28968-28977	intrinsic	_	
163-27	28978-28988	functional	_	
163-28	28989-29001	connectivity	_	
163-29	29001-29002	:	_	
163-30	29003-29010	mapping	_	
163-31	29010-29011	,	_	
163-32	29012-29022	assessment	_	
163-33	29023-29025	of	_	
163-34	29026-29035	stability	_	
163-35	29035-29036	,	_	
163-36	29037-29040	and	_	
163-37	29041-29049	relation	_	
163-38	29050-29052	to	_	
163-39	29053-29064	Alzheimer's	_	
163-40	29065-29072	disease	_	
163-41	29073-29074	A	_	
163-42	29075-29080	place	_	
163-43	29081-29084	for	_	
163-44	29085-29088	the	_	
163-45	29089-29100	hippocampus	_	
163-46	29101-29103	in	_	
163-47	29104-29107	the	_	
163-48	29108-29115	cocaine	_	
163-49	29116-29125	addiction	_	
163-50	29126-29133	circuit	_	
163-51	29133-29134	:	_	
163-52	29135-29144	potential	_	
163-53	29145-29150	roles	_	
163-54	29151-29154	for	_	
163-55	29155-29160	adult	_	
163-56	29161-29172	hippocampal	_	
163-57	29173-29185	neurogenesis	_	
163-58	29186-29193	Network	_	
163-59	29194-29198	hubs	_	
163-60	29199-29201	in	_	
163-61	29202-29205	the	_	
163-62	29206-29211	human	_	
163-63	29212-29217	brain	_	
163-64	29217-29218	[	_	
163-65	29218-29219	J	_	
163-66	29219-29220	]	_	
163-67	29221-29227	Shared	_	
163-68	29228-29231	and	_	
163-69	29232-29240	distinct	_	
163-70	29241-29250	intrinsic	_	
163-71	29251-29261	functional	_	
163-72	29262-29269	network	_	
163-73	29270-29280	centrality	_	
163-74	29281-29283	in	_	
163-75	29284-29290	autism	_	
163-76	29291-29294	and	_	
163-77	29295-29312	attention-deficit	_	
163-78	29312-29313	/	_	
163-79	29313-29326	hyperactivity	_	
163-80	29327-29335	disorder	_	
163-81	29336-29346	Inhibition	_	
163-82	29347-29349	of	_	
163-83	29350-29357	protein	_	
163-84	29358-29367	synthesis	_	
163-85	29368-29371	but	_	
163-86	29372-29375	not	_	
163-87	29376-29388	β-adrenergic	_	
163-88	29389-29398	receptors	_	
163-89	29399-29405	blocks	_	
163-90	29406-29421	reconsolidation	_	
163-91	29422-29424	of	_	
163-92	29425-29426	a	_	
163-93	29427-29445	cocaine-associated	_	
163-94	29446-29449	cue	_	
163-95	29450-29456	memory	_	
163-96	29457-29464	Cluster	_	
163-97	29465-29472	failure	_	
163-98	29472-29473	:	_	
163-99	29474-29477	why	_	
163-100	29478-29482	fMRI	_	
163-101	29483-29493	inferences	_	
163-102	29494-29497	for	_	
163-103	29498-29505	spatial	_	
163-104	29506-29512	extent	_	
163-105	29513-29517	have	_	
163-106	29518-29526	inflated	_	
163-107	29527-29541	false-positive	_	
163-108	29542-29547	rates	_	
163-109	29548-29555	Cocaine	_	
163-110	29556-29567	cue-induced	_	
163-111	29568-29576	dopamine	_	
163-112	29577-29584	release	_	
163-113	29585-29587	in	_	
163-114	29588-29596	amygdala	_	
163-115	29597-29600	and	_	
163-116	29601-29612	hippocampus	_	
163-117	29612-29613	:	_	
163-118	29614-29615	a	_	
163-119	29616-29631	high-resolution	_	
163-120	29632-29635	PET	_	
163-121	29636-29637	[	_	
163-122	29637-29640	18F	_	
163-123	29640-29641	]	_	
163-124	29641-29651	fallypride	_	
163-125	29652-29657	study	_	
163-126	29658-29660	in	_	
163-127	29661-29668	cocaine	_	
163-128	29669-29678	dependent	_	
163-129	29679-29691	participants	_	
163-130	29692-29703	Cue-induced	_	
163-131	29704-29711	cocaine	_	
163-132	29712-29719	craving	_	
163-133	29719-29720	:	_	
163-134	29721-29736	neuroanatomical	_	
163-135	29737-29748	specificity	_	
163-136	29749-29752	for	_	
163-137	29753-29757	drug	_	
163-138	29758-29763	users	_	
163-139	29764-29767	and	_	
163-140	29768-29772	drug	_	
163-141	29773-29780	stimuli	_	
163-142	29781-29785	Drug	_	
163-143	29786-29795	addiction	_	
163-144	29796-29799	and	_	
163-145	29800-29803	its	_	
163-146	29804-29814	underlying	_	
163-147	29815-29830	neurobiological	_	
163-148	29831-29836	basis	_	
163-149	29836-29837	:	_	
163-150	29838-29850	neuroimaging	_	
163-151	29851-29859	evidence	_	
163-152	29860-29863	for	_	
163-153	29864-29867	the	_	
163-154	29868-29879	involvement	_	
163-155	29880-29882	of	_	
163-156	29883-29886	the	_	
163-157	29887-29894	frontal	_	
163-158	29895-29901	cortex	_	
163-159	29902-29911	Different	_	
163-160	29912-29918	neural	_	
163-161	29919-29929	correlates	_	
163-162	29930-29932	of	_	
163-163	29933-29939	reward	_	
163-164	29940-29951	expectation	_	
163-165	29952-29955	and	_	
163-166	29956-29962	reward	_	
163-167	29963-29974	expectation	_	
163-168	29975-29980	error	_	
163-169	29981-29983	in	_	
163-170	29984-29987	the	_	
163-171	29988-29995	putamen	_	
163-172	29996-29999	and	_	
163-173	30000-30007	caudate	_	
163-174	30008-30015	nucleus	_	
163-175	30016-30022	during	_	
163-176	30023-30045	stimulus-action-reward	_	
163-177	30046-30057	association	_	
163-178	30058-30066	learning	_	
163-179	30067-30070	The	_	
163-180	30071-30078	ventral	_	
163-181	30079-30087	pallidum	_	
163-182	30088-30093	plays	_	
163-183	30094-30095	a	_	
163-184	30096-30100	role	_	
163-185	30101-30103	in	_	
163-186	30104-30113	mediating	_	
163-187	30114-30121	cocaine	_	
163-188	30122-30125	and	_	
163-189	30126-30132	heroin	_	
163-190	30133-30152	self-administration	_	
163-191	30153-30155	in	_	
163-192	30156-30159	the	_	
163-193	30160-30163	rat	_	
163-194	30164-30170	Neural	_	
163-195	30171-30181	mechanisms	_	
163-196	30182-30184	of	_	
163-197	30185-30194	addiction	_	
163-198	30194-30195	:	_	
163-199	30196-30199	the	_	
163-200	30200-30204	role	_	
163-201	30205-30207	of	_	
163-202	30208-30222	reward—related	_	
163-203	30223-30231	learning	_	
163-204	30232-30235	and	_	
163-205	30236-30242	memory	_	
163-206	30243-30250	Factors	_	
163-207	30251-30261	modulating	_	
163-208	30262-30268	neural	_	
163-209	30269-30279	reactivity	_	
163-210	30280-30282	to	_	
163-211	30283-30287	drug	_	
163-212	30288-30292	cues	_	
163-213	30293-30295	in	_	
163-214	30296-30305	addiction	_	
163-215	30305-30306	:	_	
163-216	30307-30308	a	_	
163-217	30309-30315	survey	_	
163-218	30316-30318	of	_	
163-219	30319-30324	human	_	
163-220	30325-30337	neuroimaging	_	
163-221	30338-30345	studies	_	
163-222	30346-30355	Amplitude	_	
163-223	30356-30369	low-frequency	_	
163-224	30370-30381	oscillation	_	
163-225	30382-30395	abnormalities	_	
163-226	30396-30398	in	_	
163-227	30399-30402	the	_	
163-228	30403-30409	heroin	_	
163-229	30410-30415	users	_	
163-230	30415-30416	:	_	
163-231	30417-30418	a	_	
163-232	30419-30426	resting	_	
163-233	30427-30432	state	_	
163-234	30433-30437	fMRI	_	
163-235	30438-30443	study	_	
163-236	30444-30454	Estimation	_	
163-237	30455-30457	of	_	
163-238	30458-30461	the	_	
163-239	30462-30475	probabilities	_	
163-240	30476-30478	of	_	
163-241	30479-30481	3D	_	
163-242	30482-30490	clusters	_	
163-243	30491-30493	in	_	
163-244	30494-30504	functional	_	
163-245	30505-30510	brain	_	
163-246	30511-30517	images	_	
163-247	30518-30527	Increased	_	
163-248	30528-30534	global	_	
163-249	30535-30538	and	_	
163-250	30539-30544	local	_	
163-251	30545-30555	efficiency	_	
163-252	30556-30558	of	_	
163-253	30559-30564	human	_	
163-254	30565-30570	brain	_	
163-255	30571-30581	anatomical	_	
163-256	30582-30590	networks	_	
163-257	30591-30599	detected	_	
163-258	30600-30604	with	_	
163-259	30605-30614	FLAIR-DTI	_	
163-260	30615-30623	compared	_	
163-261	30624-30626	to	_	
163-262	30627-30640	non-FLAIR-DTI	_	
163-263	30641-30649	Abnormal	_	
163-264	30650-30656	degree	_	
163-265	30657-30667	centrality	_	
163-266	30668-30670	in	_	
163-267	30671-30685	neurologically	_	
163-268	30686-30698	asymptomatic	_	
163-269	30699-30707	patients	_	
163-270	30708-30712	with	_	
163-271	30713-30722	end-stage	_	
163-272	30723-30728	renal	_	
163-273	30729-30736	disease	_	
163-274	30736-30737	:	_	
163-275	30738-30739	a	_	
163-276	30740-30753	resting-state	_	
163-277	30754-30758	fMRI	_	
163-278	30759-30764	study	_	
163-279	30765-30778	Dysfunctional	_	
163-280	30779-30791	connectivity	_	
163-281	30792-30800	patterns	_	
163-282	30801-30803	in	_	
163-283	30804-30811	chronic	_	
163-284	30812-30818	heroin	_	
163-285	30819-30824	users	_	
163-286	30824-30825	:	_	
163-287	30826-30828	an	_	
163-288	30829-30833	fMRI	_	
163-289	30834-30839	study	_	
163-290	30840-30849	Addiction	_	
163-291	30850-30857	related	_	
163-292	30858-30868	alteration	_	
163-293	30869-30871	in	_	
163-294	30872-30885	resting-state	_	
163-295	30886-30891	brain	_	
163-296	30892-30904	connectivity	_	
163-297	30905-30913	Abnormal	_	
163-298	30914-30919	brain	_	
163-299	30920-30932	default-mode	_	
163-300	30933-30940	network	_	
163-301	30941-30951	functional	_	
163-302	30952-30964	connectivity	_	
163-303	30965-30967	in	_	
163-304	30968-30972	drug	_	
163-305	30973-30980	addicts	_	
163-306	30981-30993	Birth-cohort	_	
163-307	30994-31000	trends	_	
163-308	31001-31003	in	_	
163-309	31004-31012	lifetime	_	
163-310	31013-31016	and	_	
163-311	31017-31026	past-year	_	
163-312	31027-31039	prescription	_	
163-313	31040-31050	opioid-use	_	
163-314	31051-31059	disorder	_	
163-315	31060-31069	resulting	_	
163-316	31070-31074	from	_	
163-317	31075-31085	nonmedical	_	
163-318	31086-31089	use	_	
163-319	31089-31090	:	_	
163-320	31091-31098	results	_	
163-321	31099-31103	from	_	
163-322	31104-31107	two	_	
163-323	31108-31116	national	_	
163-324	31117-31124	surveys	_	
163-325	31125-31130	Abuse	_	
163-326	31131-31133	of	_	
163-327	31134-31152	codeine-containing	_	
163-328	31153-31158	cough	_	
163-329	31159-31165	syrups	_	
163-330	31165-31166	:	_	
163-331	31167-31168	a	_	
163-332	31169-31175	report	_	
163-333	31176-31180	from	_	
163-334	31181-31186	India	_	
163-335	31187-31192	Brain	_	
163-336	31193-31200	regions	_	
163-337	31201-31205	with	_	
163-338	31206-31212	mirror	_	
163-339	31213-31223	properties	_	
163-340	31223-31224	:	_	
163-341	31225-31226	a	_	
163-342	31227-31240	meta-analysis	_	
163-343	31241-31243	of	_	
163-344	31244-31247	125	_	
163-345	31248-31253	human	_	
163-346	31254-31258	FMRI	_	
163-347	31259-31266	studies	_	
163-348	31267-31277	Functional	_	
163-349	31278-31285	modular	_	
163-350	31286-31298	architecture	_	
163-351	31299-31309	underlying	_	
163-352	31310-31321	attentional	_	
163-353	31322-31329	control	_	
163-354	31330-31332	in	_	
163-355	31333-31338	aging	_	
163-356	31339-31350	Infralimbic	_	
163-357	31351-31355	BDNF	_	
163-358	31355-31356	/	_	
163-359	31356-31360	TrkB	_	
163-360	31361-31372	enhancement	_	
163-361	31373-31375	of	_	
163-362	31376-31382	GluN2B	_	
163-363	31383-31391	currents	_	
163-364	31392-31403	facilitates	_	
163-365	31404-31414	extinction	_	
163-366	31415-31417	of	_	
163-367	31418-31419	a	_	
163-368	31420-31439	cocaine-conditioned	_	
163-369	31440-31445	place	_	
163-370	31446-31456	preference	_	
163-371	31457-31463	Factor	_	
163-372	31464-31473	structure	_	
163-373	31474-31476	of	_	
163-374	31477-31480	the	_	
163-375	31481-31488	Barratt	_	
163-376	31489-31502	impulsiveness	_	
163-377	31503-31508	scale	_	
163-378	31509-31512	The	_	
163-379	31513-31519	mirror	_	
163-380	31520-31526	neuron	_	
163-381	31527-31533	system	_	
163-382	31534-31538	also	_	
163-383	31539-31544	rests	_	
163-384	31545-31553	Dopamine	_	
163-385	31554-31561	release	_	
163-386	31562-31564	in	_	
163-387	31565-31573	response	_	
163-388	31574-31576	to	_	
163-389	31577-31578	a	_	
163-390	31579-31592	psychological	_	
163-391	31593-31599	stress	_	
163-392	31600-31602	in	_	
163-393	31603-31609	humans	_	
163-394	31610-31613	and	_	
163-395	31614-31617	its	_	
163-396	31618-31630	relationship	_	
163-397	31631-31633	to	_	
163-398	31634-31639	early	_	
163-399	31640-31644	life	_	
163-400	31645-31653	maternal	_	
163-401	31654-31658	care	_	
163-402	31658-31659	:	_	
163-403	31660-31661	a	_	
163-404	31662-31670	positron	_	
163-405	31671-31679	emission	_	
163-406	31680-31690	tomography	_	
163-407	31691-31696	study	_	
163-408	31697-31702	using	_	
163-409	31703-31704	[	_	
163-410	31704-31707	11C	_	
163-411	31707-31708	]	_	
163-412	31709-31719	raclopride	_	
163-413	31720-31727	Reduced	_	
163-414	31728-31736	regional	_	
163-415	31737-31748	homogeneity	_	
163-416	31749-31751	in	_	
163-417	31752-31761	bilateral	_	
163-418	31762-31776	frontostriatal	_	
163-419	31777-31783	system	_	
163-420	31784-31791	relates	_	
163-421	31792-31794	to	_	
163-422	31795-31801	higher	_	
163-423	31802-31813	impulsivity	_	
163-424	31814-31822	behavior	_	
163-425	31823-31825	in	_	
163-426	31826-31844	codeine-containing	_	
163-427	31845-31850	cough	_	
163-428	31851-31857	syrups	_	
163-429	31858-31867	dependent	_	
163-430	31868-31879	individuals	_	
163-431	31880-31887	Reduced	_	
163-432	31888-31895	ventral	_	
163-433	31896-31902	medial	_	
163-434	31903-31913	prefrontal	_	
163-435	31914-31920	cortex	_	
163-436	31921-31922	(	_	
163-437	31922-31927	vmPFC	_	
163-438	31927-31928	)	_	
163-439	31929-31935	volume	_	
163-440	31936-31939	and	_	
163-441	31940-31948	impaired	_	
163-442	31949-31962	vmPFC-default	_	
163-443	31963-31967	mode	_	
163-444	31968-31975	network	_	
163-445	31976-31987	integration	_	
163-446	31988-31990	in	_	
163-447	31991-32009	codeine-containing	_	
163-448	32010-32015	cough	_	
163-449	32016-32022	syrups	_	
163-450	32023-32028	users	_	
163-451	32029-32037	Abnormal	_	
163-452	32038-32043	white	_	
163-453	32044-32050	matter	_	
163-454	32051-32060	integrity	_	
163-455	32061-32063	in	_	
163-456	32064-32071	chronic	_	
163-457	32072-32077	users	_	
163-458	32078-32080	of	_	
163-459	32081-32099	codeine-containing	_	
163-460	32100-32105	cough	_	
163-461	32106-32112	syrups	_	
163-462	32112-32113	:	_	
163-463	32114-32115	a	_	
163-464	32116-32127	tract-based	_	
163-465	32128-32135	spatial	_	
163-466	32136-32146	statistics	_	
163-467	32147-32152	study	_	
163-468	32153-32162	Intrinsic	_	
163-469	32163-32168	brain	_	
163-470	32169-32176	network	_	
163-471	32177-32190	abnormalities	_	
163-472	32191-32193	in	_	
163-473	32194-32212	codeine-containing	_	
163-474	32213-32218	cough	_	
163-475	32219-32234	syrup-dependent	_	
163-476	32235-32239	male	_	
163-477	32240-32251	individuals	_	
163-478	32252-32260	revealed	_	
163-479	32261-32263	in	_	
163-480	32264-32277	resting-state	_	
163-481	32278-32282	fMRI	_	
163-482	32283-32297	Stress-induced	_	
163-483	32298-32305	relapse	_	
163-484	32306-32308	to	_	
163-485	32309-32315	heroin	_	
163-486	32316-32319	and	_	
163-487	32320-32327	cocaine	_	
163-488	32328-32335	seeking	_	
163-489	32336-32338	in	_	
163-490	32339-32343	rats	_	
163-491	32343-32344	:	_	
163-492	32345-32346	a	_	
163-493	32347-32353	review	_	
163-494	32354-32363	Selective	_	
163-495	32364-32373	induction	_	
163-496	32374-32376	of	_	
163-497	32377-32382	c-Fos	_	
163-498	32383-32399	immunoreactivity	_	
163-499	32400-32402	in	_	
163-500	32403-32406	the	_	
163-501	32407-32416	prelimbic	_	
163-502	32417-32423	cortex	_	
163-503	32424-32430	during	_	
163-504	32431-32444	reinstatement	_	
163-505	32445-32447	of	_	
163-506	32448-32454	heroin	_	
163-507	32455-32462	seeking	_	
163-508	32463-32470	induced	_	
163-509	32471-32473	by	_	
163-510	32474-32479	acute	_	
163-511	32480-32484	food	_	
163-512	32485-32496	deprivation	_	
163-513	32497-32499	in	_	
163-514	32500-32504	rats	_	
163-515	32505-32515	Adolescent	_	
163-516	32516-32521	cough	_	
163-517	32522-32530	medicine	_	
163-518	32531-32536	abuse	_	
163-519	32537-32539	in	_	
163-520	32540-32544	Hong	_	
163-521	32545-32549	Kong	_	
163-522	32549-32550	:	_	
163-523	32551-32563	implications	_	
163-524	32564-32567	for	_	
163-525	32568-32571	the	_	
163-526	32572-32578	design	_	
163-527	32579-32581	of	_	
163-528	32582-32590	positive	_	
163-529	32591-32596	youth	_	
163-530	32597-32608	development	_	
163-531	32609-32617	programs	_	
163-532	32618-32620	in	_	
163-533	32621-32625	Hong	_	
163-534	32626-32630	Kong	_	
163-535	32631-32639	Prenatal	_	
163-536	32640-32655	methamphetamine	_	
163-537	32656-32664	exposure	_	
163-538	32665-32672	induces	_	
163-539	32673-32685	long-lasting	_	
163-540	32686-32697	alterations	_	
163-541	32698-32700	in	_	
163-542	32701-32707	memory	_	
163-543	32708-32711	and	_	
163-544	32712-32723	development	_	
163-545	32724-32726	of	_	
163-546	32727-32731	NMDA	_	
163-547	32732-32741	receptors	_	
163-548	32742-32744	in	_	
163-549	32745-32748	the	_	
163-550	32749-32760	hippocampus	_	
163-551	32761-32771	Functional	_	
163-552	32772-32784	connectivity	_	
163-553	32785-32792	density	_	
163-554	32793-32800	mapping	_	
163-555	32801-32809	Aberrant	_	
163-556	32810-32818	learning	_	
163-557	32819-32822	and	_	
163-558	32823-32829	memory	_	
163-559	32830-32832	in	_	
163-560	32833-32842	addiction	_	
163-561	32842-32843	[	_	
163-562	32843-32844	J	_	
163-563	32844-32845	]	_	
163-564	32846-32856	Activation	_	
163-565	32857-32859	of	_	
163-566	32860-32867	orbital	_	
163-567	32868-32871	and	_	
163-568	32872-32878	medial	_	
163-569	32879-32889	prefrontal	_	
163-570	32890-32896	cortex	_	
163-571	32897-32899	by	_	
163-572	32900-32915	methylphenidate	_	
163-573	32916-32918	in	_	
163-574	32919-32935	cocaine-addicted	_	
163-575	32936-32944	subjects	_	
163-576	32945-32948	but	_	
163-577	32949-32952	not	_	
163-578	32953-32955	in	_	
163-579	32956-32964	controls	_	
163-580	32964-32965	:	_	
163-581	32966-32975	relevance	_	
163-582	32976-32978	to	_	
163-583	32979-32988	addiction	_	
163-584	32989-32996	Codeine	_	
163-585	32997-33006	analgesia	_	
163-586	33007-33009	is	_	
163-587	33010-33013	due	_	
163-588	33014-33016	to	_	
163-589	33017-33024	codeine	_	
163-590	33024-33025	-	_	
163-591	33025-33026	6	_	
163-592	33026-33027	-	_	
163-593	33027-33038	glucuronide	_	
163-594	33038-33039	,	_	
163-595	33040-33043	not	_	
163-596	33044-33052	morphine	_	
163-597	33053-33058	Graph	_	
163-598	33059-33070	theoretical	_	
163-599	33071-33079	analysis	_	
163-600	33080-33082	of	_	
163-601	33083-33093	functional	_	
163-602	33094-33099	brain	_	
163-603	33100-33108	networks	_	
163-604	33108-33109	:	_	
163-605	33110-33121	test-retest	_	
163-606	33122-33132	evaluation	_	
163-607	33133-33135	on	_	
163-608	33136-33141	short	_	
163-609	33141-33142	-	_	
163-610	33143-33146	and	_	
163-611	33147-33156	long-term	_	
163-612	33157-33170	resting-state	_	
163-613	33171-33181	functional	_	
163-614	33182-33185	MRI	_	
163-615	33186-33190	data	_	
163-616	33191-33196	Brain	_	
163-617	33197-33207	anatomical	_	
163-618	33208-33216	networks	_	
163-619	33217-33219	in	_	
163-620	33220-33225	world	_	
163-621	33226-33231	class	_	
163-622	33232-33240	gymnasts	_	
163-623	33240-33241	:	_	
163-624	33242-33243	a	_	
163-625	33244-33247	DTI	_	
163-626	33248-33260	tractography	_	
163-627	33261-33266	study	_	
163-628	33267-33273	DPARSF	_	
163-629	33273-33274	:	_	
163-630	33275-33276	a	_	
163-631	33277-33283	MATLAB	_	
163-632	33284-33291	toolbox	_	
163-633	33292-33295	for	_	
163-634	33296-33297	“	_	
163-635	33297-33305	pipeline	_	
163-636	33305-33306	”	_	
163-637	33307-33311	data	_	
163-638	33312-33320	analysis	_	
163-639	33321-33323	of	_	
163-640	33324-33337	resting-state	_	
163-641	33338-33342	fMRI	_	
163-642	33343-33356	Investigation	_	
163-643	33357-33360	and	_	
163-644	33361-33369	analysis	_	
163-645	33370-33372	on	_	
163-646	33373-33386	personalities	_	
163-647	33387-33389	of	_	
163-648	33390-33402	male-codeine	_	
163-649	33403-33412	phosphate	_	
163-650	33413-33420	addicts	_	
163-651	33421-33423	by	_	
163-652	33424-33428	MMPI	_	
163-653	33429-33431	An	_	
163-654	33432-33443	examination	_	
163-655	33444-33446	of	_	
163-656	33447-33450	the	_	
163-657	33451-33463	psychometric	_	
163-658	33464-33474	properties	_	
163-659	33475-33477	of	_	
163-660	33478-33481	the	_	
163-661	33482-33489	Chinese	_	
163-662	33490-33497	version	_	
163-663	33498-33500	of	_	
163-664	33501-33504	the	_	
163-665	33505-33512	Barratt	_	
163-666	33513-33526	impulsiveness	_	
163-667	33527-33532	scale	_	
163-668	33532-33533	,	_	
163-669	33534-33538	11th	_	
163-670	33539-33546	version	_	
163-671	33547-33549	in	_	
163-672	33550-33551	a	_	
163-673	33552-33558	sample	_	
163-674	33559-33561	of	_	
163-675	33562-33569	Chinese	_	
163-676	33570-33581	adolescents	_	
163-677	33582-33586	Gray	_	
163-678	33587-33593	matter	_	
163-679	33594-33601	density	_	
163-680	33602-33612	negatively	_	
163-681	33613-33623	correlates	_	
163-682	33624-33628	with	_	
163-683	33629-33637	duration	_	
163-684	33638-33640	of	_	
163-685	33641-33647	heroin	_	
163-686	33648-33651	use	_	
163-687	33652-33654	in	_	
163-688	33655-33660	young	_	
163-689	33661-33669	lifetime	_	
163-690	33670-33686	heroin-dependent	_	
163-691	33687-33698	individuals	_	
163-692	33699-33706	Altered	_	
163-693	33707-33718	small-world	_	
163-694	33719-33724	brain	_	
163-695	33725-33735	functional	_	
163-696	33736-33744	networks	_	
163-697	33745-33748	and	_	
163-698	33749-33757	duration	_	
163-699	33758-33760	of	_	
163-700	33761-33767	heroin	_	
163-701	33768-33771	use	_	
163-702	33772-33774	in	_	
163-703	33775-33779	male	_	
163-704	33780-33789	abstinent	_	
163-705	33790-33806	heroin-dependent	_	
163-706	33807-33818	individuals	_	
163-707	33819-33827	Distinct	_	
163-708	33828-33841	resting-state	_	
163-709	33842-33847	brain	_	
163-710	33848-33858	activities	_	
163-711	33859-33861	in	_	
163-712	33862-33878	heroin-dependent	_	
163-713	33879-33890	individuals	_	
163-714	33891-33899	Abnormal	_	
163-715	33900-33905	white	_	
163-716	33906-33912	matter	_	
163-717	33913-33923	structural	_	
163-718	33924-33932	networks	_	
163-719	33933-33945	characterize	_	
163-720	33946-33962	heroin-dependent	_	
163-721	33963-33974	individuals	_	
163-722	33974-33975	:	_	
163-723	33976-33977	a	_	
163-724	33978-33985	network	_	
163-725	33986-33994	analysis	_	
163-726	33996-34003	Network	_	
163-727	34004-34014	centrality	_	
163-728	34015-34017	in	_	
163-729	34018-34021	the	_	
163-730	34022-34027	human	_	
163-731	34028-34038	functional	_	
163-732	34039-34049	connectome	_	
